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Abstract 
LL Z1640 2 (5Z 7 Oxo zeaenol) was first isolated in 1978 from a culture broth.  
Although LL Z1640 2 was initially classified as an anti protazoan agent, it was 
not until 1999 that it’s cytokine release inhibiting activity was discovered.  More 
recently LL Z1640 2 has been reported to selectively inhibit the kinase activity 
of TAK1. 
TAK1  (transforming  growth  factor  β activated  protein  kinase  1)  is  a  major 
member of the mitogen activated protein kinase kinase kinase (MAPKKK) family.  
TAK1 is responsible for the activation and control of at least three signalling 
pathways that play crucial roles in the inflammatory response.  Hence, TAK1 has 
emerged  as  a  prime  target  for  the  treatment  and  regulation  of  chronic 
inflammatory diseases such as rheumatoid arthritis, psoriasis and inflammatory 
bowel disease. 
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LL Z1640 2 is structurally related to other 14 membered resorcylic lactones such 
as 7 oxo zeaenol, zeaenol and radicicol.  Although there has been a significant 
amount of work dedicated to the synthesis of radicicol, the efforts towards LL 
Z1640 2  have  been  rather  limited.    At  the  outset  of  the  research  contained 
within this thesis, only two total syntheses of LL Z1640 2 had been published.  
They  were  both  lengthy  (>20  steps)  making  them  impractical  for  lead 
development. Murray N Robertson, 2009    2 
The  work  described  in  this  thesis  illustrates  the  attempted  flexible  and 
convergent  synthesis  of  LL Z1640 2  from  the  simple,  commercially  available, 
starting materials 2 deoxy D ribose and methyl 2,4,6 trihydroxybenzoate. 
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1  Introduction 
1.1 Resorcylic Acid Lactones 
The resorcylic acid lactone (RAL) family are a group of compounds characterised 
by a macrcrocyclic lactone incorporating the acid functionality of a resorcylic 
acid  1.    The  RAL  family  has  grown  significantly  since  the  first  isolation  of 
radicicol 2 in 1953 (Figure 1.1).
1 
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HO
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O
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Radicicol
OH
HO
OH
O
1
ß-Resocylic Acid  
Figure 1.1  β Resocylic acid and Radicicol. 
 
The  original  biological  activities  of  most  of  the  RALs  did  not  attract  much 
interest from organic chemistry community.
2  However in 1992 the inhibition of 
a specific protein kinase by radicicol was reported.
3  After this new discovery, 
radicicol  became  popular  with  biochemists  and  synthetic  chemists  alike.  
Multiple potential biological uses were reported with the most significant coming 
in 1998 when its ability to inhibit the APT binding of the 90 kDa heat shock 
protein (Hsp90) was reported.
4  The significance of this being that numerous 
mutated  and  overexpressed  proteins  rely  upon  the  Hsp90  protein  folding 
machinery for tumor progression.  The mechanism of Hsp90 which mediates the 
protein folding process is dependent upon ATP.  Therefore, when inhibitors of 
ATP are present, the Hsp90 machinery is unable to fold unwanted proteins into 
their  biologically  active  form  thus  resulting  in  the  degradation  of  protein 
substrates.  Subsequently, Hsp90 has evolved into a promising anti cancer target 
because  multiple  oncogenic  proteins  can  be  simultaneously  degraded  as  a 
consequence of Hsp90 inhibition.
5  As a result of this, radicicol 2 has now been 
used as a lead compound and potent derivatives have been synthesised and are 
currently in clinical trials.
6 
The first total synthesis of radicicol was reported by Lett in 1992.
7, 8  Since this 
initial  report  several  other  total  synthesis  approaches  have  been  reported 
including one from Danishefsky.
9 14  Murray N Robertson, 2009    Chapter 1, 16 
1.2 LL-Z1640-2 
The  RAL  LL Z1640 2  (also  known  as  5Z 7 Oxo zeaenol)  3  was  first  isolated  in 
1978 from an unidentified fungus
15 and then later from the fungal strain f6024.
16  
Although it was originally classified as an anti protozoan agent,
15 it was not until 
1999 that the potential for LL Z1640 2 3 to be therapeutically useful for treating 
inflammatory and immunological diseases was discovered.
17 
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Figure 1.2  LL Z1640 2 and a selection of structurally related RAL’s 
 
Ninomiya Tsuji
16  identified  LL Z1640 2  3  activity  during  a  screen  of  90 
compounds as inhibitors of the MAPKKK (Mitogen activated protein kinase kinase 
kinase) TAK1 (transforming growth factor β activated kinase 1).  LL Z1640 2 3 
was found to be a very potent inhibitor of TAK1, with an IC50 of 8 nM (Figure 
1.2).    The  other  structurally  related  RALs  2,  4  and  5  had  little  inhibitory 
activity. 
It  was  also  shown  that  LL Z1640 2  3  had  no  significant  effect  on  the  kinase 
activities  of  other  members  of  the  MAPKKK  family  such  as  MEKK1  (MAP 
extracellular  signal regulated  KKK  1)  and  ASK1  (Apoptosis  signal regulating 
kinase 1).
16 Murray N Robertson, 2009    Chapter 1, 17 
1.3 IC50 
In order to appreciate the biological significance of LL Z1640 2 3, a number of 
terms and concepts have to be defined and explained.  The IC50 of a compound is 
the concentration required to provide 50 % inhibition.  This is most commonly 
used  to  represent  the  inhibitory  effect  of  compounds  on competition  binding 
assays and functional antagonist assays. 
 
Figure 1.3  Dose response curve 
 
The IC50 is a quantitative measure that is used to indicate the concentration of 
that needed to inhibit a given biological process by half.  The IC50 of a compound 
is  calculated  by  plotting  a dose  response curve  relating concentration  of  the 
compound  to  the  activity  of  the  biological  process.    An  example  of  a  dose 
response cure is shown above (Figure 1.3).
18 
1.4 Protein Kinases 
A  protein  kinase  is  an  enzyme  that  can  modify  other  proteins  by  chemically 
adding  phosphate  groups  to  them,  otherwise  known  as  phosphorylation.
19  
Phosphorylation usually results in a functional change of the target protein by 
changing  an  enzymes  activity,  cellular  location,  or  association  with  other 
proteins.  Kinases transmit signals and control complex processes in cells. Up to 
518 different kinases have been identified in humans.
20  Murray N Robertson, 2009    Chapter 1, 18 
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Figure 1.4  Schematic representation of protein phosphorylation 
 
The chemical activity of a kinase involves removing a phosphate group from ATP 
6 (adenosine triphosphate) and covalently attaching it to one of three amino 
acids that have a free hydroxyl group (serine 7, threonine 8 or tyrosine 9)(Figure 
1.4).  Most kinases act on both serine 7 and threonine 8.  Others act on tyrosine 
9,  and  a  number,  referred  to  as  dual  specificity  kinases,  act  on  all  three 
residues. There are also some protein kinases that phosphorylate basic amino 
acid residues.  For example histidine kinases phosphorylate histidine residues.  
Effectively, many enzymes, receptors and other proteins can be turned on or off 
by phosphorylation (Figure 1.5). Murray N Robertson, 2009    Chapter 1, 19 
 
Figure 1.5  Phosphorylation turning enzymes and receptors “on” and “off”. 
 
Kinases have been defined as a significant drug target of the 21
st century as 
abnormal  or  deregulated  kinase  activity  is  a  common  cause  of  disease  and 
disorders such as cancer, inflammation and diabetes.
21  Furthermore their wide 
diversity makes them attractive drug targets for modern day drug design. 
1.5 Inflammation 
Inflammation  is  a  highly  ordered  process  and  plays  a  major  role  in  the  host 
defence system.  It is a protective attempt by the organism to remove harmful 
stimuli and to start the healing process of the tissue.   
Without inflammation, wounds and infections would never heal which could lead 
tissue  destruction  and  death  of  the  organism.    However,  uncontrolled  over 
stimulation  can  lead  to  unwanted  cell  responses  and  to  the  development  of 
inflammatory diseases.
22 
Inflammation can be classified as either acute or chronic.  Acute inflammation is 
the initial reaction of the host to harmful stimuli.  A cascade of biochemical 
events propagates and matures the inflammatory response.  The term chronic 
inflammation is used when the immune response persists for a prolonged period 
of time.  Chronic inflammation leads to a progressive shift in the type of cells 
present  at  the  site  of  inflammation  and  is  characterised  by  simultaneous 
destruction and healing of tissue. 
1.6 Inflammatory Disorders 
Conditions  connected  with  inflammation  include  a  large,  unrelated  group  of 
disorders which cause a variety of human diseases.  The immune system is often Murray N Robertson, 2009    Chapter 1, 20 
involved  with  inflammatory  disorders  which  are  demonstrated  in  allergic 
reactions and in some myopathies. 
Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder where the 
immune  system  attacks  the  body causing  inflammation  which  results  in  pain, 
swelling, stiffness and bone and cartilage destruction.
23  RA is thought to affect 
about 1 % of the adult population worldwide.
24  RA affects women three times 
more often as men and can also develop at any age.  However, the risk of first 
developing the disease is greatest in women between the ages of 40 and 50 years 
old and in later years with men. 
Crohn’s Disease 
Crohn’s  disease  (also  known  as  regional  enteritis)  is  an  autoimmune  disease 
which can affect any part of the gastrointestinal tract.  The symptoms of Crohn’s 
disease  vary  among  afflicted  individuals.    The  main  symptoms are abdominal 
pain, diarrhoea, constipation, vomiting, weight loss or weight gain.  The disease 
can also cause problems outside the gastrointestinal tract such as skin rashes, 
arthritis and inflammation of the eye.  Crohn's disease can occur at any age 
although it tends to develop most in the teens and twenties, with another peak 
incidence in the fifties to seventies.
25 
Acute Coronary Syndrome 
Acute coronary syndrome (ACS) greatly increase the risk of death and/or the 
recurrence  of  serious  cardiovascular  events.    ACS  is  due  to  the  disorder  of 
atherosclerotic plaque of which inflammation is a component. 
Antithrombotic therapy is presently the cornerstone of the treatment of ACS.
26  
Findings  indicate  the  importance  of  inflammation  in  atherothrombosis  and 
support therapeutic use of anti inflammatory treatment.  As a result of these 
findings there is now evidence showing that blocking inflammation could lower 
thrombosis and therefore ACS.
27 
Cancer 
It has been shown that up to 15 % of cancer cases worldwide can be linked to 
infections.
28  A possible pathway for these infections to progress to cancer is for Murray N Robertson, 2009    Chapter 1, 21 
the infection to persist within the host and induce chronic inflammation.
29  This 
inflammation  is  often  accompanied  by  the  formation  of  reactive  oxygen  and 
nitrogen species (ROS and RNOS) at the site of inflammation.  ROS and RNOS 
have the potential to damage DNA, proteins and cell membranes and therefore 
favour carcinogenesis.  In addition to this, chronic inflammation often results in 
repeated cycles of damage and compensating cell proliferation.  This in turn 
increases the number of cells that are dividing and therefore subject to DNA 
damage that promotes the growth of malignant cells.
30 
1.7 The Mitogen-activated Protein Kinase Pathway 
Cell  surface  receptors  of  eukaryotes  are  used  to  sense  and  respond  to 
extracellular  stimuli.    Commonly,  signal  transduction  pathways  in  eukaryotes 
regulate protein kinases that phosphorylate and control the activity of proteins 
involved  in  metabolic  and  transcriptional  events.    Many  signal  transduction 
pathways regulated by different cell surface receptors are highly conserved in 
evolutionarily distant organisms.   
The mitogen activated protein kinase (MAPK) pathway is a conserved eukaryotic 
signalling  module  that  converts  receptor  signals  into  various  outputs.
31    The 
pathway includes three protein kinases: MAPKKK, MAPKK and MAPK.  MAPK is 
activated  through  phosphorylation  by  MAPKK,  which  is  first  activated  by 
MAPKKK. 
1.8 TAK1 
TAK1  is  a  member  of  the  mitogen activated  protein  kinase  kinase  kinase 
(MAPKKK) family that phosphorylates and activates MKK3, MKK4, MKK6 and MKK7 
MAPKKs, which in turn activate the c Jun N terminal kinase (JNK) and p38 MAPKs 
(Figure  1.6).
32,  33    TAK1  participates  in  proinflammatory  cellular  signaling 
pathways such as the interleukin 1 (IL 1) pathway by activating both JNK/p38 
MAPKs and IKKs (I kappa B kinase).
16, 34  The MAPK cascades constitute functional 
units that couple upstream input signals to a variety of outputs.  MAPK cascades 
have been identified and characterised in organisms as diverse as yeasts and 
mammals.
35 Murray N Robertson, 2009    Chapter 1, 22 
 
Figure 1.6  MAPK cascades 
 
1.9 TAK1 as a Potential Drug Target 
TAK1 along with it’s regulatory subunits TAB1 (TAK1 binding protein 1) and TAB2 
(TAK1 binding protein 2) or the structurally related TAB3 (TAK1 binding protein 
3)  lie  at  the  head  of  three  pro inflammatory  kinase  cascades.
36,  37    The 
significance of TAK1 was reinforced by Cohen et al in 2003
36 when they showed 
that SAPK2a/p38α had feedback control on TAK1 via TAB1.  They also found that 
the downregulation of TAK1 by SAPK2a/p38α was not just a feedback control 
device  for  limiting  the  activation  of  SAPK2a/p38α,  but  may  also  limit  the 
activation of IKK and JNK and hence synchronise three signalling pathways that 
play key roles in the inflammatory response. Murray N Robertson, 2009    Chapter 1, 23 
 
Figure 1.7  Schematic representation of the feedback control of TAK1 activity by 
SAPK2a/p38α. 
 
Figure 1.7 A shows the downregulation of TAK1 by SAPK2a/p38α, best thought to 
be via TAB1.  In B, SAPK2a/p38α is inhibited and eliminates the feedback control 
of TAK1, causing upregulation of the JNK and IKK pathways.  This discovery led 
to  important  implications  in  the  development  of  anti inflammatory  drugs  as 
previous studies had been focused on inhibiting SAPK2a/p38α.  Potent, selective 
inhibitors  of  SAPK2a/p38α  have  in  fact  been  studied  for  the  treatment  of 
rheumatoid arthritis and other chronic inflammatory diseases.
38 40 
Several lines of evidence suggest that TAK1 is a key molecule in proinflammatory 
signaling pathways.  Various proinflammatory cytokines and endotoxins activate 
the kinase activity of endogenous TAK1.
41  Therefore, it can be expected that 
inhibition  of  TAK1  activity  may  be  effective  in  preventing  inflammation  and 
tissue destruction promoted by proinflammatory cytokines. 
1.10  LL-Z1640-2 as a TAK1 Inhibitor 
Ninomiya Tsuji  discovered  that  LL Z1640 2  3  inhibited  the  kinase  activity  of 
purified TAK1, whereas no significant inhibition of TAK1 activity was observed 
with structurally related compounds including radicicol 2(Figure 1.2).
16  It was 
also  discovered  that  LL Z1640 2  3  had  no  significant  effect  on  the  kinase 
activities of other members of the MAPKKK family, such as MEKK1 and ASK1.  
This was surprising as it had previously been shown that the two compounds, Ro Murray N Robertson, 2009    Chapter 1, 24 
09 2210
42 14 and L 783,277
43 15, with very similar structures to LL Z1640 2 3 
inhibit MEK kinase activity (Figure 1.8). 
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Figure 1.8 Structurally related compounds and their MEK IC50 
 
LL Z1640 2 3 did inhibit MEK1 activity, however the concentration required was 
more than 50 fold higher than that required to inhibit TAK1.  Therefore, LL 
Z1640 2 3 was shown as a selective inhibitor of TAK1. 
Ninomiya Tsuji also went on to show that binding of LL Z1640 2 3 to TAK1 was 
either irreversible or very slowly reversible and also a competitive inhibitor of 
ATP  binding.    They  did  not  hypothesise  any  possible  mechanisms  for  this 
inhibition, however Santi in 2006 published results showing that RALs containing 
a cis enone are susceptible to Michael addition reactions with cysteine residues 
16 within MAPK kinases (Figure 1.9).
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Figure 1.9  Michael addition of the cis enone function of RAL with a cysteine residue. 
 
Santi’s  work  discovered  that  the  conserved  Cys  residue  adjacent  to  the 
completely conserved Asp that is involved in the binding of Mg
2+ complexed to Murray N Robertson, 2009    Chapter 1, 25 
ATP in kinases inhibited by RALs.  The work by Santi is further strengthened by 
the fact that kinases that are not inhibited by RALs have no Cys residue at that 
position.    Upon  screening  the  human  kinome,  46  kinases  were  identified  as 
having the essential Cys residue.  During their initial screen of 124 kinases, 19 
Cys containing kinases were evaluated using hypothemycin 18 (Figure 1.10) as 
the inhibitor.  Hypothemycin 18 inhibited 18 of the 19 Cys containing kinases 
and only 3 of the other related kinases.   
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Figure 1.10  Hypothemycin 
 
1.11  Irreversibility Issues 
There  is  a  common  prejudice against irreversible inhibitors as drug  discovery 
programmes almost never set out to make irreversible inhibitors.  However, this 
assumption  is  contradicted  by  the  fact  that  19  of  the  71  enzyme  targets  of 
marketed  drugs  are  covalently  modified  by  the  drug.
45    Providing  target 
selectivity can be achieved, there are a number of advantages of irreversible 
inhibitors over reversible binding agents.  One of the main advantages includes 
the  thermodynamic  drive  towards  the  formation  of  the  covalent  adduct.    As 
such, high concentrations of the inhibitor are not required to obtain effective 
inhibition.    Also,  once  covalently  bound  the  inhibitor  will  not  readily  detach 
from the enzyme and as a result restoration of the enzyme function requires 
new synthesis.  Work by Haber
46 has shown irreversible inhibition can avoid drug 
resistance thus potentially providing treatment for tumours that have become 
resistant to other forms of treatment.  
1.12  Selectivity 
Inhibition caused by drugs may be either reversible or irreversible.  A reversible 
situation occurs when an equilibrium is established between the enzyme and the 
inhibitory drug.  Competitive inhibition occurs when the drug mimics the normal 
substrate  and  competes  for  the  active  site  of  the  enzyme.    Non competitive 
inhibitors combine with the enzyme at a different site other than the active site.  Murray N Robertson, 2009    Chapter 1, 26 
This interaction causes the enzyme to change shape and disturbs the active site 
conformation.  
Many of the first kinase inhibitors were ATP mimetics that bound to the active 
site and competed with cellular ATP.  The ATP site is highly conserved across the 
kinome thus making it difficult to identify selective inhibitors that only target 
the therapeutically relevant kinase.  Studies on isoforms of the p38 MAPK by 
Goldsmith
47, 48 showed that residues close to the ATP binding site could be used 
to achieve selectivity.  This was even demonstrated between the closely related 
kinases p38 and ERK2.  Development of these strategies that exploit the amino 
acids  in,  or  close  to,  the  ATP binding  site  of  kinases  continues.    The  ever 
increasing  number  of  solved  kinase  structures  also  aids  current  and  future 
development of these targets.  A high degree of selectivity is on show in the 
majority of the kinase inhibitors that are currently in clinical trials.  Most of 
these  seem  to  be  ATP  mimics,  however  the  discovery  of  alternative  binding 
modes has been exploited.
49 
1.13  Total Synthesis of LL-Z1640-2 
The  first  total  synthesis  of  LL Z1640 2  3  was  reported  by  Tatsuta  2001.
50  
Tatsuta’s approach was a mainly linear approach with longest linear sequence 
containing 19 steps with an overall yield of 2.3 % (Scheme 1.1). Murray N Robertson, 2009    Chapter 1, 27 
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a) CSA, BnOH, 89 %. b) MOMCl, i-Pr2NEt, MeCN, 85 %. c) H2, Pd(OH)2,EtOH, 100 %. d)
TMS-acetylene, n-BuLi, BF3.Et2O, THF. e) PivCl, Py, 2 steps 48 %. f) TBAF, AcOH, THF,
100 %. g) 21, Pd(OAc)2, CuI, Ph3P, Et3N, 85 %. h) ClCO2Et, Py, 98 %. i) H2, Pd/BaCO3,
quinoline, EtOH. j)Pd2(dba)3CHCl3, n-Bu3P, HCOONH4, 1,4-dioxane, 2 steps 96 %. k)
NaOMe, MeOH, 95 %. l) (COCl)2, DMSO, Et3N, DCM. m) Ph3P, CBr, DCM, 2 steps 85 %. n)
n-BuLi, BF3.Et2O, THF, 45 %. o) H2, Pd/BaCO3, quinoline, AcOEt. p) 2M NaOH, MeOH, 1,4-
dioxane. q) Mukaiyama reagent, Et3N, MeCN, 3 steps 47 %. r) 5 % HCl, MeOH, 76 %. s)
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Scheme 1.1  Tatsuta’s overall scheme. 
 
It was envisioned by Tatsuta that the two stereogenic alcohols present in the 
final product 3 could originate from a carbohydrate source.  D ribose 19 was 
used  and  compound  20  was  derived  in  6  steps  in  36  %  yield.    Sonagashira 
coupling  of  20  and  the  aromatic  fragment  21  proceeded  in  85  %  to  give 
compound  22.    Hydrogenolysis  under  Tsuji’s  conditions
51  gave  the  desired  E 
olefin,  which  was  converted  to  the  carbonate  ester.    The  allyl  carbonate 
intermediate was then eliminated using palladium(0) (Pd2(dba)3) and ammonium 
formate  as  the  hydride  source.    Selective  deprotection  and  oxidation  of  the 
primary alcohol followed by a Corey Fuchs reaction gave the alkyne unit which 
was  used  to  open  S propylene  oxide  in  the  same  pot  to  give  alkyne  23.  
Hydrogenation  using  Lindlar’s  catalyst  afforded  the  desire  Z  olefin  24.  
Saponification  of  the  ester  24  and  subsequent  cyclisation  using  Mukaiyama 
conditions
52 afforded the  lactone  fragment.    Final  deprotection  and  selective 
oxidation  of  the  allyl  alcohol  using  Dess Martin  periodinane  gave  the  α,β 
unsaturated ketone and completed the first total synthesis of LL Z1640 2 3. Murray N Robertson, 2009    Chapter 1, 28 
1.14  The Second Total Synthesis 
The second synthesis of LL Z1640 2 3 was reported by Selles and Lett in 2002.
53, 
54  They proposed a convergent and flexible approach and also showed conditions 
to selectively epoxidise 3 to hypothemycin 18.  However, their longest linear 
sequence contained 25 steps with an overall yield of 1.3 %. 
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a) TBSCl, iPr2NEt, DMF. b) Et2NAlMe2, toluene, 2 steps 98 %. c) t-BuLi, Et2O, Br2, 75 %. d)
Me3O+, BF4-, DCM. e) Na2CO3, MeOH, 2 steps 76 %. f) NaOH, DME, 100 %.
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Scheme 1.2  Lett’s synthesis of aromatic fragment 27 
 
In Lett’s approach, LL Z1640 2 3 orginated from the key aromatic 27, C1’ C6’ and 
the  C7’ C10’  enantiopure  subunits  33  and  38.    The  aromatic  unit  27  was 
synthesised from 4 methoxysalicylic acid 25 in 5 steps with an overall yield of 57 
% (Scheme 1.2). 
Synthesis  of  the  C7’ C10’  subunit  began  with  (trimethylsilyl)acetylene  29.    (R) 
propylene oxide 30 was opened In the presence of the lithio derivative of 29 to 
give 31.  Silyl protection of the alcohol followed by specific deprotection of the 
TMS alkyne gave 32 in 76 % over 3 steps.  The iodoalkyne of 32 was produced 
then subjected to Corey’s hydroboration procedure using Sia2BH and acetic acid 
to form the enantiopure Z vinyl iodide 33 (Scheme 1.3).
55 
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a) n-BuLi, 30, BF3.Et2O, Et2O, 89 %. b) TBSCl, imidazole, DMF. c) K2CO3, MeOH, 2 steps 86
%. d) n-BuLi, I2, THF, 86 %. e) Sia2BH, THF, AcOH, 89 %.
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Scheme 1.3  Lett’s synthesis of the C7’ C10’ subunit 
 
The synthesis of the C1’ C6’ sub unit began with 1,4 butynediol 34 which was 
converted to the silyl protected iodide 35 over 4 steps.  The iodide was then 
coupled with (trimethylsilyl)acetylene 29 and then selective deprotected using Murray N Robertson, 2009    Chapter 1, 29 
DDQ (5 mol %) to yield the free hydroxyl.  Sharpless asymmetric epoxidation of 
the alkyneol afforded the desired epoxyalcohol 36 (Scheme 1.4). 
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a) Red-Al/ toluene, THF, 81 %. b) NaH, THF, then TBSCl, 76 %. c) MsCl, NEt3, DCM. d)
NaI, acetone. e) 29, n-BuLi, THF, then 35 and HMPA. f) DDQ (5 mol%), MeCN/H2O (9/1).
g) Ti(OiPr)4, (+)-DET, DCM, tBuOOH.  
Scheme 1.4  Lett’s synthesis of the C1’ C6’ subunit 
 
Regio   and  stereospecific  epoxide  opening  gave  the  carbonate  37.    Finally, 
protecting group manipulation and Swern oxidation gave aldehyde 38 in a total 
of 14 steps from 34 and in 13 % yield (Scheme 1.5) 
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a) PhNCO, DCM/pyridine. b) BF3.Et2O, Et2O, then 1M H2SO4. c) MeONa, MeOH. d) TBSCl,
imidazole, DMF. e) 2-methoxypropene, TsOH, DCM. f) nBuLi/hexane, Et2O, then TBSCl, 98 %. g)
DDQ, MeCN/H2O (9/1), 73 %. h) oxalyl chloride, DMSO, DCM, then Et3N.
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Scheme 1.5  Lett’s regio  and stereospecific epoxide opening 
 
Condensation of units 38 and 33 gave two diastereoisomers 39, epimeric at the 
C6’ position.  Deprotection of the TMS alkyne and protection of the free C6’ OH 
gave 40 as a 60/40 inseparable mixture C6’ OPMB ethers.  Conversion of alkyne 
40 to the corresponding vinyl borane followed by intermolecular Suzuki coupling 
with  28,  TBAF  deprotection  and  methyl  ester  cleavage  gave  the  cyclisation 
precursor 41 in 47 % yield. Murray N Robertson, 2009    Chapter 1, 30 
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a) 33, Et2O, then t-BuLi/pentane. b) K2CO3, MeOH. c) PMB-trichloroacetimidate, Et2O, CF3SO3H.
d) TBAF 1M/THF. e) 28, DCC, DMAP, DCM
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Scheme 1.6  Lett’s synthesis of the complete scaffold. 
 
It should be noted at this point that the diastereomeric mixture did not worry 
the authors.  They had previously shown during their synthesis of radicicol 2 that 
the mixture of epimers could be carried forward in comparable yields throughout 
all the steps of their sequence.
56 
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a) 0.007 M hydroxy-acid, PPh3, DEAD, toluene, 67 % b) DDQ, DCM, 94 %. c) PCC, 2,5-DMP,
DCM, 62 %. d) pTsOH, DCM/MeOH, 76 %. e) MCPBA/NaHCO3 17 %.  
Scheme 1.7  Lett’s macrolatonisation and completion of the synthesis. 
 
Macrolatonisation of 41 via Mitsunobu conditions afforded the desired macrolide 
42 with complete inversion of configuration at C10’.  Completion of the synthesis 
proved troublesome, but an effective route was found involving an interesting 
oxidation  step  that  differentiated  between  the  two  diasteroisomers.  
Deprotection  of  the  PMB  group  gave  the  free  hydroxyl  at  the  C6’  position.  
Oxidation of this hydroxyl proved difficult and the authors decided to cleave the 
acetonide group to form the triol which was the precursor to Tatsutas
50 final 
compound.  Tatsuta reported this final step to be tricky and reported that only Murray N Robertson, 2009    Chapter 1, 31 
Dess Martin reagent was effective.  Lett also had problems at this stage and did 
not report any successful attempts at converting the triol into the desired final 
product 3.  Lett did have success however treating the epimeric mixture of free 
hydroxyls at the C6’ position with PCC in the presence of 2,5 dimethylpyrazole.  
The  major  epimer  was  converted  quantitatively  into  the  Z enone  while  the 
minor  one  was  recovered  unchanged.    It  was  then  found  that  fast  Jones 
oxidation  of  the  recovered  minor  epimer  gave  the  desired  Z  enone  in  35  %.  
Finally, acetonide cleavage, 76 %, gave the desired LL Z1640 2 3 in a total of 26 
linear steps and an overall yield of 1.2 % (Scheme 1.7). 
As part of Lett’s investigation into the flexible synthesis of LL Z1640 2 3, he 
looked into intermolecular Suzuki couplings as another approach to building the 
14 membered macrocycyle (Scheme 1.8). 
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Scheme 1.8  Lett’s Suzuki coupling approach. 
 
The synthesis towards the Suzuki coupling precursor was very similar to his initial 
approach.  Vinyl iodide 43 was obtained using the same procedure as to obtain Murray N Robertson, 2009    Chapter 1, 32 
33 (Scheme 1.3) but (S) propylene oxide was opened to give the S derivative.  
The  condensation  of  subunits  38  and  43  and  further  steps  to  44  were  also 
carried  using  the  same  procedures  as  before.    The  acid  derivative  46  was 
obtained  quantitatively  from  methyl  ester  28  using  sodium  hydroxide.    TBAF 
deprotection of 44 followed by DCC esterification of alcohol 45 and acid 46 gave 
the intramolecular Suzuki precursor 47 in 74 % over the two steps. 
Optimised  conditions  for  the  intramolecular  Suzuki  coupling  were  found  on 
model systems.  These showed best results were obtained when excess Sia2BH 
was  destroyed  by  the  addition  of  anhydrous  acetone.    After  this  addition  of 
acetone, a successful Suzuki coupling was achieved.  However, when applying 
these conditions to alkyne 47, the desired macrolide 42 was isolated in 15 %.  
Interestingly, studies were also carried out on similar systems, compounds 48 
and 49 (Figure 1.11) It was assumed that these systems should be energetically 
more favoured by less ring strain and steric interactions but these gave no trace 
of corresponding macrocycles. 
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Figure 1.11  Energetically favoured compounds 48 and 49. 
 
1.15  Modular Synthesis Approach 
Most  recently,  a  third  total  synthesis  of  LL Z1640 2  3  was  published  by 
Wissinger.
9  Their work took advantage of fluorous isolation technology which 
allowed the synthesis of LL Z1640 2, radicicol A 50 and a radicicol A analogue 51 
in the same mixture (Figure 1.12).  This technique  was also advantageous to 
future  work  as  the  system  could  be  potentially  automated  opening  up  the 
possibilities of high throughput synthesis. 
O
OH
MeO
O
O
OH
HO
O
OH
MeO
O
O
OH
HO
OMe Cl
50 51  
Figure 1.12  Radicicol A 50 and Radicicol A analogue 51 Murray N Robertson, 2009    Chapter 1, 33 
 
In Wissinger’s approach the aromatic fragments 55 57 were synthesised in two 
steps from the acids 52 54 by esterification with 2 (trimethylsiyl)ethanol and 
successive  formation  of  the  selenide  using  LDA  to  deprotonate  the  benzylic 
position (Scheme 1.9).This two step stage was achieved in yields between 85 89 
%. 
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Scheme 1.9  Wissinger’s aromatic fragments 55 57. 
 
Reduction of 58 with LiAlH4 followed by selective silyl protection and oxidation 
using an immobilised version of IBX afforded the aldehyde 59 in 63 % over 3 
steps (Scheme 1.10). 
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a-c
 
Scheme 1.10  Wissinger’s approach to intermediate 59. 
 
The longest linear sequence of the synthesis began with the protection of (R) 2 
hydroxypentene 60 with the fluorous version of PMB trichloroacetimidate.  Cross 
metathesis  with  vinyl  borolane  afforded  the  trans vinyl  borolane  61  with  a 
stereoselectivity better than 20:1 E:Z and a yield of 85 % over the two steps.  
Trans vinylborolane  61  was  then  stereospecifically  converted  to  the  cis vinyl 
bromide 62 following a procedure by Brown et al.
57  Treatment of 62 with tBuLi 
and  addition  of  aldehyde  59  followed  by  EOM  protection  afforded  63  as  a 
mixture of diastereoisomers (3:1).  The silyl protected hydroxyl was converted 
to the iodide in two steps to give compound 64 (Scheme 1.11). Murray N Robertson, 2009    Chapter 1, 34 
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II, toluene, 92 %. c) Br2, Et2O, NaOMe, 89 %. d) t-BuLi, THF/Et2O, 59, 88%. e) EOMCl, iPr2EtN,
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Scheme 1.11  Wissinger’s approach to intermediate 64. 
 
Iodide 64 was then alkylated with the three different aromatic fragments 55 57 
and the selenide was oxidised and eliminated with hydrogen peroxide to give 
compounds 65 67.  The use of the fluorous tag enabled this work to be carried 
out  without  the  need  of  traditional  workups  and  purification.    The  crude 
reaction mixtures were simply loaded onto fluorous silica and eluted with 75 % 
MeOH  in  water  to  remove  all  non florous tagged  components.    The  tagged 
compounds  were  then  recovered  in  the  MeOH  wash.    The  PMB  group  was 
removed with DDQ while the TMSE ester was cleaved using TBAF.  Mitsunobu 
macrocylisation  using  fluorous tagged  triphenyl  phosphine  and  diazo 
dicarboxylate gave the macrocycles 68 70 that were also recovered using the 
fluorous solid phase extraction method.  BCl3 cleaved the EOM, acetonide group 
and selectively the ortho phenol, in the presence of the other methyl ethers, in 
one  step.    The  allylic  alcohols  were  then  oxidised  with  the  polymer  bound 
version of IBX to afford LL Z1640 2 3, Radicicol A 50 and the radicicol analogue 
51.  In total the longest synthetic sequence contained 14 linear steps and the 
three macrocyles 3, 50 and 51 were obtained in an excellent 14.6 17.3 % yield 
(Scheme 1.12). Murray N Robertson, 2009    Chapter 1, 35 
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Scheme 1.12  Wissinger’s macrolactonisation and completion of the synthesis 
 
1.16  Retrosynthetic Analysis 
As part of our approach we envisioned a flexible and robust synthesis of LL 
Z1640 2 3 as originating from the macrolactonisation of acids 70/71 or from a 
Grubbs’ catalyst mediated ring closing metathesis (RCM) of dienes 72/73.  The 
acids 70/71, in turn could be the product of the cross methathesis of aryl alkene 
80 and the complete straight chain fragments 74/75.  Alternatively, dienes 72, 
73 could be the product of an esterification of acid 80 and complete straight 
chain fragments 74/75.  This flexibility in our approach was advantageous as we 
could foresee potential problems with the ring closing step due to the size and 
functionality of compounds 70 73 (Scheme 1.13). Murray N Robertson, 2009    Chapter 1, 36 
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Scheme 1.13  Retrosynthetic Analysis 
 
The  complete  C1’ C10’  straight  chain  fragments  74/75  was  thought  to  best 
originate from alkyne 76 and aldehyde 77.  Aldehyde 77 is the oxidised product 
of the Wittig olefination of 2 deoxy D ribose 79.  The aromatic fragment 80 was 
thought  best  to  come  from  commercially  available  methyl  2,4,6 
trihydroxybenzoate 81. 
It should be noted that the timing of the oxidation of the alcohol at position C6’ 
in the final ring and the selective reduction of the alkyne to the required  Z 
alkene were both variable within our original plan.  This again gave us more 
flexibility and thus, making our approach more desirable. Murray N Robertson, 2009    Chapter 1, 37 
Allowing for the use of suitable orthogonal protecting groups it was proposed to 
make  protected  derivatives  of  74/75  and  80  both  in  5  steps  respectively.  
Coupling of the two fragments and the remaining steps were also proposed to 
take 5 or 6 steps.  This proposed route therefore formed the basis of a robust, 
cost and step efficient route which should allow the target compound 3 and it’s 
related structures to be considered as realistic chemical biological leads for the 
first time.     38 
2  Results and Discussion 
2.1 Synthesis of the C1’-C10’ Unit 
The synthesis of the C1’ C10’ unit began with the Wittig olefination of 2 deoxy D 
ribose  79  using  the  stabilised  ylide,  methyl(triphenylphosphoranylidene) 
acetate, which afforded the desired triol 82 in 83 % and as a 9.5:1 E:Z ratio of 
diastereomers (Scheme 2.1). 
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Scheme 2.1  Wittig olefination of 2 deoxy D ribose 79 
 
The olefination proceeded due to the masked aldehyde character of C1 in the 
sugar.  This was then exploited via Wittig conditions (Scheme 2.2). 
O
RO
OR
O
OR
OR
O
OH
OR
OR
OH
R
R = H / PG
H
84 85 86
H
 
Scheme 2.2  Wittig chemistry on sugars. 
 
The  primary  alcohol  was  selectively  protected  as  the  TBS  ether  83  and  the 
remaining vicinal diol was then converted into the dimethyl ketal unit 87 in good 
overall yield (83 % and 86 % respectfully). 
Initial attempts at the deprotection using TBAF resulted in the production of the 
pyran unit 88 with none of the desired free alcohol 89 being isolated.  Although 
disappointing, this was not surprising considering  the relative basic nature of 
TBAF and the presence of the dimethyl ketal unit, which might be facilitating 
the  cyclisation  via  the  Thorpe Ingold  Effect.
58    Deprotection  using  HF pyr 
however yielded the required primary alcohol 89 in 98 % with no evidence of any 
cyclisation product 88 (Scheme 2.3). Murray N Robertson, 2009    Chapter 2, 39 
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Scheme 2.3  TBS deprotection and formation of undesired pyran unit 88. 
 
Faced  with  the  competing  cyclisation  process  during  the  deprotection  step 
coupled with the need to protect and then de protect the primary alcohol unit, 
it  was  decided  that  ketal  protection  of  the  carbohydrate  starting  material 
followed  by  olefination  of  the  resulting  lactol  might  prove  a  more  efficient 
process (Scheme 2.4). 
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Scheme 2.4  Ketal protection of 2 deoxy D ribose 
 
Our initial ketal introduction attempts were based on the procedure reported by 
Horton  and  co workers.
59    Unfortunately,  reproducible  and  acceptable  yields 
were hard to maintain especially during scaling up.  Conditions were then tested 
to optimise the step (Table 2.1). 
Faced with an unreliable method for the scaling up of the first step of a total 
synthesis  prompted  us  to  develop  an  improved  and  optimised method,  which 
could be readily and reproducibly scaled up.  We were particularly concerned 
about the use of DMF in the initial procedure.  DMF was used to deal with the 
poor  solubility  of  the  starting  material  79  but,  especially  on  larger  scale 
reactions,  the  DMF  caused  issue  during  the  reaction  work  up.    Either  large 
amounts  of  water  had  to  be  used  to  remove  the  DMF  completely,  or  higher 
temperatures than normal had to be used during concentration under vacuum.  Murray N Robertson, 2009    Chapter 2, 40 
Unfortunately, it was found that the protected lactol 58 was very soluble in 
water and could only be extracted through the use of highly polar solvents like 
EtOAc.  The use of EtOAc on the other hand, resulted in the DMF being extracted 
also from the aqueous phase.  An alternative approach to the aqueous work up 
was  to  simply concentrate the  reaction.   However, temperatures  required to 
remove large amounts of DMF resulted in decomposition of any product formed. 
As part of our optimisation steps different combinations of solvents, catalyst and 
ketal generating reagents were explored.  It was found that by switching from 
DMF to EtOAc as the solvent greatly improved yields.  Furthermore, EtOAc could 
be  easily  removed  under  vacuum  at  lower  temperature  as  to  avoid 
decomposition of product.  The best combination of conditions included using 2 
methoxy propene in EtOAc and  using  PPTS  as  a  catalyst  (86  %  yield).    These 
conditions were reproduced on a larger scale with only a small drop in yield.(75 
80 %). Murray N Robertson, 2009    Chapter 2, 41 
Table 2.1  Conditions for ketal protection 
  Solvent  Reagent  Catalyst 
Temperature 
(˚C) 
Time 
(h) 
Yield 
(%) 
1  DMF  2MP  pTSA  0  1  33 
2  DMF  2MP  pTSA   10  1  40 
3  DMF  2MP  CSA   10  1  34 
4  DMF  2MP  PPTS   10  1  42 
5  DMF  2,2DMP  pTSA   10  1  38 
6  DMF  2,2DMP  CSA   10  1  67 
7  DMF  2,2DMP  PPTS   10  1  43 
8  Toluene  2,2DMP  CSA   10  1  0 
9  Acetone  2,2DMP  CSA   10  2  17 
10  EtOAc  2,2DMP  CSA   10  6  72 
11  EtOAc  2,2DMP  PPTS   10  6  78 
12  EtOAc  2MP  PPTS   10  6  86 
13  EtOAc  2MP  pTSA   10  6  43 
2 methoxypropane (2MP), 2,2 dimethoxypropane (22DMP),  
 
Wittig  olefination  of  the  protected  sugar  58  with  stabilised  ylide, 
methyl(triphenylphosphoranylidene) acetate gave the desired E alcohol 89 in 89 
%  yield.    Traces  of  the  Z  olefin  were  also  recovered  but  were  impure  and 
contained traces of the E product and further side products of the reaction.  The 
alcohol 89 was then oxidised under Swern conditions to generate the desired 
aldehyde 90 in quantitative yield (Scheme 2.5). 
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Scheme 2.5  Synthesis of aldehyde fragment 90. 
 
Having successfully generated the desired aldehyde 90 the introduction of the 
remaining part of the C1’ C10’ unit as an alkyne block was explored. Murray N Robertson, 2009    Chapter 2, 42 
There were initial concerns that the presence of the ester unit would render the 
molecule  too  unstable  to  undergo  a  successful  nucleophilic  addition.    It  was 
quite feasible for the protons gamma to the ester unit could be removed under 
basic  conditions  employed,  resulting  with  delta elimination  of  the  ketal  unit 
through the expulsion of acetone (Scheme 2.6). 
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Scheme 2.6  Possible delta elimination of the ketal unit mechanism. 
 
Another, relatively minor concern was the possibility that the alkoxy generated 
during the reaction could potentially perform a conjugated addition onto the 
conjugated ester unit similar to that observed during the deprotection of 87 
(Scheme 2.3). 
The  required  coupling  was  initially  tested  using  aldehyde  90  and  alkyne  94 
(obtained in 88 % yield through the TBS protection of the commercially available 
3 butynol).  Initial attempts using n BuLi and KHMDS as bases to generate the 
corresponding alkynyl anion failed to give any product and only yielded starting 
materials.  Lewis acid catalysts (BF3 etherate and zinc triflate additives) were 
also  evaluated,  but  no  desired  product  could  be  detected.    Carreira’s 
conditions
60  were  also  attempted,  however,  just  as  in  the  previous  case,  no 
alkyne addition was observed (Scheme 2.7). 
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Scheme 2.7  Attempted test coupling of aldehyde 90 and alkyne 94 
 Murray N Robertson, 2009    Chapter 2, 43 
The  inability  of  the  alkyne  to  add  successfully  under  both  lithium  and  zinc 
promoted  conditions  prompted  us  to  consider  the  use  of  a  different  metal 
counter  ion  during  the  addition  process.    Treatment  of  alkyne  94  with 
ethylmagnesium bromide at a low temperature (–78 ˚C) failed to deprotonate 
the alkyne unit 94, affording instead the ethyl addition product 96 when treated 
with aldehyde 90 (Scheme 2.8).  
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Scheme 2.8  Failed ethylmagnesium bromide deprotonation of of alkyne 94 
 
Treatment  of  alkyne  94  with  ethylmagnesium  bromide  at  room  temperature 
successfully generated the magnesium acetylide which upon trapping with the 
aldehyde  90  gave  the  desired  alkyne  product  97  as  a  50:50  mixture  of 
diastereomers  in  88  %  yield  based  on  aldehyde  recovered  (Scheme  2.9).    It 
should also be noted that no 1,4 addition side products was detected either. 
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Scheme 2.9  Successful coupling of units 90 and 94  
 
Having successfully achieved the addition of the alkyne model unit, we turned 
our attention to making the desired optically pure alkyne.  Lithium acetylide 
ethylene diamine complex 98 was coupled with S propylene oxide 78 to give the 
crude  volatile  alkynol  76  which  was  immediately  protected  to  afford  the 
required homo propargylic silyl ether 99 in 71 % over 2 steps (Scheme 2.10)  Murray N Robertson, 2009    Chapter 2, 44 
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Scheme 2.10  Synthesis of fragment 99. 
 
The TBS protected alkyne 99 was then treated with ethylmagnesium bromide 
under same conditions as those used in the model system and the resulting anion 
was added to aldehyde 90 to yield propargylic alcohol 100 as a 60:40 mixture of 
diastereomers in 69 % yield based on aldehyde recovered (Scheme 2.11).  The 
propargylic alcohol diastereomeric mixture was then oxidised using TPAP/NMO 
conditions (59 %) and under Swern conditions (21 %) to give the spectroscopically 
simpler  alkynone  101  that  was  used  to  corroborate  the  structure  of  the 
compound. 
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Scheme 2.11  Coupling of fragments 90 and 99 and oxidation. 
 
Having successfully introduced the fully elaborated side chain with no apparent 
side  products  being  formed,  attempts  were  then  made  to  selectively  reduce 
alkynol 100 to the necessary Z alkene 102.  Despite the apparent simplicity of 
the step, this transformation proved to be extremely troublesome and resulted 
in  a  large  amount  of  optimisation  work  before  the  reaction  proceeded 
successfully (Table 2.2).  Murray N Robertson, 2009    Chapter 2, 45 
Table 2.2  Conditions for selective reduction of 100 to Z alkene 102 
  Catalyst  Quinoline  Solvent  Product 
1  Toluene  SM  
2 
Palladium 5 wt % on calcium 
carbonate unreduced 
No 
MeOH  SM  
3  Toluene  SM  
4 
Palladium 5 wt % on calcium 
carbonate, poisonied with lead 
No 
MeOH  SM  
5  Toluene  SM  
6 
Palladium 5 wt % on barium sulphate 
unreduced 
No 
MeOH  77 % 
7  Toluene  SM  
8 
Palladium 5 wt % on calcium 
carbonate unreduced 
Yes 
MeOH  SM  
9  Toluene  SM  
10 
Palladium 5 wt % on barium sulphate 
unreduced 
Yes 
MeOH  83 % 
 
Surprisingly,  most  conditions  were  unsuccessful  with  the  only  reproducible 
results being obtained with Palladium on barium sulphate using MeOH as the 
solvent.    The  newly  obtained  alkenol  diastereomeric  mixture  102  was  then 
oxidised under TPAP/NMO conditions (26 %) to generate the enone 103.  Also 
recoverd  from  the  reaction  was  alkyneone  101  and  alkyneol  100  as  impure 
fractions.  This was expected though as the hydrogenation was never recorded as 
quantitative.  Enone 103 was used to corroborate the structure of alkene ol 102 
(Scheme 2.12). Murray N Robertson, 2009    Chapter 2, 46 
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Scheme 2.12  Alkyne reduction of 100 and oxidation. 
 
2.2 Synthesis of the Aromatic Fragment 
With the 10 carbon skeleton now in place, our attention was directed towards 
the synthesis of the aromatic fragment.  Our synthesis began with commercially 
available methyl 2,4,6 trihydroxybenzoate 81 which was methylated selectively 
to afford the desired diphenol 104.  Mono protection of diol 104 then proceeded 
in good yield to give the TBS silyl ether 105.  Initial attempts at converting the 
remaining hydroxyl group into the corresponding triflate 106 resulted in partial 
cleavage of the TBS group, yielding 107.  It was likely that this cleavage could 
be due to the acid (1 M HCl) workup.  Subsequent attempts using citric acid 
during the workup gave the protected triflate 106 in quantitative yield.  Stille 
coupling of the newly generated triflate 106 with vinyltributyl tin proceeded in 
excellent yield to afford the vinyl benzene unit 108, interestingly, the TBS group 
was removed once again during the procedure (Scheme 2.13). 
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a) TMS-CH2N2, CHCl3, MeOH, 98 %. b) TBSCl, Et3N, DCM, 100 %. c) Tf2O, Pyr, 98 %. d)
tributyl vinyl tin, Pd(PPh3)4, 97 %.  
Scheme 2.13  Synthesis of vinyl aromatic unit 108 
 Murray N Robertson, 2009    Chapter 2, 47 
The difficulties that arose with the relative instability of the TBS group during 
the synthesis of the vinyl benzene unit 108 made us reconsider our choice of 
protecting group.  A different protecting group also had the potential to ease 
possible conflicts and cross reactivity issues in future steps.  As an alternative to 
the labile TBS group the introduction of the trityl, TBDPS and MOM groups was 
explored. 
Treatment of diol 104 with either TrtCl or TBDPSCl afforded the desired trityl 
and  TBDPS  mono  protected  products  109  and  110  in  39  %  and  99  %  yields 
respectively, no bis protected product was isolated.  The MOM derivative proved 
to be more difficult.  Initial attempts using MOMCl resulted in a mixture of mono 
111 and bis protected 114 products in 16 % and 83 % yields respectively (Scheme 
2.14).  Unfortunately, the lack of commercial availability of MOMCl meant that it 
was not possible to optimise the production of 111.  The same protection was 
attempted using MOMBr, however, this yielded none of the desired product 111 
and resulted in complete decomposition of the starting material.  No compound 
of any use was isolated from the reaction. 
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Scheme 2.14  Alternative protecting group strategies for aromatic unit 104. 
 
The  remaining  hydroxyl  group  on  109  and  110  was  converted  to  the 
corresponding triflates  112 and  113 using the citric acid workup as for 106.  
Triflates 112 and 113 were both obtained in 99 % yield. Murray N Robertson, 2009    Chapter 2, 48 
2.3 Cross Couplings 
Having  successfully  completed  the  synthesis  of  the  C1’ C10’  and  aromatic 
fragments of LL Z1640 2 3, the key cross metathesis couplings were attempted.  
Having a limited amount of the C1’ C10’ ester, cross metathesis was attempted 
between the aromatic alkene unit and a model conjugated ester unit 118. 
The  test  coupling  partner  118  was  synthesised  quickly  from  pentane 1,5 diol 
115 in 3 steps.  Mono protection of diol 115 using stoichiometric NaH afforded 
the  silyl  ether  116  in  94  %.
61    The  alcohol  was  then  oxidised  under  Swern 
conditions to yield the aldehyde 117 in 77 % and finally Wittg olefination of 
aldehyde  117  using  the  stabilised  ylide,  methyl(triphenylphosphoranylidene) 
acetate, afforded the desired conjugated ester 118 in 56 % (Scheme 2.15). 
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Scheme 2.15  Synthesis of test coupling partner 117. 
 
2.4 Olefin metathesis 
Metathesis, with its numerous aspects, has become one of the most important 
chemical reactions and is now extremely useful.
62 
The name metathesis was given for the first time to this reaction by Calderon in 
1967
63 but it was first observed 1931.  Catalysed metathesis reactions were first 
reported  in  the  1950’s  by  industrial  chemists  at  Du  Pont,  Standard  Oil  and 
Phillips  Petroleum  when  they  reported  that  propene  led  to  ethylene  and  2 
butenes when it was heated with molybdenum.
62 
Classically cross metathesis is the coupling of two terminal alkenes under release 
of  ethene,  catalyzed  by  transition  metal  catalyst  (ruthenium,  molybdenum, 
tungsten).  In theory, the reaction can lead to three possible pairs of geometric 
isomers, the E/Z pairs for two homocouplings and the cross coupling products.  
However, there are various examples of two alkenes with different reactivity 
giving  the  cross coupled  product  with  excellent  yields  and  excellent 
selectivity.
64 Murray N Robertson, 2009    Chapter 2, 49 
Hérison  and  Chauvin  first  proposed  the  widely  acknowledged  mechanism  of 
transition metal alkene metathesis in 1971.
65  The direct [2+2] cycloaddition of 
two alkenes is formally symmetry forbidden and thus has a very high activation 
energy. The Chauvin mechanism involves the [2+2] cycloaddition of an alkene 
double  bond  to  a  transition  metal  alkylidene  to  form  a  metallocyclobutane 
intermediate 119. The metallocyclobutane 119 produced can then give the new 
alkene 120 and alkylidene 121.  Interaction with the d orbitals on the metal 
catalyst  lowers  the  activation  energy  enough  that  the  reaction  can  proceed 
rapidly at modest temperatures (Scheme 2.16). 
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Scheme 2.16  Cross metathesis mechanism. 
 
Conjugated ester 118 was then used to screen catalysts and conditions to find 
the most suitable for the actual coupling of 100 and 101. 
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Scheme 2.17  Cross metathesis model system. 
 
The aromatic unit 107 was used in test couplings with the conjugated ester 118.  
At the same time it was decided to screen commercially available styrene 122.  
It was chosen due to it being readily available and it also had the advantage of Murray N Robertson, 2009    Chapter 2, 50 
not having any electron withdrawing groups which could result in an electronic 
mismatch (Scheme 2.17) 
Unfortunately, no desired coupling was observed during our screen of Grubbs’ 
First and Second generation catalyst.  The ratios of the partners were varied 
from 1:1 to 2:1 in favour of both partners.  Reaction time was also adjusted from 
6 hours to 24 hours.  Microwave assisted reactions were also investigated but 
none of the examples shown below (Table 2.3) yielded any desired product. 
Table 2.3  Grubbs’ cross coupling conditions. 
  Partner   
Temp. / 
Time 
  Partner   
Temp. / 
Time 
  107  117  Cat  (˚C)  (h)    121  117  Cat  (˚C)  (h) 
1  1 eq  1 eq  1
st  45  6  11  1 eq  1 eq  1
st  45  6 
2  1 eq  1 eq  2
nd  45  6  12  1 eq  1 eq  2
nd  45  6 
3  1 eq  2
 eq  1
st  45  6  13  1 eq  2 eq  1
st  45  6 
4  1 eq  2
 eq  2
nd  45  6  14  1 eq  2 eq  2
nd  45  6 
5  2
 eq  1 eq  1
st  45  6  15  2 eq  1 eq  1
st  45  6 
6  2
 eq  1 eq  2
nd  45  6  16  2 eq  1 eq  2
nd  45  6 
7  2
 eq  1 eq  1
st  45  24  17  2 eq  1 eq  1
st  45  24 
8  2
 eq  1 eq  2
nd  45  24  18  2 eq  1 eq  2
nd  45  24 
9  2
 eq  1 eq  1
st  110  0.5  19  2 eq  1 eq  1
st  110  0.5 
10  2
 eq  1 eq  2
nd  110  0.5  20  2 eq  1 eq  2
nd  110  0.5 
 
The only new compound to be isolated and characterised from any of the above 
reactions  was  dimerised  styrene  123  from  the  reactions  11 20.    With  these 
disappointing results from the screen it was thought best to look into different 
coupling partners as the use of conjugated esters in cross metathesis did not 
look promising. 
In an attempt to make another potential Grubbs coupling partner, alkyneol 100 
was treated with DIBAL H to give diol 124 in a quantitative yield (Scheme 2.18).  
Cross coupling of diol 124 and aromatic fragment 107 also failed. Murray N Robertson, 2009    Chapter 2, 51 
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Scheme 2.18  Reduction of 100 to form coupling partner 124. 
 
2.5 A New Approach to the C1’-C10’ Unit 
As part of our new approach, it was decided to remove the ester functionality 
from  the  alkene  unit.    Wittig  olefination  of  the  dimethyl  ketal  protected  2 
deoxy D ridose 58 using methyltriphenyl phosphonium iodide gave the desired 
terminal alkene 125 in reasonable yield.
66  Unfortunately, oxidation of the newly 
formed alcohol 125 generated a very unstable aldehyde 126 which decomposed 
within minutes of being formed.  At the moment, we still cannot account for the 
reasons behind the aldehydes inherent instability (Scheme 2.19). 
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Scheme 2.19  Synthesis of terminal olefin 125 and subsequent oxidation. 
 
In an attempt to increase the stability of aldehyde 126 the olefins substitution 
was increased.  As such, the gem dimethyl 127 and the phenyl substituted 128 
olefins were generated from the corresponding ylides in 56 % and 67 % yield 
respectively (Scheme 2.20).  Olefin 128 was obtained as an inseparable mixture 
of E:Z diastereomers. Murray N Robertson, 2009    Chapter 2, 52 
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Scheme 2.20  Wittig derivatives of 125 and their corresponding aldehydes. 
 
The  newly  obtained  alcohols  were  then  oxidised  under  Swern  conditions  to 
generate the desired aldehydes 129 and 130 in good yields.  Significantly, in 
contrast  to  the  terminal  olefin  126,  these  newly  generated  aldehydes  were 
stable  enough  to  be  purified  by  flash  column  chromatography.    A  sample  of 
aldehyde 130 was stable enough to be stored for months in the freezer without 
any noticeable decomposition. 
With stable aldehydes now being accessible, the next step was to introduce the 
required  alkyne  unit.    A  similar  system  using  (triisopropylsilyl)acetylene  was 
employed to test conditions.  As in previous cases, deprotonation of the alkyne 
could not be effectively achieved when using either n BuLi or KHMDS as bases.  
The best result obtained through this method was a non reproducible 28 % yield 
for the generation of alkynol 131 from aldehyde 130 (Scheme 2.21) 
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Scheme 2.21  Alkynye coupling of aldhyde 130. 
 Murray N Robertson, 2009    Chapter 2, 53 
Despite  having  been  able  to  successfully  synthesise  the  desired  aldehyde 
intermediates, the alkene substitution presented a potential problem which we 
felt could present an insurmountable obstacle later in the synthesis.  Therefore 
alternative routes were investigated for the generation and manipulation of the 
terminal  olefin,  which  would  have  a  better  chance  of  success  in  the  cross 
metathesis coupling.  A possible route was found via the mixed anhydride 133.
67  
This could then be coupled with lithium acetylide to yield the acetylenic ketone 
134 directly (Scheme 2.22). 
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complex.  
Scheme 2.22  Jones Oxidation of 125 and alternative approach to alkyne addition. 
 
Alcohol 125 was oxidised to carboxylic acid 132 using Jones reagent in an un 
optimised 42 %.  The low yield can be accounted for as the oxidation goes via 
the unstable aldehyde 126 (Scheme 2.23). 
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Scheme 2.23  Jones Oxidation Mechanism. 
 Murray N Robertson, 2009    Chapter 2, 54 
The  resulting  carboxylic  acid  132  was  treated  with  triethylamine  and  ethyl 
chloroformate to yield the mixed anhydride  133 in a poor 11 % yield with a 
further 15 % starting material recovered.  Lithium acetylide, ethylenediamine 
complex  was  treated  with  the  crude  mixed  anhydride  133,  but  no  desired 
acetylenic ketone 134 was isolated.  With the two previous low yielding steps 
and a troublesome third step our attention focused on other routes towards the 
aliphatic chain. 
2.6 One-Pot Oxidation Alkyne Coupling 
Before looking to radically change our overall synthetic route towards LL Z1640 
2 3, it was decided to have one more look at the oxidation of compound 125.  In 
previous efforts, as part of the oxidation step consumption of starting material 
was observed.  In some cases, traces of the aldehyde were detected in the crude 
1H NMRs.  This led us to believe that the aldehyde was being produced, but was 
decomposing within minutes of being formed.  This raised the possibility that a 
successful addition might be possible by trapping the crude aldehyde with the 
Grignard acetylide in a one pot process. 
As  part  of  our  modified  procedure,  alcohol  125  was  oxidised  under  standard 
Swern  conditions  and  quenched  with  triethylamine.    The  reaction  was  then 
stirred at room temperature for 30 minutes and treated with ethyl magnesium 
bromide.  After 2 hours the desired alcohol 140 was isolated as a mixture of 
diastereomers in a good yield of 66 % (Scheme 2.24).   
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Scheme 2.24  One pot oxidation alkyne coupling. 
 
Based on this primary result, the same one pot procedure was applied to the 
coupling  of  the  crude  aldehyde  126  with  the  Grignard  acetylide  to  produce 
alkyneol 141 (Scheme 2.25).  The Grignard acetylide was prepared using the 
same conditions as to make alkyne 100.  Murray N Robertson, 2009    Chapter 2, 55 
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Scheme 2.25  Coupling of desired fragments 99 and 125 and synthesis of coupling partners 
143 and 145 
 
Alkyneol  141  was  produced  and  isolated  in  54  %  yield  as  a  mixture  of 
diastereomers.    This  was  extremely  encouraging  considering  the  apparent 
instability of the aldehyde intermediate.  The free alcohol was protected with 
the bulky TIPS group to give the disilyl compound 142.  The TBS group was then 
selectively removed using HF.Pyr to give the free secondary alcohol 143 in 60 % 
yield.  An alternative route in which the alkynone unit was introduced earlier in 
the synthesis was pursued by oxidising 141 to the alkynone 144 under Swern 
conditions,  94  %.    TPAP/NMO  and  manganese  dioxide  oxidations  were  also 
attempted,  the  yields  were  significantly  lower  (66  %  and  12  %  respectively).  
Attempts to remove the secondary TBS group of ketone 144 yielded none of the 
desired product  145.  Consumption of starting material was observed but no 
alcohol product 145 was observed (Scheme 2.25). Murray N Robertson, 2009    Chapter 2, 56 
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Scheme 2.26  Hydrogenation of alkyne 146. 
 
Once the alkyne unit was in place, the selective hydrogenation to generate the 
desired Z olefin was attempted.  The secondary free hydroxyl group was first 
protected  as  a  TMS  ether  using  trimethylsilyl  chloride  in  93  %.    Surprisingly, 
hydrogenation under the previously optimised conditions failed to generate any 
of the desired alkene 148, affording instead the terminal alkane unit 147 in 12 
%.    Terminal  alkene  bond  over  reduction  is  unusual,  as  there  are  examples 
showing similar alkyne reductions in the presence of alkenes in the literature.
68  
However,  a  similar  example  of  over  reduction  has  been  shown  within  the 
Marquez group on a related framework (Scheme 2.26).
69 
2.7 Alkyne Protecting Group Optimisation 
Based on the difficulties observed during the removal of the TBS group and with 
the aim of getting a higher yield between the protecting group manipulation 
steps (141 to 143), the protecting group was changed.  The TBS silyl ether was 
exchanged  for  a  PMB  group  which  was  introduced  to  the  crude  alkyne  76, 
previously discussed, in excellent yield (Scheme 2.27). 
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a) 78, DMSO. b) PMBCl, NaH, DMF, 83 %.
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Scheme 2.27  Alterative PMB protection of 76 
 
The  newly  formed  PMB  protected  alkyne  149  was  converted  to  the  Grignard 
acetylide and was coupled to the acetonide unit 125 via a similar one pot Swern 
oxidation Grignard addition coupling step in 54 % giving the desired product 150 Murray N Robertson, 2009    Chapter 2, 57 
as a 55:45 mixture of diastereomers.  Protection of the secondary alcohol as the 
TBS ether yielded the orthogonally protected unit 151 in 85 %.  Treating ether 
151  with  DDQ  selectively  removed  the  PMB  group  and  gave  the  desired 
secondary alcohol 152 in 81 % (Scheme 2.8). 
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Scheme 2.28  Coupling of 125 and 149 and protecting group manipulation 
 
With both the PMB ether 150 and the free alcohol 152 efficiently synthesised 
they were now ready to be coupled to the aromatic fragment.  However, due to 
previous difficulties encountered during the cross metathesis steps a modified 
strategy was pursued allowing the esterification step to take precedence.  This 
would  effectively  change  the  cross  metathesis  into  a  ring  closing  metathesis 
(RCM) and as such increase the possibility of success.  It must be noted that 
although there were some concerns about the geometrical arrangement of the 
reaction, the fact that a 14 membered macrocycle was being generated, gave us 
confidence that the E olefin could be easily accommodated.  To minimise the 
chances of side reactions, it was decided to mask the free hydroxyl unit on the 
aromatic unit 108 using MOMCl to give the MOM ether 153 in 97 %.  As stated 
previously, the commercial availability of MOMCl became a problem during the 
course of this research and further attempts to make 153 had to be approached 
using MOMBr.  Similar to before, the MOMBr based reactions did not yield any 
product and results in degradation of the starting materials.  Base hydrolysis of 
ester 153 using sodium hydroxide gave the desired carboxylic acid 154, which 
was visible upon analysis of the crude reaction mixture but unstable to column 
chromatography (Scheme 2.29). Murray N Robertson, 2009    Chapter 2, 58 
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a) MOMCl, K2CO3, Et3N, acetone, 97 %. b) NaOH, dioxane, 81 %.  
Scheme 2.29  Formation of acid 154 
 
Coupling  of  the  free  acid  154  with  the  secondary  alcohol  143  was  first 
attempted under traditional Yamaguchi esterification conditions.  The choice of 
Yamaguchi  conditions  was  based  on  the  ample  literature  precedence  for  the 
synthesis of highly functionalized esters under its mild conditions.  The reaction 
is a two step process which starts with the formation of a mixed anhydride 158 
between  Yamaguchi’s  reagent  (2,4,6 trichlorobenzoyl  chloride)  157  and  the 
carboxylic acid 155 coupling partner (Scheme 2.30). 
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Scheme 2.30  Yamaguchi esterification 
 
The  mixed  anhydride  158  then  reacts  with  the  alcohol  in  the  presence  of  a 
stoichiometric amount of DMAP 159, which acts as an acyl transfer reagent, to 
generate the desired ester 163 (Scheme 2.31). 
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Scheme 2.31  Yamaguchi esterification 
 
Treatment of the carboxylic acid 154 with Yamaguchi’s reagent 157 proceeded 
to form the mixed anhydride in situ, however, addition of alcohol 143 failed to 
generate the desired ester 165 (Scheme 2.32). Murray N Robertson, 2009    Chapter 2, 59 
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Scheme 2.32  Yamaguchi esterification of 154 and 143 
 
Interestingly,  we  were  able  to  isolate  and  characterise  the  coupling  product 
which was the product of Yamaguchi’s reagent and the alcohol in 77 % yield, 
compound 164 (Scheme 2.32). 
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Scheme 2.33  Hindrance of path a by rotation of the MOM and vinyl groups of 166. 
 
Although this was disappointing, the formation of ester 164 can be explained by 
considering the Yamaguchi mechanism.  Once the mixed anhydride is formed, we 
believe that DMAP reacts regioselectively at the less hindered carbonyl site.  In 
the above case, the desired route, a, is hindered by rotation of the MOM group 
and of the vinyl group.  The combination of these two groups must be greater 
than that of the chlorines hindrance, route b (Scheme 2.33).  Therefore, the 
DMAP  159  should  attack  the  anhydride  via  route  b  and  the  resulting 
intermediate then reacts with alcohol 143 to give the coupling product 164. 
Faced  with  a  disappointing  Yamaguchi  coupling,  a  Steglich  esterification  was 
then  explored.    The  Steglich  esterification  was  chosen,  based  on  the  same 
rationale  as  the  Yamaguchi  esterification,  namely  it  uses  mild  conditions  to 
esterify sterically demanding substructures. Murray N Robertson, 2009    Chapter 2, 60 
Looking at the mechanism of the Steglich esterification it can be seen that the 
carboxylic acid is activated by the DCC.  This allows the alcohol to attack at the 
desired carbonyl carbon.  Unlike the Yamaguchi, where the sterics dictate the 
approach of the alcohol towards the mixed anhydride, the Steglich esterification 
only has one available carbonyl 170 and should therefore resolve the problems 
encountered during the Yamaguchi esterification attempts (Scheme 2.34). 
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Scheme 2.34  DCC coupling 
 
In addition, DMAP 159 can be added to the reaction as a catalyst.  The DMAP 
159 is a stronger nucleophile than the alcohol 162 therefore it reacts with the 
intermediate  compound  170  leading  to  the  reactive  amide  174.    This 
intermediate cannot form intramolecular side products but reacts rapidly with 
alcohol 162 (Scheme 2.35). Murray N Robertson, 2009    Chapter 2, 61 
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Scheme 2.35  DMAP catalysed DCC coupling 
 
Carboxylic acid 175 was made using the same procedure that was used to form 
acid  154.    For  the  initial  studies,  it  was  decided  to  use  acid  175  without 
protecting the free hydroxyl in the ortho position.  Coupling of the acid 175 with 
the TIPS protected alkynol 143 proceeded in 32 % to afford the desired ester 
unit 176.  The same conditions using the TBS protected derivative 152 gave the 
esterified product 177 in 68 %. 
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Scheme 2.36  DDC coupling of 175 with 143 and 152 
 
With the successful coupling of the two partners in an acceptable yield, it was 
thought  best  to  protect  the  free  hydroxyl  on  the  aromatic  fragment  in  an 
attempt to minimise unwanted side reaction and perhaps improve the yield.  A 
PMB group was introduced to 108 in 95 % yield and hydrolysed to the acid 179 
(Scheme  2.37).    The  PMB  protected  acid  179,  similar  to  the  MOM  protected 
derivative 154, was unstable to column purification and it was thought best to 
carry the acid on crude as it appeared relatively pure by 
1H and 
13C NMR spectra 
(Scheme 2.37). Murray N Robertson, 2009    Chapter 2, 62 
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Scheme 2.37  PMB protection of 108 and subsequent hydrolysis to acid 179 
 
The  coupling  of  acid  179  and  alcohol  152  was  carried  out  using  the  same 
conditions as to make 176 and 177.  This time however the esterified product 
180 was only isolated in 17 % yield (Scheme 2.38). 
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Scheme 2.38  DDC coupling of 179 with 152 
 
Having succeeded at the generation of the ester linkages, a revised end game 
strategy was considered.  After some consideration, it was decided that the ring 
closing metathesis would take precedence over the alkyne hydrogenation step 
(Scheme 2.39).   
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Scheme 2.39  Proposed RCM of 176 and 177 
 
This decision was largely based on the rationale that selective hydrogenation in 
the  presence  of  terminal  alkene  had  proved  troublesome.    There  were  still Murray N Robertson, 2009    Chapter 2, 63 
concerns over the rigidity of the product and whether the presence of the alkyne 
would compete with the alkenes in the presence of Grubbs’ catalyst. 
The key cross coupling was attempted using Grubbs’ First and Second generation 
catalysts.    Unfortunately,  despite  repeated  attempts,  no  desired  products 
181/182 could be isolated.  TLC analysis of the crude reactions indicated that a 
number of side reactions were taking place and consuming all of the starting 
material. 
2.8 Cobalt Complex Work 
Faced with this complete lack of success from the RCM reactions it made us 
consider the real possibility that the alkyne unit might be actively involved in 
the cross metathesis process detrimentally affecting the reaction outcome. 
A number of ways have been developed for the temporary masking of alkyne 
units,  one  of  the  most  widely  used  is  the  use  of  cobalt  hexacarbonyl 
complexes.
70, 71 
In our case, the use of a Co(CO)6 complex was particularly attractive as it would 
not only protect the alkyne unit but it would also modify the molecules overall 
geometry and might improve the RCM’s likelihood of working by reducing the 
strain to be introduced during cyclisation. 
Complete  and  accurate  characterisation  of  these  cobalt  complexes  proved 
difficult as NMR analysis gave broad peaks and loss of resolution.  This resulted 
in  uncharacterisable  spectra  (Figure  2.1).    Obtaining  an  accurate  mass  also 
proved difficult as the complex fragmented very easily under mass spectrometry 
conditions.    It  was  found  though  that  treating  the  deuterated  solvent  with 
sodium  hydrogen  carbonate  and  filtering  the  NMR  sample  through  charcoal 
improved the quality of the spectra of the sample significantly (Figure 2.2). Murray N Robertson, 2009    Chapter 2, 64 
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Figure 2.1  
1H NMR of cobalt complex 183 
 
7 6 5 4 3 2 1 0 ppm
-
0
.
0
2
7
0
.
0
2
9
0
.
0
6
4
0
.
0
9
0
0
.
8
2
9
0
.
8
5
7
0
.
8
6
4
0
.
8
7
5
0
.
9
0
5
1
.
2
4
9
1
.
2
7
2
1
.
2
8
8
1
.
3
2
3
1
.
3
3
9
1
.
3
6
3
1
.
4
0
2
1
.
4
1
4
1
.
4
3
3
1
.
4
5
8
1
.
5
6
0
2
.
1
6
9
2
.
1
9
5
2
.
2
1
6
2
.
3
1
6
2
.
3
2
0
2
.
3
2
4
2
.
3
2
8
2
.
3
3
2
2
.
3
3
6
2
.
3
5
1
3
.
0
7
1
3
.
0
9
1
3
.
1
0
1
4
.
0
1
7
4
.
0
2
2
4
.
0
2
7
4
.
0
3
1
4
.
0
3
7
4
.
0
4
2
4
.
4
8
4
4
.
4
9
2
4
.
5
0
1
4
.
5
0
8
4
.
5
1
6
4
.
5
2
5
4
.
5
3
3
4
.
8
8
4
4
.
9
0
1
5
.
0
6
0
5
.
0
6
4
5
.
0
8
4
5
.
1
0
7
5
.
1
1
0
5
.
7
9
1
5
.
8
1
7
5
.
8
3
4
5
.
8
5
9
7
.
2
6
1
5
.
4
0
7
8
.
2
8
2
2
.
9
9
7
2
.
5
8
1
2
.
7
5
7
1
.
0
7
0
1
.
0
0
1
1
.
8
3
9
1
.
0
3
0
0
.
8
4
5
0
.
8
6
9
1
.
8
1
3
1
.
0
0
0
TBSO
O
O
O
Co
Co
(CO)3
(CO)3
183
 
Figure  2.2   
1H  NMR  of  cobalt  complex  183  after  CDCl3  treatment  and  filtering  through 
charcoal. 
 
Treatment of the RCM precursor 177 with dicobalt octacarbonyl proceeded to 
generate the desired cobalt complex 184 in quantative yield (Scheme 2.40). Murray N Robertson, 2009    Chapter 2, 65 
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Scheme 2.40  Formation of cobalt complex 184 
 
With the cobalt complex now in place, the diene unit 184 was treated with 
Grubbs’ First and Second generation catalysts under varying conditions and with 
different ratios.  Unfortunately, TLC analysis of the crude reactions mixtures 
indicated the formation of multiple products and no desired product 185 was 
ever isolated (Scheme 2.41). 
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Scheme 2.41  Attempted RCM of cobalt complex 184 to macrocycle 185 
 
Having failed to generate the desired macrocylce 185, our last alternative was 
explored in our modified approach.  The alkynone unit 144 was treated with 
dicobalt  octacarbonyl  and  proceeded  to  generate  the  desired cobalt  complex 
186 in quantative yield (Scheme 2.42). 
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Scheme 2.42  Generation of cobalt complex 186 
 Murray N Robertson, 2009    Chapter 2, 66 
With the possibility of the above (Scheme 2.41) system still being too strained an 
effort at cross coupling fragment 108 with 186 was attempted (Scheme 2.43).  
Again, as above, many conditions and ratios of reagents were attempted but no 
desired product 187 was isolated. 
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Scheme 2.43  Attempted cross coupling of 108 and 186 
 
As shown in Scheme 2.25, the silyl deprotection of 144 resulted in decomposition 
of material and no free alcohol was isolated.  Similar conditions were attempted 
with  the  cobalt  complexed  derivative  186  and  this  yielded  the  stable  free 
alcohol 188 in 42 % (Scheme 2.44). 
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Scheme 2.44  Deprotection of 186 
 
This  successful  deprotection  gave  another  possible  coupling  partner  for  the 
esterification step as in (Scheme 2.36).  Under similar conditions however no 
esterified  product  was  isolated  from  the  complex  reaction  mixture  (Scheme 
2.45).  This though was no great loss as alternative, more efficient routes to 
similar  structures  had  already  been  found  and  further  ring  closing  steps  had 
proved to be troublesome. Murray N Robertson, 2009    Chapter 2, 67 
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Scheme 2.45  Attempted coupling of 175 and 188 
 
2.9 Alternative Metal Couplings 
Based on the difficulties encountered during the final RCM step of the synthesis 
and its continuous failure despite extensive experimentation, a new approach 
was developed. 
Our  new  approach  was  based  on  our  previous  results  which  showed  that 
tributyl(vinyl)tin  underwent  an  efficient  Stille  Coupling  with  the  aromatic 
triflate 106.  Furthermore, results obtained previously in the group have showed 
that  substituted  vinyl  stannanes  can  also  couple  efficiently  with  aromatic 
triflates.   
Hence in our new approach we proposed to couple the aliphatic C1’ C10’ chain to 
the aromatic unit via an alternative metal mediated coupling. 
2.10  Stille Coupling 
The homologation of aldehydes to E alkenylstannanes using Bu3SnCHBr2 has been 
reported  by  Hodgson.
72    Adapting  these  conditions,  it  was  proposed  that  the 
synthesis  of  E alkenylstannane  derivatives  of  previously  discussed  terminal 
alkenes should be attempted. 
It was decided to initially look into making a unit such as 190 which could be 
coupled with an aromatic triflate 106 (Scheme 2.46).  With unit 191 in place 
similar steps as shown before could be used to build up the molecule and the 
ring  could  be  completed  with  a  macrolactonisation  step  similar  to  the 
esterification previously used.  Alternatively, the synthesis of the vinyl stannane 
derivative of the complete C1’ C10’ chain 190 could be attempted. Murray N Robertson, 2009    Chapter 2, 68 
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Scheme 2.46  Proposed Stille coupling of 106 and 190 
 
Our modified synthesis began with the attempted ozonolysis of silyl ether 192 
which was obtained from previously described 125 in 95 % yield.  Ozonolysis of 
the alkene gave a low conversion, 33 %, to the desired aldehyde 193 (Scheme 
2.47).  However, quantitative amounts of starting material were recovered from 
the reaction mixture.  Faulty ozonolysis equipment prevented the optimisation 
of  this  procedure.    Nevertheless,  the  approach  was  continued  as  enough 
aldehyde was obtained from the initial attempt. 
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Scheme 2.47  Ozonolysis of the alkene 192 
 
An alternative approach was also proposed to effectively liberate the aldehyde 
component of the lactol 58, which could then potentially undergo the desired 
stannyl olefination to give 197.  However, it must be noted that the Hodgson 
olefination has never been reported on lactol systems to date. Murray N Robertson, 2009    Chapter 2, 69 
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Scheme 2.48  Preparation of 195 and attempted Hodgson’s olefination of 193 and 58. 
 
Treatment  of  dibromomethane  with  freshly  prepared  LDA,  followed  by 
tributyltin chloride 194 yielded the stannane 195 in 81 %, which was stable to 
flash chromatography.  Studies were then carried out to couple stannane 195 
with  aldehyde  193  and  pyranose  58  using  optimised  conditions  from  the 
literature (Scheme 2.48). 
72  Problems arose during the reaction, as the handling 
of the anhydrous chromium chloride proved extremely challenging and it was 
apparent  that  it  was  reacting  in  air  before  it  could  be  introduced  to  the 
reaction.    Unfortunately,  no  desired  product  could  be  detected  from  either 
reaction.   
The reactivity of both the lactol and aldehyde towards the Hodgson olefination 
prompted us to consider other palladium catalysed couplings which would allow 
us to use the aryl triflate 106 to introduce the troublesome E double bond. 
2.11  Heck Coupling 
The classic Heck reaction involves the palladium catalysed coupling between an 
aryl  or  vinyl  halide  with  an  activated  alkene  in  the  presence  of  base  with 
excellent E selectivity.  However, there are examples of non activated olefins 
coupling  with  aryl  triflates.
73    Most  of  the  examples  however  show  that  the 
competing reaction of the α regioselective arylation 200 can be favoured over 
the desired β product 201 (Scheme 2.49). Murray N Robertson, 2009    Chapter 2, 70 
ArOTf R
R
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Product (%) 
  Ar  Olefin  E/Z 
α  β 
1  3 CH3COPh  CH2OH  >99/1  75  0 
2  4 CH3 OPh  CH(OH)CH3  >99/1  83  2 
3  Ph   CH2CH2OH  >99/1  67  23 
4  4 CH3 OPh  COOCH3  >99/1  0  84 
Scheme 2.49  Literarature examples of Heck couplings of non activated olefins 
 
Following literature precedence the Heck coupling between triflate 106 and the 
terminal alkene 192 was attempted.  Unfortunately, neither the desired product 
202 nor the potential side product was observed in the crude reaction mixture.  
A  number  of  further attempts  were  carried  out  altering  conditions,  including 
microwave assisted procedures, but no product could ever be detected (Scheme 
2.50). 
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Scheme 2.50  Attempted Heck coupling of of fragments triflate 106 and alkene 192 
 
2.12  Suzuki Coupling 
Based on the disappointing Heck coupling results the Suzuki coupling of the aryl 
triflate  with  a  suitable  vinyl  boronic  acid  was  also  considered.    The  only 
potential draw back to this approach was that the obvious route needed for the 
formation of the vinyl boronic acid would be via a cross metathesis of alkene 
192  and  commercially  available  vinylboronic  acid  pinacol  ester  203  (Scheme 
2.51).  The lack of success with the cross metathesis reactions attempted up to 
this point made us apprehensive about it’s likelihood to succeed but the study 
was carried out.  Murray N Robertson, 2009    Chapter 2, 71 
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Scheme 2.51  Cross coupling of 203 and 192 
 
Using  Grubbs’  second  generation  catalyst  206  at  5  mol  %  and  a  2:1  ratio  of 
vinylboronic acid pinacol ester 203 and alkene 192 the desired vinyl boronic 
acid pinacol ester 204 was isolated in 73 % with a 4:1, separable, E:Z ratio.  The 
use  of  Grubbs’  first  generation  catalyst  205  under  similar  conditions,  gave 
alkene 204 in 71 % in the same diastereomeric ratio.   
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Figure 2.3  Grubbs’ first 205 and second 206 generation catalysts 
 
This was very significant, as not only did it allow us to carry on with our Suzuki 
coupling  based approach,  but it also  opened  up  the  possibility of  performing 
other cross coupling reactions using the same partner 192. Murray N Robertson, 2009    Chapter 2, 72 
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Scheme 2.52  Proposed Suzuki couplings of 204 and 208 with 113. 
 
The  coupling  of  204  with  113  was  tested  using  Pd(PPh)4  and  PdCl2(dppf)  as 
catalysts.    None  of  these  combinations  lead  to  the  formation  of  any  of  the 
desired product 207 and prompted us to wonder if the presence of the ester had 
made the triflate too unreactive.  Ester 204 was converted to acid 208 using 
sodium  metaperiodate  and  ammonium  acetate.    Due  to  concerns  about  the 
stability  of  acid  208,  no  purification  was  carried  out  at  this  stage  and  was 
carried onto the next stage where it was subjected to the same conditions as the 
ester above.  Once again, none of the desired product 207 could be isolated 
from any of the reactions. 
2.13  Grubbs Mediated Cross Metathesis 
Despite the lack of success in the Suzuki coupling reactions, the fact that alkene 
192 was able to successfully undergo Grubbs mediated cross metathesis opened 
a myriad of new possibilities.  Hence, it was decided to screen conditions for the 
coupling of the vinyl aryl unit 108 and the terminal alkene 125 and 192 (Scheme 
2.53). Murray N Robertson, 2009    Chapter 2, 73 
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Scheme 2.53  Grubbs mediated cross metathesis of 125 and 192 with 108. 
 
The conditions tested are summarised below in Table 2.4.  The successful cross 
metatheses  were  achieved  using  Hoveyda Grubbs  catalyst  second  generation 
(Figure 2.4).  Grubbs’ first and second generation catalyst either gave no desired 
product or reaction failed to proceed. 
N N
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Figure 2.4  Hoveyda Grubbs catalyst second generation. 
 
Successful cross metathesis gave the desired hetrodimer as a consistent 9:1 E/Z 
mixture in all cases.  The homodimer 212 amounts isolated were proportional to 
the success of the formation of hetrodimer 182 and could not be prevented.  
The optimised yield of 73 % for the cross metathesis was achieved using 30 mol % 
of catalyst (entry 10, Table 2.4). Murray N Robertson, 2009    Chapter 2, 74 
Table 2.4  Conditions for Grubbs mediated cross metathesis 
  108  125/192  R  Catalyst 
Loading 
(%) 
Time 
(h) 
Product 
(%) 
Homodimer 
(%) 
1  2  1  H  1st  10  21  0  0 
2  2  1  H  2nd  10  21  0  0 
3  2  1  H  Hov  10  21  0  0 
4  2  1  TBS  1st  10  21  0  0 
5  2  1  TBS  2nd  10  21  0  0 
6  2  1  TBS  Hov  10  21  32  15 
7  1  1  TBS  Hov  20  21  35  16 
8  1  2  TBS  Hov  20  21  65  22 
9  1  2  TBS  Hov  20  48  71  25 
10  1  2  TBS  Hov  30  48  73  27 
 
The free hydroxyl of the coupled product 182 was then protected as the MOM 
ether.  Despite the difficulties securing MOMCl and all the tendencies of MOMBr 
to  destroy  the  aromatic  substrates  the  MOM  group  was  still  the  favoured 
protecting group.  However, treatment of 182 with MOMBr and Hunig's base gave 
the desired MOM ether 213 in 90 % yield (Scheme 2.54).  Although there is no 
clear  explanation  for  this  change  in  reactivity,  it’s  possible  that  the  extra 
functionality  on  the  ring  has  stabilised  the  compound  and  prevented  it  from 
decomposing  under  identical  conditions  to  those  used  before  (Scheme  2.29).  
TBAF assisted removal of the TBS group proceeded in quantitative yield to give 
the free alcohol 214.   
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Scheme 2.54  Formation of free alcohol 214 
 
Unfortunately  by  this  stage,  time  constraints  prevented  me  from  taking  the 
synthesis  any  further  forward.    Confidence  was  high  though  that  the  total Murray N Robertson, 2009    Chapter 2, 75 
synthesis  can  be  completed  from  this  stage.    However,  synthetic  organic 
chemistry is as much an art as it is a science and small substrate modification 
can drastically affect its reactivity and chemical behaviour.  Yet, we were still 
positive about the synthesis with the only potential troublesome step being the 
macrolactonisation of 216 to 217 (Scheme 2.55). 
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Scheme 2.55  Proposed future work 
 
The completion of the synthesis from alcohol  214 was thought to follow the 
same one pot Swern oxidation Grignard acetylide coupling as before to produce 
alkyneol 215.  Selective hydrogenation to generate the desired Z olefin could 
then be attempted followed by selective deprotection of the secondary hydroxyl 
and base hydrolysis of the ester unit to give the desired carboxylic acid 216.  
Macrolactonisation  of  carboxylic  acid  216  should  yield  the  macrocycle  217.  
Global deprotection and oxidation of the allylic alcohol should then afford LL 
Z1640 2 3. 
2.14  Multi-substituted Pyrans from Carbohydrates 
Pyrans  are  present  in  a  large  number  of  natural  products  and  have  been 
extensively  used  in  biological  and  synthetic  studies.    Their  significance  as 
building blocks is reflected by the countless number of approaches employed for 
their synthesis.  Unfortunately, most of the synthetic routes developed thus far 
tend to be either lengthy or of limited flexibility with regard to which products 
can be accessed. Murray N Robertson, 2009    Chapter 2, 76 
During the undesired cyclisation of 87 shown previously (Scheme 2.56) led us to 
believe that our carbohydrate intermediates could be used as starting materials 
for the rapid formation of highly substituted pryan rings. 
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Scheme 2.56  Formation of pyran unit 88 
 
Treatment  of  the  propargylic  alcohol  100  under  basic  conditions  cleanly 
afforded  the  desired  tetrasubstituted  pyran  rings  219  and  220  in  good  yield 
(Scheme 2.57).  The relative stereochemistry of the pyran ring was determined 
through the use of coupling (J) values. 
This approach has the advantage of offering the pyran ring in 3 steps from the 
protected carbohydrate starting material. 
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Scheme 2.57  Formation of tetrasubstituted pyran rings 219 and 220 
 
Although  time  constraints  prevented  us  from  further  investigating  this 
methodology we believe that the stereochemistry of the nucleophilic addition 
onto the aldehyde unit could be controlled through the use of organoboranes Murray N Robertson, 2009    Chapter 2, 77 
(Scheme  2.58).
74    The  resulting  alcohols  could  be  used  to  generate 
diastereomerically  pure  polysubstituted  pyrans  in  just  4  steps  from  readily 
available carbohydrates. 
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Scheme 2.58  Proposed control of nucleophilic addition to aldehydes using organoboranes 
 
Furthermore,  it  is  also  possible  that  the  corresponding  anti pyrans  could  be 
accessed through the cyclisation of the Z conjugated esters.  The Z conjugated 
esters could potentially be accessed through the use of Taylors conditions.
75 
Eventually,  it  is  proposed  that  this  chemistry  could  be  applied  to  the 
convergent,  flexible  and  efficient  synthesis  of  many  natural  products.    Of 
specific interest to our group is the Amphidinols and particularly amphidinol 7 
(AM7) 229 (Figure 2.5).
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Figure 2.5  Amphidinol 7 
 
AM7 229 is a challenging synthetic target displaying two heavily hydroxylated 
side  chains,  an  alternating  polyene  chain  and  two  highly  substituted 
tetrahydropyran  units.    AM7  229  possess  a  55  carbon  backbone  and  24 
stereocentres. Murray N Robertson, 2009    Chapter 2, 78 
A successful total synthesis of AM7 229 or the structurally related AM3 has yet to 
be reported, although a number of lengthy approaches have been reported for 
the syntheses of the pyran and polyol sections.
77 80 
The work of significant interest to our research is the efficient synthesis and 
coupling of the pyran bearing fragments 233 and 234 to generate the bis pyran 
unit 232 (Scheme 2.59). 
Unfortunately, this project was not taken beyond the early pyran ring formation 
due  to  time  constraints  and  difficulties  arising  from  my  main  project.    This 
project has however been passed onto other members of the Marquez research 
group. 
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Scheme 2.59  Retrosynthetic analysis of AM7 and the interesting pyran fragments 233 and 
234.     79 
3  Experimental 
3.1 General 
All  reactions  were  performed  in  oven dried  glassware  under  an  inert  argon 
atmosphere unless otherwise stated.  Anhydrous dimethylformamide (DMF) and 
triethylamine  (TEA)  was  purchased  from  Aldrich  Chemical  Company.  
Tetrahydrofuran (THF), diethyl ether and dichloromethane (DCM) were distilled 
before use or were purified through a Pure Solv 400 5MD solvent purification 
system (Innovative Technology, Inc).  Anhydrous DCM was obtained by refluxing 
over  calcium  hydride  for  one  hour,  followed  by  distillation  under  argon.  
Anhydrous  THF  and  diethyl  ether  were  obtained  by  refluxing  over  sodium 
benzophenone for one hour, followed by distillation under argon.  All reagents 
were used as received, unless otherwise stated.  Solvents were evaporated at 
reduced pressure at 35°C using a Buchi Rotavapor unless otherwise stated. 
IR  spectra  were  recorded  as  thin  films  on  NaCl  plates  using  a  Perkin Elmer 
Spectrum  BX  Fourier  Transform  and  JASCO  FT/IR410  Fourier  Transform 
spectrometers.    Only  significant  absorptions  (nmax)  are  reported  in 
wavenumbers (cm
 1).  
Proton magnetic resonance spectra (
1H NMR) were recorded at 300, 400 or 500 
MHz  using  Bruker  DPX300,  Bruker  DPX  Avance400  instrument  and  Bruker 
Avance500 instruments.  Chemical shifts (dH) are reported in parts per million 
(ppm) and are referenced to the residual solvent peak.  The order of citation in 
parentheses is (1) multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
qn = quintet, m = multiplet, br = broad), (2) coupling constant (J) quoted in 
Hertz to the nearest 0.1Hz and (3) number of equivalent nuclei (by integration).  
Carbon  magnetic  resonance  spectra  (
13C)  were  recorded  at  75.1,  100  or 
125.7MHz  using  Bruker  DPX300,  Bruker  DPX  Avance400  and  Bruker  Avance500 
instruments.  Chemical shifts (dC) are quoted in parts per million (ppm) and are 
referenced to the appropriate solvent peak. 
High resolution mass spectra were recorded on a JEOL JMS 700 spectrometer by 
electrospray  and  chemical  ionisation  mass  spectrometer  operating  at  a 
resolution of 15000 full widths at half height. Murray N Robertson, 2009    80 
Flash chromatography was performed using silica gel (Apollo Scientific Silica Gel 
60,  40 63  micron) as  the  stationary  phase.  TLC  was  performed  on  aluminium 
sheets precoated with silica (Merck Silica Gel 60 F254). The plates were visualised 
by  the  quenching  of  UV  fluorescence  (λmax254  nm)  and/or  by  staining  with 
anisaldehyde, potassium permanganate, iodine or cerium ammonium molybdate 
followed by heating. 
3.2 Experimental and Characterisation 
2,2 Dimethyl tetrahydro [1,3]dioxolo[4,5 c]pyran 6 ol, 58
59 
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To a stirred solution of 2 deoxy ribose (200 mg, 1.49 mmol) in EtOAc (7 mL) at  
10 ˚C was added PPTS (15 mg) and 2 methoxypropene (0.19 mL, 1.98 mmol).  
The reaction mixture at  10 ˚C was then stirred for 6 hours.  The reaction was 
then quenched with triethylamine (0.10 mL) and allowed to warm up to room 
temperature.    The  reaction  was  then  concentrated  at  reduced  pressure  and 
purified by silica gel column chromatography using EtOAc (gradient 10 30 %) in 
40 60  petroleum  ether  to  afford  58  as  an  inseparable  mixture  of  α  and  β 
anomers (2.5:1) as a colourless oil (220 mg, 1.28 mmol, 86 %). 
Major, α Anomer   
1H NMR (500 MHz, CDCl3) δ 1.33 (s, 3H), 1.48 (s, 3H), 1.77 (ddd, J = 14.8, 7.1, 
4.2 Hz, 1H), 2.22 (dt, J = 14.8, 4.2 Hz, 1H), 3.68 (dd, J = 12.8, 3.6, 1H), 3.94 
(dd, J = 12.8, 3.3 Hz, 1H), 4.12 4.19 (m, 1H), 4.46 (dt, J = 6.6, 4.3 Hz, 1H), 5.24 
(dd, J = 7.1, 4.2 Hz, 1H)   
13C NMR (125MHz, CDCl3) δ 25.4, 27.3, 32.2, 62.1, 70.7, 71.6, 90.9, 108.8. 
νmax(film)/cm
 1 2984, 2936, 1664, 1371. Murray N Robertson, 2009    81 
Minor, β Anomer  
1H NMR (500 MHz, CDCl3) δ 1.34 (s, 3H), 1.55 (s, 3H), 2.02 2.12 (m, 2H), 3.68 
3.73 (m, 1H), 3.93 3.97 (m, 1H) 4.12 4.19 (m, 1H), 4.35 4.42 (m, 1H), 5.03 5.08 
(m, 1H).   
13C NMR (125MHz, CDCl3) δ 25.7, 28.1, 32.9, 60.8, 70.7, 71.3, 91.6, 109.5. 
νmax(film)/cm
 1 2984, 2936, 1664, 1371. 
HRMS calcd for C8H14NaO4 (M
++Na): 197.0784.  Found 197.0772. 
[α]
20
D –28.5 (c=1.0, CH2Cl2) 
(S) Pent 4 yn 2 ol, 76
81 
OH  
 
A stirred suspension of lithium acetylide, ethylenediamine complex (6.50 g, 70.6 
mmol)  in  dry  DMSO  (125  mL)  at  0  ˚C  was  treated  with  a  solution  of  S ( ) 
propyleneoxide (4.10 mL, 58.8 mmol) in DMSO (20 mL) dropwise.  The reaction 
was  then  allowed  to  warm  up  to  room  temperature  and  it  was  stirred  for  a 
further 48 hours.  The reaction was quenched with saturated NH4Cl (150 mL) and 
extracted with Et2O (200 mL x 3).  The organic layers were then combined, dried 
over  anhydrous  MgSO4,  filtered  and  concentrated  at  atmospheric  pressure  to 
yield 6.09 g of the crude alcohol 76 as an orange oil which was used without 
further purification. 
1H NMR (400 MHz, CDCl3) δ 1.27 (d, J = 6.2 Hz, 3H), 2.00 (br, 1H), 2.06 (t, J = 2.6 
Hz, 1H), 2.32 (ddd, J = 16.6, 6.6, 2.6 Hz, 1H), 2.40 (ddd, J = 16.6, 5.0, 2.6 Hz, 
1H), 3.93 4.01 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ 22.4, 41.1, 66.3, 71.0, 81.0. 
νmax (film)/cm
 1 3397, 2972, 2914, 2116, 1436, 1119, 1025. 
 Murray N Robertson, 2009    82 
Methyl (2E, 5S, 6R) 5,6,7 trihydroxyhept 2 enoate, 82
82 
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To a stirred solution of 2 deoxy D ribose 79 (2.0 g, 15.0 mmol) in THF (40 mL) 
was  added methyl(triphenylphosphoranylidene)acetate (6.0 g, 18.0 mmol) and 
refluxed at 75 °C for 5 hours.  Additional methyl(triphenylphosphoranylidene) 
acetate (1.1 g, 3.3 mmol) was addedand refluxing was continued overnight.  The 
reaction  was  then  allowed  to  cool  down  to  room  temperature  and  was 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with MeOH (0 25 %) in CHCl3 as the eluant) afforded the desired E 
conjugated  ester  82  as  a  brown  oil  (2.15  g,  11.3  mmol,  75  %)  plus  the  Z 
conjugated ester (240 mg, 1.26 mmol, 8 %). 
1H NMR (500 MHz, CDCl3) δ 2.34 2.41 (m, 1H), 2.48 (dddd, J = 14.8, 7.0, 3.6, 1.4 
Hz, 1H), 3.55 3.58 (m, 1H), 3.61 3.74 (m, 2H), 3.79 (s, 3H), 3.75 3.78 (m, 1H), 
3.86 (brs, 3H), 5.92 (dt, J = 15.7, 1.4 Hz, 1H), 6.99 (dt, J = 15.7, 7.3 Hz, 1H). 
13C NMR (125MHz, CDCl3) δ 36.3, 51.0, 63.5, 72.0, 73.5, 123.8, 145.3, 167.0. 
HRMS (CI
+) calcd for C8H15O5 (M
++H): 191.0919.  Found 191.0918. 
νmax (film)/cm
 1 3423, 2952, 1720, 1655, 1325, 1276, 1067. 
[α]
24
D –1.2 (c=1, CHCl3) 
(5S,6R,E) Methyl 7 (tert butyldimethylsilyloxy) 5,6 dihydroxyhept 2 enoate, 
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To a stirred solution of alcohol 82 (1.52 g, 7.99 mmol) in DCM (10 mL) at room 
temperature  was  added  tert-butyldimethylsilyl  chloride  (1.44  g,  9.60  mmol), Murray N Robertson, 2009    83 
triethylamine (1.67 mL, 12.00 mmol) and DMAP (0.20 g, 1.60 mmol) and stirred 
for 14 hours before being quenched with saturated aqueous ammonium chloride 
(20 mL) and extracted with DCM (20 mL x 3).  The organic layers were combined, 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (20 40 %) in 
40 60 petroleum ether as the eluant) afforded 83 as an orange oil (2.01 g, 6.60 
mmol, 83 %). 
1H NMR (400 MHz, CDCl3) δ 0.10 (s, 6H), 0.91 (s, 9H), 2.35 (d, J = 5.6 Hz, 1H), 
2.37 2.46 (m, 1H), 2.55 (dddd, J = 14.9, 7.2, 4.0, 1.4 Hz, 1H), 2.61 (d, J = 5.6 
Hz, 1H), 3.52 3.58 (m, 1H), 3.74 (s, 3H), 3.78 (d, J = 4.7 Hz, 2H), 3.80 3.85 (m, 
1H), 5.95 (dt, J = 15.6, 1.4 Hz, 1H), 7.03 (dt, J = 15,6, 7.2 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ  5.4,  5.3, 18.3, 26.0, 36.3, 51.6, 64.1, 71.1, 73.1, 
123.7, 145.5, 166.9. 
HRMS (CI
+) calcd for C14H29O5Si (M
++H): 305.1784.  Found 305.1781. 
νmax (film)/cm
 1 3460, 2929, 2361, 1731, 1462, 1254, 1162, 1076. 
(E) Methyl 4 ((4S,5R) 5 ((tert butyldimethylsilyloxy)methyl) 2,2 dimethyl 
1,3 dioxolan 4 yl)but 2 enoate, 87 
O
O
TBSO
MeO
O
 
 
A room temperature solution of diol 83 (2.22 g, 7.29 mmol) in acetone (15 mL) 
was treated with 2,2 dimethoxypropane (9.0 mL, 73.2 mmol) and PPTS (50 mg).  
The reaction mixture was then stirred for 14 hours before being diluted with 
EtOAc (20 mL), washed with saturated aqueous sodium bicarbonate (15 mL) and 
extracted with EtOAc (20 mL x 3).  The organic layers were combined, dried over 
anhydrous MgSO4, filtered and concentrated at reduced pressure.  Purification by 
flash column chromatography (silica gel with EtOAc (10 %) in 40 60 petroleum 
ether as the eluant) afforded 87 as a yellow oil (2.15 g, 6.23 mmol, 86 %).  Murray N Robertson, 2009    84 
1H NMR (400 MHz, CDCl3) δ 0.06 (s, 6H), 0.88 (s, 9H), 1.33 (s, 3H), 1.42 (s, 3H), 
2.42 2.52 (m, 1H), 2.53 2.62 (m, 1H), 3.63 3.68 (m, 2H), 3.73 (s, 3H), 4.13 (dd, 
J = 12.6, 6.1 Hz, 1H), 4.25 (ddd, J = 9.4, 5.6, 4.0 Hz, 1H), 5.92 (dt, J = 15.6, 
1.5, 1H), 7.03 (dt, J = 15.6, 7.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ  5.5,  5.5, 18.2, 25.4, 25.8, 28.1, 32.4, 51.4, 61.6, 
76.0, 78.0, 108.0, 122.8, 145.8, 166.7. 
HRMS (CI
+) calcd for C17H33O5Si (M
++H): 345.2097.  Found 345.2099. 
νmax (film)/cm
 1 2956, 2928, 2856, 1729, 1462, 1254, 1071. 
[α]
23
D –33.2 (c=1, CHCl3) 
Methyl 2 ((3R,7S) 2,2 dimethyltetrahydro 3H [1,3]dioxolo[4,5 ]pyran 6 
yl)acetate, 88 
O O
O MeO
O
 
 
1H NMR (400 MHz, CDCl3) δ 1.36 (s, 3H), 1.51 (s, 3H), 1.76 (ddd, J = 15.0, 11.6, 
3.6 Hz, 1H), 2.12 (d, J = 14.8 Hz, 1H), 2.42 (dd, J = 15.2, 4.8 Hz, 1H), 2.50 (dd, 
15.2, 8.0 Hz, 1H), 3.36 (dd, J = 11.5, 9.7 Hz, 1H), 3.70 (s, 3H), 3.88 (dd, J = 
11.5, 6.5 Hz, 1H), 3.92 4.06 (m, 1H), 4.06 4.14 (m, 1H), 4.34 4.39 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 26.4, 28.3, 32.5, 40.7, 52.0, 67.9, 69.2, 70.0, 71.6, 
109.2, 171.5. 
νmax(film)/cm
 1 1742, 1437, 1255, 1061 
HRMS calcd for C11H19O5 (M
++H); 231.1232.  Found 231.1232 Murray N Robertson, 2009    85 
4 (5 Hydroxymethyl 2,2 dimethyl [1,3]dioxolan 4 yl) but 2 enoic acid methyl 
ester, 89 
O
O
OH
O
O
 
 
Method A 
To a stirred solution of silyl ether 87 (72 mg, 0.21 mmol) in THF (2 mL) at 0 ˚C 
was added HF Pyr:Pyr:THF solution (1:4:10, 3 mL) and the reaction mixture was 
stirred for 5 hours at 0 ˚C before being allowed to warm up to room temperature 
over night.  Additional pyridine (1.0 mL) was added followed by HF Pyr (0.5 mL) 
and stirring was continued for 3.5 hours.  The reaction was slowly quenched with 
saturated aqueous sodium bicarbonate (20 mL) and extracted with DCM (40 mL x 
3).  The organic layers were combined, washed with citric acid (5 %, 100 mL), 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (30 60 %) in 
40 60 petroleum ether as the eluant) afforded 89 as light orange oil (47 mg, 0.21 
mmol, 98 %). 
Method B 
To a stirred solution of pyranol 58 (0.910 g, 5.22 mmol) in THF (15 mL) was  
added  methyl(triphenylphosphoranylidene)acetate  (1.92  g,  5.74  mmol)  and 
refluxed at 75 °C for 5 hours.  The reaction was then allowed to cool down to 
room temperature and was diluted with petroleum ether (30 mL).  The reaction 
mixture  was  then  filtered  and  concentrated  at  reduced  pressure  to  give  the 
crude  product  which was  purified  by  flash  column  chromatography  (silica  gel 
with EtOAc (gradient 30 35 %) in 40 60 petroleum ether as the eluant) to afford 
the desired E conjugated ester 89 as a light orange oil (1.07 g, 4.66 mmol, 89 %) 
plus a fraction of partially separated E/Z diastereomers. 
1H NMR (500 MHz, CDCl3) δ 1.37 (s, 3H), 1.48 (s, 3H), 1.84 (brs, 1H), 2.44 (m, 
1H), 2.54 (m, 1H), 3.66 (m, 2H) 3.73 (s, 3H), 4.22 (q J = 5.8 Hz, 1H) 4.29 (ddd, J 
= 8.8, 6.1, 4.6 Hz, 1H), 5.94 (m, 1H), 6.98 (dt, J =15.7, 6.9 Hz, 1H). Murray N Robertson, 2009    86 
13C NMR (125MHz, CDCl3) δ 25.3, 28.0, 32.5, 51.6, 61.4, 75.4, 77.6, 108.6, 123.2, 
145.0, 166.7 
HRMS calcd for C11H18NaO5 (M
++Na) 253.1052.  Found 253.1055 
νmax(film)/cm
 1 2841, 2120, 1640, 1107. 
[α]
20
D –31.9 (c=1.0, CH2Cl2) 
Methyl (2E) 4 [(4S,5S) 5 formyl 2,2 dimethyl 1,3 dioxolan 4 yl]but 2 enoate, 
90 
O
O
O
O
O H
 
 
A  78 ˚C solution of oxalyl chloride (0.35 mL, 4.05 mmol) in DCM (10 mL) was 
treated with DMSO (0.57 mL, 8.10 mmol) and the reaction mixture was stirred at 
–78 ˚C for 40 minutes.  A solution of alcohol 89 (0.62 g, 2.70 mmol) in DCM (3 
mL) was added via canula and the reaction mixture was stirred for 1 hour at –78 
˚C before triethylamine (1.69 mL, 12.15 mmol) and DCM (5 mL) was added and 
the mixture allowed to warm up to room temperature over 1 hour.  The reaction 
mixture was washed with brine (15 mL) and extracted with EtOAc (25 mL x 3).  
The  organic  layers  were  combined,  dried over  anhydrous  MgSO4,  filtered  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with EtOAc (30 %) in 40 60 petroleum ether as the eluant) afforded 90 
as a yellow oil (0.62 g, 2.70 mmol, 100 %). 
1H NMR (500 MHz, CDCl3) δ 1.41 (s, 3H), 1.59 (s, 3H), 2.36 (m, 1H), 2.51 (m, 1H), 
3.73 (s, 3H), 4.33 (dd, J = 7.2, 3.0 Hz, 1H), 4.45 (ddd, J = 9.1, 7.2, 4.1 Hz, 1H), 
5.92 (dt, J = 15.7, 1.4 Hz, 1H), 6.93 (dt, J = 15.7, 6.9 Hz, 1H), 9.68 (dd, J = 3.0, 
0.4 Hz, 1H). 
13C  NMR  (125MHz,  CDCl3)  δ  25.3,  27.7,  32.7,  51.7,  76.9,  81.7,  111.1,  124.0, 
143.6, 166.6, 202.4. 
HRMS calcd for C11H17O5 (M
++H); 229.1075.  Found 229.1071 Murray N Robertson, 2009    87 
νmax(film)/cm
 1 2841, 1820, 1625, 1056. 
[α]
20
D –59.4 (c=1.0, CH2Cl2) 
(But 3 ynyloxy)(tert butyl)dimethylsilane, 94
83 
OTBS
 
 
To a stirred solution of 3 butyn 1 ol (2.00 g, 28.5 mmol) in DCM (70 mL) at room 
temperature  was  added  tert-butyldimethylsilyl  chloride  (5.16  g,  34.2  mmol), 
triethylamine (6.0 mL, 43.1 mmol) and DMAP (0.23 g, 1.8 mmol).  The reaction 
was  stirred  for  4  hours  before  being  quenched  with  saturated  aqueous 
ammonium chloride (50 mL) and extracted with EtOAc (60 mL x 3).  The organic 
layers were combined, dried over anhydrous MgSO4, filtered and concentrated at 
reduced pressure.  Purification by flash column chromatography (silica gel with 
EtOAC  (30 50  %)  in  40 60  petroleum  ether  as  the  eluant)  afforded  94  as  a 
colourless oil (4.63 g, 25.1 mmol, 88 %). 
1H NMR (400 MHz, CDCl3) δ 0.08 (s, 6H), 0.90 (s, 9H), 1.96 (t, J = 2.6 Hz, 1H), 
2.40 (td, J = 7.1, 2.6 Hz, 2H), 3.77 (t, J = 7.1 Hz, 2H). 
13C NMR (100 MHz, CDCl3) δ  5.2, 18.5, 23.0, 26.0, 61.9, 69.4, 81.7. 
HRMS (CI
+) calcd for C10H21OSi (M
++H): 185.1362.  Found 185.1365 
νmax(film)/cm
 1 2960, 2927, 2118, 1480, 1255. Murray N Robertson, 2009    88 
(R) (+) 4 tert Butyldimethylsiloxypent 1 yne, 99
84 
OTBS
 
 
A solution of the freshly generated crude alcohol 76 (5.13 g) in DMF (40 mL) at 
room  temperature  was  treated  with  imidazole  (7.61  g,  111.74  mmol)  and 
TBDMSCl (9.26 g, 61.46 mmol).  The reaction was stirred for 20 hours before 
being quenched by the addition of water (20 mL) and extracted with a 50 % 
solution of EtO2 / 40 60 petroleum ether (100 mL).  The organic phase was then 
washed  with  brine  (50  mL  x  4)  followed  by  water  (50  mL  x  2),  dried  over 
anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure  at  20  ˚C.  
Purification by flash column chromatography (silica gel with EtO2 (2 %) in 40 60 
petroleum ether as the eluant) afforded 99 as a clear oil (3.51 g, 41.75 mmol, 
71 % over 2 steps). 
1H NMR (400 MHz, CDCl3) δ 0.06 (s, 3H). 0.06 (s, 3H), 0.87 (s, 9H), 1.22 (d, J = 
6.0 Hz, 3H), 1.97 (t, J = 2.7 Hz, 1H), 2.23 (ddd, J = 16.5, 7.1, 2.7 Hz, 1H), 2.34 
(ddd, J = 16.5, 5.6, 2.6, 1H), 3.90 4.00 (m, 1H). 
13C NMR (125MHz, CDCl3) δ  4.8,  4.7, 18.1, 23.2, 25.7, 29.3, 67.5, 69.6, 81.8. 
HRMS (CI
+) calcd for C11H23OSi (M
++H); 199.1518  Found 199.1521 
νmax(film)/cm
 1 2956, 2929, 2122, 1472, 1256. 
[α]
20
D  1.8 (c=1.0, CH2Cl2) Murray N Robertson, 2009    89 
(E) 4 ((4S,5R) 5 [(S) 5 (tert-Butyl dimethyl silanyloxy) 1 hydroxy hex 2 
ynyl] 2,2 dimethyl [1,3]dioxolan 4 yl) but 2 enoic acid methyl ester, 100 
O
O
TBSO
HO
O
O
 
 
A room temperature solution of alkyne 99 (480 mg, 2.43 mmol) in THF (9 mL was 
treated with ethylmagnesium bromide (3.0 M solution) (0.81 mL, 2.43 mmol) and 
the resulting mixture stirred for 2 hours at room temperature.  The solution was 
then cooled down to  78 °C and treated with a solution of aldehyde 90 (0.62 g, 
2.70 mmol) in THF (9 mL) and the stirring at  78 °C was continued for 2.5 hours.  
The reaction was quenched with a saturated solution of ammonium chloride (5 
mL) and extracted with EtOAc (30 mL x 3).  The organic layers were combined, 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel, with EtOAc (10 %) in 40 
60 petroleum ether as the eluant) generated the desired propargylic alcohols 
100 as an inseparable mixture of diastereoisomers (0.52 g, 1.21 mmol, 45 %) and 
a  significant  amount  of  unreacted  starting  aldehyde  99  which  was  cleanly 
recovered  (154  mg,  0.67  mmol,  25  %).    Yield  based  on  starting  material 
recovered 69 %. 
1H NMR (500 MHz, CDCl3) δ 0.07 (s, 3H). 0.07 (s, 3H), 0.86 (s, 9H), 1.21 (d, J = 
6.15 Hz, 3H), 1.34 (s, 3H), 1.48 (s, 3H), 3.94 2.25 (m, 4H), 3.92 (s, 3H) 3.93 (m, 
1H), 4.29 (m, 1H), 4.43 (d, J = 5.5 Hz, 1H), 5.91 (d, J = 15.7, 1H), 6.99 (m, 1H),  
13C NMR (125MHz, CDCl3) δ  4.5, 23.4, 25.4, 25.9, 29.7, 32.7, 51.5, 61.3, 62.1, 
75.8, 80.3, 81.9, 85.2, 108.8, 122.9, 145.3, 166.9 
HRMS calcd for C22H39O6Si1 (M
++H); 427.2510.  Found 427.2492 
νmax(film)/cm
 1 2953, 2930, 2857, 2300, 1726, 1658, 1166. Murray N Robertson, 2009    90 
(E) 4 [(4S,5S) 5 ((S) 5 Methoxy hex 2 ynoyl) 2,2 dimethyl [1,3]dioxolan 4 
yl] but 2 enoic acid methyl ester, 101 
O
O
TBSO
O
O
O
 
 
Method A 
A mixture of alcohol 100 (65 mg, 0.15 mmol), 4 Ǻ molecular sieves (150 mg) and 
NMO (31 mg, 0.23 mmol) in DCM (1 mL) at room temperature was stirred for 30 
minutes.  TPAP (3 mg, 0.008 mmol)  was  added and the resulting dark green 
suspension was stirred at room temperature for 2 hours.  The reaction was then 
filtered through silica and concentrated at reduced pressure.  Purification by 
flash column chromatography (silica gel, with EtOAc (elution gradient 0 10 %) in 
40 60 petroleum ether as the eluant) afforded the desired alkynone 101 (38 mg, 
0.089 mmol, 59 %) as a clear oil. 
Method B 
A  78 ˚C solution of oxalyl chloride (0.02 mL, 0.20 mmol) in DCM (1 mL) was 
treated with DMSO (0.03 mL, 0.40 mmol) dropwise and the reaction mixture was 
stirred for 30 minutes.  A solution of alcohol 100 (57 mg, 0.134 mmol) in DCM (1 
mL) was added dropwise via canula followed by a DCM (1 mL) rinse and the 
reaction mixture was stirred for 1 hour at  78 ˚C before triethylamine (0.08 mL, 
0.60 mmol) and DCM (1 mL) was added and the mixture allowed to warm up to 
room temperature over 45 minutes.  DCM (1 mL) was added and the solution was 
washed with HCl (1 M) (2 mL) and saturated aqueous sodium bicarbonate (2 mL).  
The organic fraction was dried over anhydrous MgSO4, filtered and concentrated 
at reduced pressure.  Purification by flash column chromatography (silica gel 
with EtOAc (10 %) in 40 60 petroleum ether as the eluant) afforded 101 as a 
yellow oil (12 mg, 0.03 mmol, 21 %). Murray N Robertson, 2009    91 
1H NMR (500 MHz, CDCl3) δ 0.07 (s, 3H), 0.07 (s, 3H), 0.88 (s, 9H), 1.25 (d, J = 
6.1, 3H), 1.38 (s, 3H), 1.63 (s, 3H), 2.37 (m, 1H), 2.59 2.48 (m, 3H), 3.73 (s, 
3H), 4.04 (m, 1H), 4.47 (m, 1H), 4.57 (d, J = 7.3 Hz, 1H), 5.92 (dt, J = 15.8, 1.5, 
1H), 6.95 (dt, J = 6.93, 1.85, 1H). 
13C NMR (125MHz, CDCl3) δ  4.7,  4.6, 18.2, 23.7, 25.4, 25.9, 27.2, 30.2, 33.3, 
51.7, 66.8, 76.7, 83.0, 97.3, 111.2, 123.7, 144.3, 166.7, 186.3. 
HRMS calcd for C22H36NaO6Si (M
++Na); 447.2173.  Found 447.2176 
νmax(film)/cm
 1 2929, 2211, 1825, 1725, 1256. 
[α]
20
D  21.2 (c=1.0, CH2Cl2) 
(E) Methyl 4 ((4S,5R) 5 ((S,Z) 5 (tert butyldimethylsilyloxy) 1 hydroxyhex 2 
enyl) 2,2 dimethyl 1,3 dioxolan 4 yl)but 2 enoate, 102 
O
O HO
O
O
TBSO
 
 
To a stirred solution of alkyne 100 (170 mg, 0.40 mmol) in MeOH (2 mL) was 
added palladium on barium sulphate (250 mg) and quinoline (0.5 mL) at room 
temperature.  The flask was evacuated and purged with hydrogen 5 times and 
hydrogen was bubbled through the solution for 10 minutes.  After 7 hours under 
hydrogen the reaction mixture was filtered through celite and concentrated at 
reduced pressure.  Analysis of the crude showed 102 as a colourless oil and was 
taken onto the next step without an further purification.  
1H NMR (500 MHz, CDCl3) δ 0.03 0.08 (m, 12H), 0.88 0.90 (m, 18H), 1.13 1.17 
(m, 6H), 1.33 1.37 (m, 6H), 1.41 1.44 (m, 6H), 2.23 2.59 (m, 8H), 3.64 3.66 (m, 
2H), 3.72 (s, 3H), 3.73 (s, 3H), 3.79 4.42 (m, 6H), 5.47 5.55 (m, 2H), 5.65 5.83 
(m, 2H), 5.89 5.96 (m, 2H), 6.95 7.15 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ  4.4,  4.2, 18.3, 18.4, 23.8, 24.4, 25.4, 25.7, 26.0, 
26.1, 27.9, 28.0, 28.2, 29.1, 33.2, 33.8, 38.1, 38.6, 51.6, 51.7, 65.2, 66.0, 75.7, Murray N Robertson, 2009    92 
76.5,  77.0,  77.3,  77.4,  77.7,  80.5,  80.8,  108.6,  108.8,  122.9,  123.2,  129.5, 
129.7, 131.9, 132.4, 145.5, 146.5. 
HRMS (CI
+) calcd for C22H41O6Si (M
++H): 429.2672.  Found 429.2675. 
(E) Methyl 4 ((4S,5S) 5 ((S,Z) 5 (tert butyldimethylsilyloxy)hex 2 enoyl) 2,2 
dimethyl 1,3 dioxolan 4 yl)but 2 enoate, 103 
O
O O
O
O
TBSO
 
 
A mixture of alcohol 102 (157 mg, 0.37 mmol), 4 Ǻ molecular sieves (400 mg) 
and NMO (75 mg, 0.56 mmol) in DCM (2 mL) at room temperature was stirred for 
30 minutes.  TPAP (7 mg, 0.02 mmol) was added and the resulting dark green 
suspension was stirred at room temperature for 4 hours.  The reaction was then 
filtered through silica and concentrated at reduced pressure.  Purification by 
flash column chromatography (silica gel, with EtOAc (elution gradient 0 10 %) in 
40 60 petroleum ether as the eluant) afforded the desired alkynone 103 (41 mg, 
0.10  mmol,  26  %)  as  a  clear  oil.    Alkenol  100  and  alkynone  101  were  also 
recovered as impure fractions  
1H NMR (500 MHz, CDCl3) δ 0.04 (s, 3H), 0.05 (s, 3H), 0.87 (s, 9H), 1.14 (d, J = 
6.2 Hz, 3H), 1.37 (s, 3H), 1.59 (s, 3H), 2.29 2.46 (m, 4H), 2.73 2.82 (m, 1H), 
3.65 (s, 3H), 3.93 4.00 (m, 1H), 4.47 (d, J = 7.6 Hz, 1H), 5.61 5.80 (m, 1H), 
5.92 5.92 (m, 1H), 6.17 6.35 (m, 1H), 6.97 7.14 (m, 1H). 
13C NMR (125 MHz, CDCl3) δ  4.4, , 18.3, 23.8, 24.4, 25.7, 29.7, 33.2, 38.4, 50.7, 
65.1, 66.5, 75.1, 76.6, 77.0, 109.3, 122.9, 129.5, 140.5 145.5, 199.6. 
HRMS (CI
+) calcd for C22H39O6Si (M
++H): 427.2516.  Found 427.2517. Murray N Robertson, 2009    93 
Methyl 2,6 dihydroxy 4 methoxybenzoate, 104 
MeO
OH
OH
OMe
O
 
 
To  a  solution  of  methyl  2,4,6 trihydroxybenzoate  81  (19.2  g,  0.10  mol)  in 
CHCl3:MeOH (3:1, 1.0 L) at 0 ˚C was added trimethylsilyl diazomethane (2.0 M, 
65 mL, 0.13 mol) and stirred for 15 hours.  A second aliquot of trimethylsilyl 
diazomethane (2.0 M, 35 mL, 0.70 mol) was added and the reaction stirred for a 
further 10 hours before being diluted with MeOH (150 mL) and quenched with 
acetic  acid  (30  mL).    The  reaction  was  concentrated  at  reduced  pressure  to 
afford a crude solid which upon washing with 40 60 petroleum ether resulted in 
104 as white crystals (20.21 g, 0.10 mol, 98 %). 
1H NMR (400 MHz, CDCl3) δ 3.80 (s, 3H), 4.04 (s, 3H), 6.04 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ 52.3, 55.6, 91.6, 93.5, 160.1, 166.5, 171.8. 
HRMS (CI
+) calcd for C9H11O5 (M
++H): 199.0606.  Found 199.0609. 
νmax (film)/cm
 1 3413, 1647, 1430, 1314, 1203, 1153. 
Methyl 2 (tert butyldimethylsilyloxy) 6 hydroxy 4 methoxybenzoate, 105 
MeO
TBSO
OH
OMe
O
 
 
To a stirred solution of alcohol 104 (13.10 g, 66.10 mmol) in DCM (330 mL) at 
room  temperature  was  added  tert-butyldimethylsilyl  chloride  (8.47  g,  56.19 
mmol) and triethylamine (20.3 mL, 145.64 mmol) and stirred for 20 hours before 
quenched with saturated aqueous ammonium chloride (200 mL) and extracted 
with DCM (250 mL x 3).  The organic layers were combined, dried over anhydrous 
MgSO4,  filtered  and  concentrated  at  reduced  pressure.    Purification  by  flash 
column chromatography (silica gel with EtOAc (5 %) in 40 60 petroleum ether as 
the  eluant)  afforded  105  as  a  white  solid  (16.39  g,  52.29  mmol,  93  %)  plus Murray N Robertson, 2009    94 
unreacted starting material (2.73 g, 13.76 mmol, 21 %).  Yield based on starting 
material recovered, 100 %. 
1H NMR (400 MHz, CDCl3) δ 0.22 (s, 6H), 1.00 (s, 9H), 3.77 (s, 3H), 3.88 (s, 3H), 
5.89 (d, J = 2.5 Hz, 1H), 6.12 (d, J = 2.5 Hz, 1H), 11.84 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ  4.3, 18.3, 25.6, 51.6, 55.3, 94.5, 99.4, 99.4, 158.3, 
164.8, 165.8, 171.6. 
HRMS (CI
+) calcd for C15H25O5Si (M
++H): 313.1471.  Found 313.1473. 
νmax (film)/cm
 1 3429, 3103, 3009, 2955, 2850, 1648, 1260, 1073. 
Methyl 2 (tert butyldimethylsilyloxy) 4 methoxy 6 
(trifluoromethylsulfonyloxy)benzoate, 106 
MeO
TBSO
OTf
OMe
O
 
 
A 0 ˚C solution of alcohol 105 (9.16 g, 29.33 mmol) in DCM (50 mL) was treated 
with  pyridine  (8.54  mL,  105.6  mmol)  and  trifluoromethanesulfonic  anhydride 
(10.0 g, 35.18 mmol) and the reaction mixture was stirred for 3 hours.  The 
reaction  was  quenched  with  water  (25  mL),  citric  acid  (1  M,  25  mL)  and 
extracted with Et2O (75 mL x 3).  The organic layers were combined, washed 
with brine (100 mL), dried over anhydrous MgSO4, filtered and concentrated at 
reduced pressure.  Purification by flash column chromatography (silica gel with 
DCM (25 %) in 40 60 petroleum ether as the eluant) afforded 106 as an orange oil 
(12.81 g, 28.82 mmol, 98 %)  
1H NMR (400 MHz, CDCl3) δ 0.24 (s, 6H), 0.97 (s, 9H), 3.80 (s, 3H), 3.87 (s, 3H), 
6.38 (d, J = 2.2 Hz, 1H), 6.46 (d, J = 2.2 Hz, 1H) 
13C NMR (125MHz, CDCl3) δ  4.3, 18.2, 25.5, 52.5, 60.6, 107.1, 111.4, 113.5, 
120.0, 148.0, 155.9, 158.5, 163.9. 
HRMS (CI
+) calcd for C16H24O7F3SiS (M
++H): 445.0964.  Found 445.0963. Murray N Robertson, 2009    95 
νmax (film)/cm
 1 2955, 2860, 1740, 1619, 1570, 1427. 
Methyl 2 hydroxy 4 methoxy 6 (trifluoromethylsulfonyloxy)benzoate, 107 
MeO
OH
OTf
OMe
O
 
 
1H NMR (400 MHz, CDCl3) δ 3.79 (s, 3H), 3.98 (s, 3H), 6.34 (d, J = 2.3 Hz, 1H), 
6.49 (d, J = 2.3 Hz, 1H), 11.71 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ 52.6, 56.1, 100.4, 101.0, 103.4, 118.8 (q, J = 320.7 
Hz), 149.6, 164.6, 165.5, 168.9. 
HRMS (EI
+) calcd for C10H9F3O7S (M
++H): 330.0021.  Found 330.0019.  
νmax (film)/cm
 1 2960, 1680, 1577, 1205. 
Methyl 2 hydroxy 4 methoxy 6 vinylbenzoate, 108
85 
MeO
OH
OMe
O
 
 
A suspension of lithium chloride (3.63 g, 85.6 mmol) in DMF (200 mL) was heated 
to 60 ˚C.  A solution of triflate 107 (12.68 g, 28.5 mmol) in DMF (80 mL) was 
then  added  followed  by  tri 2 furylphosphine  (1.06  g,  4.6  mmol)  and 
tris(dibenzylideneacetone)dipalladium(0)  (0.52  g,  0.57  mmol).    The  reaction 
mixture was stirred at room temperature for 30 minutes, then tributyl vinyl tin 
(10.0 mL, 34.2 mmol) was added and the reaction was heated to 60 ˚C for 5 
hours.    The  reaction  was  then  quenched  with  saturated  aqueous  potassium 
fluoride solution (200 mL) and extracted with EtOAc (250 mL x 3).  The organic 
layers were combined, dried over anhydrous MgSO4, filtered and concentrated at 
reduced pressure.  Purification by flash column chromatography (silica gel with 
Et2O  (10  %)  in  40 60  petroleum  ether  as  the  eluant)  afforded  108  as  white 
crystals (5.76 g, 27.7 mmol, 97 %). Murray N Robertson, 2009    96 
1H NMR (400 MHz, CDCl3) δ 3.83 (s, 3H), 3.92 (s, 3H), 5.24 (dd, J = 10.8, 1.5 Hz, 
1H), 5.46 (dd, J = 17.2, 1.5 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 6.51 (d, J = 2.6 Hz, 
1H), 7.23 7.30 (m, 1H), 11.66 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ 52.1, 55.5, 100.3, 103.9, 108.3, 115.8, 138.4, 143.6, 
164.3, 165.1, 171.7. 
HRMS (EI
+) calcd for C11H12O4 (M
+): 208.0736.  Found 208.0733. 
νmax (film)/cm
 1 2925, 2854, 1733, 1648, 1437, 1328, 1257, 1159. 
Methyl 2 hydroxy 4 methoxy 6 (trityloxy)benzoate, 109 
MeO
O
OH
OMe
O
Ph
Ph
Ph
 
 
To a stirred solution of alcohol 104 (0.73 g, 3.68 mmol) in DCM (15 mL) at room 
temperature  was  added  triphenylmethyl  chloride  (0.98  g,  3.50  mmol)  and 
triethylamine (1.13 mL, 8.10 mmol) and the reaction mixture was stirred for 48 
hours.  The reaction was quenched with saturated aqueous ammonium chloride 
(15 mL) and extracted with DCM (20 mL x 3).  The organic layers were combined, 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (10 %) in 40 
60 petroleum ether as the eluant) afforded 109 as a white solid (0.64 g, 1.45 
mmol, 39 %)  
1H NMR (400 MHz, CDCl3) δ 3.44 (s, 3H), 3.74 (s, 3H), 5.61 (d, J = 2.4 Hz, 1H), 
5.95 (d, J = 2.4 Hz, 1H), 7.20 7.24 (m, 3H), 7.27 7.32 (m, 6H), 7.43 7.46 (m, 
6H), 11.69 (s, 1H).   
13C NMR (100 MHz, CDCl3) δ 51.8, 55.0, 92.2, 94.8, 99.7, 100.9, 127.3, 127.7, 
128.8, 143.7, 158.6, 163.5, 164.7, 171.6. 
HRMS (CI
+) calcd for C9H11O5 (M
+ C19H15): 199.0606.  Found 199.0610. 
νmax (film)/cm
 1 1648, 1577, 1491, 1435, 1264. Murray N Robertson, 2009    97 
Methyl 2 (tert butyldiphenylsilyloxy) 6 hydroxy 4 methoxybenzoate, 110 
MeO
TBDPSO
OH
OMe
O
 
 
To a stirred solution of alcohol 104 (0.70 g, 3.56 mmol) in DCM (15 mL) at room 
temperature was added  tert-butyldiphenylsilyl chloride (0.88 mL, 3.38 mmol) 
and triethylamine (1.09 mL, 7.83 mmol) and the reaction mixture was stirred for 
48  hours.    The  reaction  was  quenched  with  saturated  aqueous  ammonium 
chloride (15 mL), extracted with DCM (20 mL x 3).   The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc (10 
%) in 40 60 petroleum ether as the eluant) afforded 110 as a white solid (1.47 g, 
3.37 mmol, 99 %) plus recovered starting material (37 mg, 0.19 mmol). 
1H NMR (400 MHz, CDCl3) δ 1.10 (s, 9H), 3.36 (s, 3H), 3.89 (s, 3H), 5.54 (d, J = 
2.5 Hz, 1H), 6.03 (d, J = 2.5 Hz, 1H), 7.36 7.44 (m, 6H), 7.71 7.73 (m, 4H). 
13C  NMR  (100  MHz,  CDCl3)  δ  19.6,  26.2,  51.8,  54.8,  95.1,  98.7,  99.1,  127.6, 
127.9, 130.1, 132.1, 135.5, 158.2, 164.4, 165.2. 
HRMS (CI
+) calcd for C25H29O5Si (M
++H): 437.1784.  Found 437.1786. 
νmax (film)/cm
 1 2857, 1652, 1615, 1575, 1427, 1210, 1100. 
Methyl 2 hydroxy 4 methoxy 6 (methoxymethoxy)benzoate, 111 
MeO
MOMO
OH
OMe
O
 
 
A  stirred  solution  of  diol  104  (130  mg,  0.63  mmol)  in  DCM  (2  mL)  at  room 
temperature was treated with DIPEA (0.26 mL, 1.51 mmol) and chloromethyl 
methyl ether (0.07 mL, 0.95 mmol) and the reaction mixture was stirred for 18 
hours .  The reaction was quenched with water (3 mL) and the resulting mixture 
was extracted with EtOAc (5 mL x 3).  The organic layers were combined, dried 
over anhydrous MgSO4, filtered and concentrated.  Purification by flash column Murray N Robertson, 2009    98 
chromatography (silica gel with EtOAc (20 %) in 40 60 petroleum ether as the 
eluant) afforded 111 as a colourless oil (20 g, 0.10 mmol, 16 %) and 114 as a 
colourless oil (150 g, 0.53 mmol, 83 %) 
1H NMR (400 MHz, CDCl3) δ 3.50 (s, 3H), 3.77 (s, 3H), 5.18 (s, 2H), 6.16 (s, 2H), 
11.90 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ 52.4, 55.6, 56.6, 94.9, 95.2, 95.2, 159.7, 165.3, 
165.6, 171.6. 
HRMS (EI
+) calcd for C11H15O6 (M
+): 242.0790.  Found 242.0792. 
νmax (film)/cm
 1 2955, 1732, 1579, 1436, 1218. 
Methyl 4 methoxy 2 (trifluoromethylsulfonyloxy) 6 (trityloxy)benzoate, 112 
MeO
O
OTf
OMe
O
Ph
Ph
Ph
 
 
A 0 ˚C solution of alcohol 109 (0.67 g, 1.52 mmol) in pyridine (4 mL) was treated 
with trifluoromethanesulfonic anhydride (0.27 ml, 1.67 mmol) and the reaction 
mixture was stirred for 4 hours.  The reaction was quenched with water (5 mL), 
citric acid (1 M, 5 mL) and extracted with Et2O (15 mL x 3).  The organic layers 
were  combined,  washed  with  brine  (20  mL),  dried  over  anhydrous  MgSO4, 
filtered  and  concentrated  at  reduced  pressure.    Purification  by  flash  column 
chromatography  (silica  gel  with  DCM  (20  %)  in  40 60  petroleum  ether  as  the 
eluant) afforded 112 as an orange oil (0.86 g, 1.50 mmol, 99 %).  
1H NMR (400 MHz, CDCl3) δ 3.84 (s, 3H), 3.93 (s, 3H), 6.87 (s, 2H), 7.25 7.26 (m, 
15H). 
13C NMR (100 MHz, CDCl3) δ 53.1, 56.6, 82.1, 108.8, 113.5, 113.8, 117.0, 127.2, 
127.3, 128.0, 147.0, 148.9, 149.0, 161.0, 162.6. 
HRMS (CI
+) calcd for C10H10F3O7S (M
+ C19H15): 331.0099.  Found 331.0101. Murray N Robertson, 2009    99 
νmax (film)/cm
 1 3061, 1737, 1562, 1490, 1433, 1322, 1211, 1144. 
Methyl 2 (tert-butyldiphenylsilyloxy) 4 methoxy 6 
(trifluoromethylsulfonyloxy)benzoate, 113 
MeO
TBDPSO
OTf
OMe
O
 
 
A 0 ˚C solution of alcohol 110 (1.52 g, 2.29 mmol) in pyridine (6 mL) was treated 
with trifluoromethanesulfonic anhydride (0.41 ml, 2.52 mmol) and the reaction 
mixture was stirred for 4 hours.  The reaction was quenched with water (10 mL), 
citric acid (1 M, 10 mL) and extracted with Et2O (20 mL x 3).  The organic layers 
were  combined,  washed  with  brine  (25  mL),  dried  over  anhydrous  MgSO4, 
filtered  and  concentrated  at  reduced  pressure.    Purification  by  flash  column 
chromatography  (silica  gel  with  DCM  (20  %)  in  40 60  petroleum  ether  as  the 
eluant) afforded 113 as an orange oil (1.29 g, 2.27 mmol, 99 %).  
1H NMR (400 MHz, CDCl3) δ 1.08 (s, 9H), 3.29 (s, 3H), 3.94 (s, 3H), 5.92 (d, J = 
2.2 Hz, 1H), 6.36 (d, J = 2.2 Hz, 1H), 7.32 7.50 (m, 6H), 7.7 7.76 (m, 4). 
13C NMR (100 MHz, CDCl3) δ 18.2, 24.9, 53.4, 56.7, 82.4, 108.8, 113.2, 117.0, 
129.2, 130.4, 137.0, 153.9, 157.0, 161.5, 162.2. 
HRMS (EI
+) calcd for C26H28F3O7SSi (M
++H): 569.1277.  Found 569.1281.  
Methyl 4 methoxy 2,6 bis(methoxymethoxy)benzoate, 114 
MeO
MOMO
OMOM
OMe
O
 
 
1H NMR (400 MHz, CDCl3) δ 3.46 (s, 6H), 3.78 (s, 3H), 3.80 (s, 3H), 5.15 (s, 4H), 
6.39 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ 52.4, 55.7, 56.4, 94.9, 95.2, 156.1, 162.3, 166.9. 
HRMS (EI
+) calcd for C13H18O7 (M
+): 286.1053.  Found 286.1049.  Murray N Robertson, 2009    100 
νmax (film)/cm
 1 2920, 2852, 1732, 1433, 1268. 
5 (tert Butyldimethylsilyloxy)pentan 1 ol, 116
86 
HO OTBS  
 
To a suspension of NaH (60 % in mineral oil, 1.53 g, 38.25 mmol) in THF (90 mL) 
at 0 ˚C was added a solution of 1,5 pentanediol 115 (4.1 mL, 39.0 mmol) in THF 
(90  mL).    The  mixture  was  stirred  for  45  minutes,  a  solution  of  tert-
butyldimethylsilyl chloride (5.50 g, 36.5 mmol) in THF (60 mL).  The reaction 
was allowed to reach room temperature and stirred for 2 hours.  The reaction 
mixture was diluted with water (250 mL) and extracted with EtOAc (250 mL x 3).  
The organic fractions were combined, concentrated at reduced pressure, washed 
with brine (200 mL), dried over anhydrous MgSO4, filtered and concentrated at 
reduced pressure.  Purification by flash column chromatography (silica gel with 
EtOAc  (30  %)  in  40 60  petroleum  ether  as  the  eluant)  afforded  116  as  a 
colourless oil (7.47 g, 34.20 mmol, 94 %).
 
1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.89 (s, 9H), 1.38 1.44 (m, 2H), 1.48 (br, 
1H), 1.51 1.62 (m, 4H), 3.61 (t, J = 6.4 Hz, 2H), 3.64 (t, J = 6.6 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ  4.8, 18.1, 22.5, 25.7, 31.9, 34.3, 62.2, 62.9. 
HRMS (CI
+) calcd for C11H27O2Si (M
++H): 219.1780.  Found 219.1779.  
νmax (film)/cm
 1 2936, 2858, 1254, 1101. 
5 (tert Butyldimethylsilyloxy)pentanal, 117
86 
O OTBS
H
 
 
A  78 ˚C solution of oxalyl chloride (2.8 mL, 32.25 mmol) in DCM (100 mL) was 
treated with DMSO (4.58 mL, 64.50 mmol) and the reaction mixture was stirred 
for 30 minutes.  A solution of alcohol 116 (4.70 g, 21.50 mmol) in DCM (30 mL) 
was added via canula and the reaction mixture was stirred for 1 hour at  78 ˚C 
before triethylamine (13.5 mL, 96.8 mmol) and DCM (50 mL) was added and the 
mixture allowed to warm up to room temperature over 1 hour.  The reaction Murray N Robertson, 2009    101 
mixture was washed with brine (150 mL) and extracted with EtOAc (250 mL x 3).  
The  organic  layers  were  combined,  dried over  anhydrous  MgSO4,  filtered  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with Et2O (10 %) in 40 60 petroleum ether as the eluant) afforded 117 
as a colourless oil (3.58 g, 16.56 mmol, 77 %). 
1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.51 1.58 (m, 2H), 1.66 
1.73 (m, 2H), 2.46 (dt, J = 7.3, 1.8 Hz, 2H), 3.62 (t, J = 6.2 Hz, 2H), 9.77 (t, J = 
1.8 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ  4.8, 18.1, 25.7, 29.9, 44.3, 63.2, 199.7. 
HRMS (CI
+) calcd for C11H25O2Si (M
++H); 217.1624.  Found 217.1621. 
νmax (film)/cm
 1 2941, 1727, 1453, 1123, 1035. 
(E) Methyl 7 (tert butyldimethylsilyloxy)hept 2 enoate, 118
87 
O
O OTBS
 
 
To a stirred solution of freshly prepared aldehyde 117 (4.65 g, 21.50 mmol) in 
THF  (100  mL)  was  added  methyl(triphenylphosphoranylidene)acetate  (13.0  g, 
56.48 mmol) and refluxed at 75 °C for 5 hours.  The reaction was then allowed 
to cool down to room temperature and was diluted with petroleum ether (100 
mL).    The  reaction  mixture  was  then  filtered  and  concentrated  at  reduced 
pressure  to  give  the  crude  product  which  was  purified  by  flash  column 
chromatography (silica gel with EtOAc (0 5 %) in 40 60 petroleum ether as the 
eluant) afforded 118 as a colourless oil (3.25 g, 11.94 mmol, 56 %). 
1H NMR (400 MHz, CDCl3) δ  0.02 (s, 6H), 0.83 (s, 9H), 1.43 1.50 (m, 4H), 2.14 
2.19 (m, 2H), 3.55 (t, J = 5.5 Hz, 2H), 3.65 (s, 3H), 5.76 (d, J = 15.1 Hz, 1H), 
6.91 (dt, J = 15.1, 7.4 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ  5.3, 18.3, 24.4, 26.0, 32.0, 32.2, 51.3, 62.7, 121.0, 
149.5, 167.1. Murray N Robertson, 2009    102 
HRMS (CI
+) calcd for C14H29O3Si (M
++H): 273.1886.  Found 273.1887. 
νmax (film)/cm
 1 2934, 2857, 1726, 1461, 1317. 
(S) 5 (tert Butyldimethylsilyloxy) 1 ((4R,5S) 5 ((E) 4 hydroxybut 2 enyl) 2,2 
dimethyl 1,3 dioxolan 4 yl)hex 2 yn 1 ol, 124 
O
O
TBSO
HO
HO  
 
A 0 ˚C solution of ester 100 (40 mg, 0.10 mmol) in DCM (1 mL) was treated with 
dibal H (1 M, 0.3 mL, 0.30 mmol) and the reaction mixture was stirred for 2 
hours.  DCM (3 mL) was added and the reaction was quenched with water (0.01 
mL) followed by aqueous sodium hydroxide (15 %, 0.01 mL) and finally water 
(0.01  mL).    The  mixture  was  allowed  to  warm  up  to  room  temperature  and 
stirred for a further 15 minutes.  Anhydrous MgSO4 was added and the reaction 
mixture was filtered and concentrated at reduced pressure.  Purification by flash 
column  chromatography  (silica  gel  with  EtOAc  (15 50  %)  in  40 60  petroleum 
ether  as  the  eluant)  afforded  124  as  a  yellow  oil  in  a  60:40  mixture  of 
diastereomers (40 mg, 0.10 mmol, 100 %). 
Major product 
1H NMR (400 MHz, CDCl3) δ 0.05 (s, 3H), 0.06 (s, 3H), 0.87 (s, 9H), 1.22 (d, J =6.1 
Hz, 3H), 1.35 (s, 3H), 1.48 (s, 3H), 1.73 (br, 2H), 2.30 2.55 (m, 4H), 3.92 4.00 
(m, 1H), 4.08 4.11 (m, 3H), 4.22 4.24 (m,1H), 4.40 4.42 (m, 1H), 5.73 5.75 (m, 
2H). 
13C NMR (100 MHz, CDCl3) δ 4.6, 4.6, 18.3, 23.5, 25.5, 26.0, 27.7, 29.5, 29.9, 
32.5, 62.4, 63.7, 67.6, 70.8, 85.1, 79.8, 107.7, 129.1, 131.7. Murray N Robertson, 2009    103 
Minor product 
1H NMR (400 MHz, CDCl3) δ 0.05 (s, 3H), 0.06 (s, 3H), 0.87 (s, 9H), 1.21 (d, J =6.2 
Hz, 3H), 1.36 (s, 3H), 1.50 (s, 3H), 1.73 (br, 2H), 2.30 2.55 (m, 4H), 3.92 4.00 
(m, 1H), 4.08 4.11 (m, 3H), 4.22 4.24 (m,1H), 4.40 4.42 (m, 1H), 5.73 5.75 (m, 
2H). 
13C NMR (100 MHz, CDCl3) δ 4.6, 4.6, 19.3, 23.5, 25.5, 26.0, 27.7, 29.8, 31.1, 
35.0, 62.4, 63.8, 67.5, 77.0, 72.5, 77.4, 99.5, 128.4, 131.6. 
HRMS (EI
+) calcd for C21H39O5 Si(M
+): 399.2567.  Found 399.2569.  
νmax (film)/cm
 1 3411, 2930, 2857, 2233, 1462, 1257, 1065. 
[(4R,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl]methanol, 125
66 
O
O
OH
 
 
To  a  stirred  suspension  of  methyltriphenyl phosphonium  iodide  (6.80  g,  16.8 
mmol) in THF (35 mL) was added KHMDS (0.5 M in toluene, 25.3 mL, 12.6 mmol) 
at  78 ˚C.  The solution was warmed to 0 ˚C and stirred for 30 minutes before 
being cooled down once again to  78 ˚C.  Acetonide 58 (0.73 g, 4.2 mmol) in 
THF (5 mL) was then added via cannula and the solution was warmed up to room 
temperature  overnight  (12  hours).    The  reaction  was  then  quenched  with 
saturated aqueous ammonium chloride (40 mL) and extracted with EtOAc (100 
mL  x  3).    The  organic  layers  were  combined,  dried  over  anhydrous  MgSO4, 
filtered  and  concentrated  at  reduced  pressure.    The  crude  was  dissolved  in 
EtOAc  (10  %)  in  40 60  petroleum  ether  to  crash  out  most  of  the 
triphenylphosphine  oxide.    The  mixture  was  filtered  and  concentrated  at 
reduced  pressure.    Purification  of  the  crude  residue  by  flash  column 
chromatography (silica gel with EtOAc (0 20 %) in 40 60 petroleum ether as the 
eluant) afforded 125 as a colourless oil (490 mg, 2.8 mmol, 67 %). 
1H NMR (400 MHz, CDCl3) δ 1.37 (s, 3H), 1.48 (s, 3H), 2.25 2.32 (m, 1H), 2.37 
2.44 (m, 1H), 3.65 (t, J = 5.7 Hz, 2H), 5.10 5.17 (m, 2H), 5.78 5.89 (m, 1H).   Murray N Robertson, 2009    104 
13C NMR (100 MHz, CDCl3) δ 25.4, 28.0, 33.6, 61.3, 76.2, 77.8, 108.1, 117.2, 
134.2. 
HRMS (CI
+) calcd for C9H17O3 (M
++H): 173.1178.  Found 173.1175. 
νmax (film)/cm
 1 3450, 3077, 2987, 2929, 2853, 1643, 1457, 1379, 1235, 1217, 
1045. 
[α]
19
D –15.6 (c=1, CHCl3) 
[(4R,5S) 2,2 Dimethyl 5 (3 methylbut 2 en 1 yl) 1,3 dioxolan 4 yl]methanol, 
127 
O
O
OH
 
 
To a suspension of isopropyltriphenylphosphonium iodide (1.40 g, 3.31 mmol) in 
THF (3 mL) at  78 °C was added n BuLi (1.6 M, 2.0 mL, 3.2 mmol) drop wise over 
10 minutes and allowed to reach 0 ˚C.  After 20 minutes the mixture was cooled 
to  78 °C and a solution of acetonide 58 (232 mg, 1.33 mmol) in THF (1 mL) was 
added.    The  reaction  was  allowed  to  reach  room  temperature  and  stirring 
continued for 10 hours.  The reaction was quenched with water (1 mL) and was 
diluted with Et2O (10 mL).  The resulting mixture was filtered through a pad a 
celite and the filtrate washed with water (10 mL).  The organic fraction was 
dried over anhydrous MgSO4, filtered and concentrated.  Purification by flash 
column  chromatography  (silica  gel  with  EtOAc  (25 40  %)  in  40 60  petroleum 
ether as the eluant) afforded 127 as a yellow oil (150 mg, 0.75 mmol, 56 %). 
1H NMR (400 MHz, CDCl3) δ 1.37 (s, 3H), 1.48 (s, 3H), 1.63 (s, 3H), 1.71 (s, 3H), 
1.83 1.90  (m,  1H),  2.18 2.27  (m,  1H),  2.29 2.39  (m,  1H),  3.57 3.68  (m,  2H), 
4.13 4.24 (m, 2H), 5.12 (t, J = 6.9 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 18.1, 25.6, 25.9, 28.2, 28.7, 61.8, 77.0, 78.0, 108.2, 
119.4, 134.5. 
HRMS (CI
+) calcd for C11H21O3 (M
++H): 201.1491.  Found 201.1487.  Murray N Robertson, 2009    105 
νmax (film)/cm
 1 3449, 2984, 2931, 1378, 1216, 1044. 
[α]
20
D 20.8 (c=1, CHCl3) 
((4R,5S) 5 cinnamyl 2,2 dimethyl 1,3 dioxolan 4 yl)methanol, 128
88 
O
O
OH
 
 
A  78 ˚C suspension of benzyltriphenylphosphonium chloride (2.75 g, 7.08 mmol) 
in THF (10 mL) was treated with KHMDS (0.5 M in toluene, 12.4 mL, 6.20 mmol) 
and allowed to reach 0 ˚C for 30 minutes.   The reaction mixture was then 
cooled down to  78 ˚C and acetonide 58 (0.616 g, 3.54 mmol) in THF (2 mL) was 
added  via  cannula  and  the  solution  was  warmed  up  to  room  temperature 
overnight  (13  hours).    The  reaction  was  quenched  with  saturated  aqueous 
ammonium chloride (40 mL) and extracted with EtOAc (30 mL x 3).  The organic 
layers were combined, dried over anhydrous MgSO4, filtered and concentrated at 
reduced pressure.  The crude was dissolved in EtOAc (10 %) in 40 60 petroleum 
ether to crash out most of the triphenylphosphine oxide which was filtered off 
and  the  crude  was  concentrated  at  reduced  pressure.    Purification  by  flash 
column chromatography (silica gel with EtOAc (30 %) in 40 60 petroleum ether as 
the eluant) afforded the desired E conjugated ester 128 as a colourless oil (590 
mg, 2.37 mmol, 67 %) and the Z conjugated ester (100 mg, 0.40 mmol, 11 %). 
E product 
1H NMR (400 MHz, CDCl3) δ 1.38 (s, 3H), 1.51 (s, 3H), 1.86 (t, J = 6.0 Hz, 1H), 
2.40 2.49 (m, 1H), 2.53 2.62 (m, 1H), 3.70 (t, J = 5.8 Hz, 2H), 4.22 (dd, J = 11.6, 
5.8 Hz, 1H), 4.27 4.35 (m, 1H), 6.23 (ddd, J = 15.9, 7.6, 6.4 Hz, 1H), 6.49 (d, J = 
15.9 Hz, 1H), 7.17 7.25 (m, 1H), 7.26 7.39 (m, 4H). 
13C NMR (75 MHz, CD3OD) δ 25.8, 28.5, 34.3, 61.9, 78.2, 79.4,  109.3, 127.1, 
128.1, 129.2, 129.5, 133.3, 138.9. Murray N Robertson, 2009    106 
Z product 
1H NMR (400 MHz, CDCl3) δ 1.38 (s, 3H), 1.46 (s, 3H), 1.79 (t, J = 5.4 Hz, 1H), 
2.53 2.62 (m, 1H), 2.64 2.73 (m, 1H), 3.55 3.58 (m, 1H), 4.22 (dd, J = 11.6, 5.8 
Hz, 1H), 4.27 4.35 (m, 1H), 5.71 (dt, J = 11.7, 7.0 Hz, 1H), 6.57 (d, J = 11.7 Hz, 
1H), 7.17 7.25 (m, 1H), 7.26 7.39 (m, 4H). 
13C NMR (75 MHz, CD3OD) δ 28.4, 29.9, 34.3, 61.9, 78.2, 79.3,  109.3, 127.5, 
127.8, 129.3, 129.8, 131.8, 138.6. 
HRMS (CI
+) calcd for C15H21O3 (M
++H): 249.1491.  Found 249.1489. 
νmax (film)/cm
 1 3456, 2986, 2935, 1598, 1494, 1449, 1163, 1043. 
(4S,5S) 2,2 Dimethyl 5 (3 methylbut 2 en 1 yl) 1,3 dioxolane 4 
carbaldehyde, 129 
O
O
O
H
 
 
A  78 ˚C solution of oxalyl chloride (0.10 mL, 1.20 mmol) in DCM (5 mL) was 
treated with DMSO (0.16 mL, 2.40 mmol) and the reaction mixture was stirred 
for 30 minutes.  A solution of alcohol 127 (120 g, 0.60 mmol) in DCM (5 mL) was 
added dropwise and the reaction mixture was stirred for 1 hour at  78 ˚C before 
triethylamine (0.63 mL, 4.80 mmol) was added and the mixture allowed to warm 
up to room temperature over 1 hour.  The reaction mixture was washed with HCl 
(1 M, 5 mL), saturated aqueous sodium bicarbonate (5 mL) and brine (5 mL).  
The  organic  layer  was  then  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with EtOAc (25 %) in 40 60 petroleum ether as the eluant) to afford 
129 as a yellow oil (110 mg, 0.55 mmol, 92 %).  
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 3H), 1.59 (s, 3H), 1.60 (s, 3H), 1.71 (s, 3H), 
2.28 (dd, J = 6.7, 6.7 Hz, 2H), 4.31 (dd, J = 7.1, 3.1 Hz, 1H), 4.39 (dt, J = 6.9, 
6.7, Hz, 1H), 5.15 (dt, J = 6.9, 1.4 Hz, 1H), 9.64 (d, J = 3.1 Hz, 1H). Murray N Robertson, 2009    107 
13C  NMR  (100  MHz,  CDCl3)  δ  18.7,  25.3,  25.9,  27.5,  28.7,  78.8,  82.0,  110.6, 
118.6, 135.3, 201.6. 
HRMS (CI
+) calcd for C11H19O3 (M
++H): 199.1334.  Found 199.1331.   
νmax (film)/cm
 1 2986, 2932, 1734, 1457, 1067. 
[α]
23
D –7.6 (c=1, CHCl3) 
(4S,5S) 2,2 Dimethyl 5 [(2E) 3 phenylprop 2 en 1 yl] 1,3 dioxolane 4 
carbaldehyde, 130
88 
O
O
O
H
 
 
A  78 ˚C solution of oxalyl chloride (0.21 mL, 2.38 mmol) in DCM (10 mL) was 
treated with DMSO (0.32 mL, 4.76 mmol) and the reaction was stirred at –78 ˚C 
for 30 minutes.  A solution of alcohol 128 (290 mg, 1.19 mmol) in DCM (5 mL) 
was added via canula and the reaction mixture was stirred for 45 minutes at –78 
˚C  before  triethylamine  (1.25  mL,  9.52  mmol)  was  added  and  the  mixture 
allowed to warm up to room temperature over 1 hour.  The reaction mixture was 
washed with HCl (1 M, 10 mL), saturated aqueous sodium bicarbonate (10 mL) 
and brine (15 mL).  The organic layer was then dried over anhydrous MgSO4, 
filtered  and  concentrated  at  reduced  pressure.    Purification  by  flash  column 
chromatography (silica gel with EtOAc (30 %) in 40 60 petroleum ether as the 
eluant) to afford the desired E conjugated ester 130 as a yellow oil (0.223 g, 
0.91 mmol, 77 %) plus a fraction of partially separated E/Z diastereomers. 
E product 
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 3H), 1.61 (s, 3H), 2.38 2.57 (m, 1H), 3.05 
3.14 (m, 1H), 4.34 (dd, J = 7.3, 3.1 Hz, 1H), 4.42 4.50 (m, 1H), 6.19 (dt, J = 
15.9, 7.0 Hz, 1H), 6.50 (d, J = 15.9 Hz, 1H), 7.24 7.18 (m, 1H), 7.28 7.36 (m, 
4H), 9.70 (d, J = 3.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 25.3, 27.5, 33.5, 78.4, 81.9, 110.8, 124.8, 126.3, 
127.5, 128.6, 128.7, 133.3, 202.1. Murray N Robertson, 2009    108 
Z product 
1H NMR (400 MHz, CDCl3) δ 1.39 (s, 3H), 1.57 (s, 3H), 2.38 2.57 (m, 1H), 3.05 
3.14 (m, 1H), 4.32 (dd, J = 7.3, 3.1 Hz, 1H), 4.42 4.50 (m, 1H), 5.69 (dt, J = 
11.7, 7.0 Hz, 1H), 6.57 (d, J = 11.7 Hz, 1H), 7.24 7.18 (m, 1H), 7.28 7.36 (m, 
4H), 9.60 (d, J = 3.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 27.5, 29.1, 33.6, 78.2, 81.8, 108.7, 126.2, 126.4, 
127.1, 128.4, 128.5, 137.0, 201.7. 
HRMS (CI
+) calcd for C15H19O3 (M
++H): 247.1334.  Found 247.1337.  
νmax (film)/cm
 1 2988, 1732, 1494, 1381, 1070. 
1 ((4R,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl)propan 1 ol, 140 
O
O HO
 
 
A  78 ˚C solution of oxalyl chloride (0.10 mL, 1.14 mmol) in THF (5 mL) in a flask 
wrapped in tin foil to eliminate light was treated  with DMSO (0.15 mL,  2.26 
mmol) and the reaction mixture was stirred for 30 minutes.  A solution of alcohol 
125 (100 mg, 0.58 mmol) in THF (5 mL) was added dropwise and the reaction 
mixture was stirred for 30 minutes at  78 ˚C before a triethylamine (0.60 mL, 
4.28  mmol)  was  added  and  the  mixture  was  allowed  to  warm  up  to  room 
temperature over 30 minutes.  The reaction mixture was cooled to –78 ˚C and 
ethylmagnesium  bromide  solution  (3.0  M,  0.29  mL,  0.87  mmol)  was  added 
dropwise.  The reaction was allowed to reach room temperature and stirred for 
2 hours.  The reaction was then quenched with saturated aqueous ammonium 
chloride (15 mL) and extracted with EtOAc (20 mL x 3).  The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc (20 
%) in 40 60 petroleum ether as the eluant) afforded 140 as a colourless oil (77 
mg, 0.38 mmol, 66 %). Murray N Robertson, 2009    109 
1H NMR (400 MHz, CDCl3) δ 0.97 (t, J = 7.4 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H), 1.32 
(s, 3H), 1.35 (s, 3H), 1.41 (s, 3H), 1.49 (s, 3H), 1.80 (ddd, J = 14.2, 7.6, 2.9 Hz, 
2H), 1.91 2.11 (m, 2H), 2.28 2.36 (m, 2H), 2.43 2.51 (m, 2H), 3.25 3.32 (m, 1H), 
3.63 (dt, J = 8.5, 2.9 Hz, 1H), 3.88 (dd, J = 8.5, 5.6 Hz, 1H), 3.95 (dd, J = 6.2, 
4.6 Hz, 1H), 4.12 4.28 (m, 2H), 5.06 5.14 (m, 4H), 5.79 5.92 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 9.4, 10.3, 25.2, 25.9, 27.7, 27.7, 27.5, 28.3, 34.6, 
35.0, 71.0, 71.1, 79.6, 80.0, 108.1, 108.2, 117.3, 134.9, 135.6. 
LRMS calcd for C11H21O3 (M
++H): 201.1491.  Found 201.2. 
νmax (film)/cm
 1 3488, 2983, 2921, 1460, 1379, 1218, 1061. 
(S) 1 ((4R,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 5 (tert 
butyldimethylsilyloxy)hex 2 yn 1 ol, 141 
O
O
TBSO
HO
 
 
A  78 ˚C solution of oxalyl chloride (0.08 mL, 0.96 mmol) in THF (3 mL), in a 
flask wrapped in tin foil to eliminate light, was treated with DMSO (0.14 mL, 
1.97 mmol) dropwise and the reaction mixture was stirred for 30 minutes.  A 
solution of alcohol 125 (110 g, 0.64 mmol) in THF (2 mL) was added dropwise 
and the reaction mixture was stirred for 1 hour at  78 ˚C before triethylamine 
(0.40 mL, 2.86 mmol) and THF (5 mL) was added and the mixture was allowed to 
warm  up  to  room  temperature  over  30  minutes.    The  reaction  mixture  was 
cooled to –78 ˚C and the solution of deprotonated alkyne was added and the 
reaction mixture was allowed to warm up to room temperature and stirred for 2 
0.5  hours  .    The  reaction  was  quenched  with  saturated  aqueous  ammonium 
chloride (15 mL), extracted with EtOAc (20 mL x 3).  The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc (0 
10  %)  in  40 60  petroleum  ether  as  the  eluant)  afforded  141  as  a  mixture of 
diastereomers (128 mg, 0.35 mmol, 54 %). Murray N Robertson, 2009    110 
Deprotonation of alkyne 99 
To  a  solution  of  alkyne  99  (250  mg,  1.28  mmol)  in  THF  (5  mL)  at  room 
temperature was added ethylmagnesium bromide solution (3.0 M, 0.32 mL, 0.96 
mmol) and stirring was continued for 2 hours. 
1H NMR (400 MHz, CDCl3) δ 0.10 0.18 (m, 6H), 0.88 0.90 (m, 9H), 1.22 1.25 (m, 
3H), 1.33 1.35 (m, 3H), 1.47 1.52 (m, 3H), 2.24 2.74 (m, 5H), 3.90 3.99 (m, 1H), 
4.02 4.09 (m, 1H), 4.18 4.28 (m, 1H), 4.39 4.47 (m, 2H), 5.06 5.16 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ  4.6,  4.5, 18.3, 23.4, 23.5, 25.5, 25.5, 25.9, 27.6, 
28.1, 29.8, 29.9, 33.9, 34.1, 61.4, 62.4, 67.5, 67.6, 76.8, 77.4, 79.8, 80.4, 84.9, 
85.1, 108.7, 108.9, 117.2, 117.3, 134.8, 135.1. 
HRMS (FAB
+) calcd for C20H37O4Si (M
++H): 369.2461.  Found 369.2462.  
νmax (film)/cm
 1 3448, 2955, 2930, 2857, 2345, 1638, 1218, 1098. 
(S) 5 ((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 3,3 diisopropyl 
2,9,11,11,12,12 hexamethyl 4,10 dioxa 3,11 disilatridec 6 yne, 142 
TBSO
TIPSO
O
O  
 
To a stirred solution of alcohol 141 (70 mg, 0.18 mmol) in DMF (3 mL) at room 
temperature  was  added  imidazole  (50  mg,  0.72  mmol)  and  triisopropylsilyl 
chloride (0.08 mL, 0.37 mmol) and stirred for 19 hours.  Imidazole (30 mg, 0.37 
mmol)  and  triisopropylsilyl  chloride  (0.04  mL,  0.19  mmol)  were  added  and 
stirring continued for a further 5 hours before the addition of saturated aqueous 
sodium bicarbonate (30 mL) and extraction with 50 % EtOAC, 40 60 petroleum 
ether (30 mL x 3).  The organic layers were combined, dried over anhydrous 
MgSO4,  filtered  and  concentrated  at  reduced  pressure.    Purification  by  flash 
column chromatography (silica gel with EtOAc (1 %) in 40 60 petroleum ether as Murray N Robertson, 2009    111 
the eluant) afforded 142 as an inseparable mixture of diastereoisomers (55:45) 
(60 mg, 0.12 mmol, 69 %). 
1H NMR (400 MHz, CDCl3) δ 0.04 0.07 (m, 12H), 0.87 (s, 9H), 0.88 (s, 9H), 1.09 
(d, J = 5.6 Hz, 36H), 1.11 1.21 (m, 6H), 1.24 (d, J = 6.0 Hz, 6H), 1.34 (s, 3H), 
1.35 (s, 3H), 1.47 (s, 3H), 1.48 (s, 3H), 2.24 (dt, J = 8.2, 1.9 Hz, 1H), 2.28 (dt, J 
= 8.2, 1.9 Hz, 1H), 2.37 2.60 (m, 6H), 3.89 3.97 (m, 2H), 4.08 (t, J = 6.2 Hz, 1H), 
4.14 (t, J = 6.3 Hz, 1H), 4.19 4.24 (m, 2H), 4.53 (dt, J = 6.6, 2.0 Hz, 1H), 4.61 
4.53 (dt, J = 6.4, 2.0 Hz, 1H), 5.07 5.13 (m, 4H), 5.84 5.95 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ  4.7,  4.6, 12.3, 12.8, 18.1, 18.3, 18.3, 23.3, 25.7, 
25.8, 26.0, 27.9, 28.1, 29.9, 30.0, 34.3, 34.7, 62.8, 62.9, 63.2, 67.6, 67.7, 77.3, 
77.4, 80.6, 80.6, 83.8, 85.0, 108.5, 108.8, 116.7, 116.8, 135.8, 135.8. 
HRMS (CI
+) calcd for C29H58O4Si2 (M
++H): 525.3795.  Found 525.3793. 
νmax (film)/cm
 1 3076, 2931, 2866, 2238, 1642, 1463, 1378, 1255, 1217, 1125. 
((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 6 (triisopropylsilyloxy)hex 4 
yn 2 ol, 143 
O
O
HO
TIPSO
 
 
To a stirred solution of silyl ether 142 (110 mg, 0.21 mmol) in THF (3 mL) at 0 
˚C was added HF Pyr:Pyr:THF solution (1:4:10, 2.4 mL) and stirred for 44 hours.  
The reaction was slowly quenched with saturated aqueous sodium bicarbonate 
(20  mL)  and  extracted  with  EtOAc  (25  mL  x  3).    The  organic  layers  were 
combined  and  washed  with  citric  acid  (5  %,  100  mL),  dried  over  anhydrous 
MgSO4,  filtered  and  concentrated  at  reduced  pressure.    Purification  by  flash 
column chromatography (silica gel with EtOAc (5 %) in 40 60 petroleum ether as 
the eluant) afforded 143 as a yellow oil in a 60:40 mixture of diastereomers (50 
mg, 0.13 mmol, 60 %). Murray N Robertson, 2009    112 
Major product 
1H NMR (400 MHz, CDCl3) δ 1.08 (d, J = 5.6 Hz, 18H), 1.12 1.18 (m, 3H), 1.23 (d, 
J = 6.2 Hz, 3H), 1.34 (s, 3H), 1.54 (s, 3H), 2.20 2.41 (m, 2H), 2.67 2.85 (m, 2H), 
3.90 4.01 (m, 1H), 4.06 4.15 (m, 1H), 4.20 4.33 (m, 1H), 4.52 (dt, J = 5.1, 1.7 
Hz, 1H), 5.06 5.13 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 12.1, 18.0, 25.4, 27.3, 29.7, 32.0, 33.5, 63.4, 66.5, 
77.5, 79.9, 80.3, 83.8, 108.7, 116.7, 135.5. 
Minor product 
1H NMR (400 MHz, CDCl3) δ 1.08 (t, J = 5.6 Hz, 18H), 1.12 1.18 (m, 3H), 1.25 (d, 
J = 6.1 Hz, 3H), 1.36 (s, 3H), 1.48 (s, 3H), 2.20 2.41 (m, 2H), 2.67 2.85 (m, 2H), 
3.90 4.01 (m, 1H), 4.06 4.15 (m, 1H), 4.20 4.33 (m, 1H), 4.59 (dt, J = 7.1, 2.2 
Hz, 1H), 5.06 5.13 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 12.7, 18.0, 25.6, 27.9, 29.5, 31.7, 34.3, 62.6, 63.3, 
77.5, 80.7, 82.7, 83.6, 108.5, 116.9,135.2. 
HRMS (FAB
+) calcd for C23H43O4Si (M
++H): 411.2931.  Found 411.2928. 
νmax (film)/cm
 1 3442, 3076, 2943, 2866, 2234, 1642, 1379, 1216, 1063. 
(S) 1 ((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 5 (tert 
butyldimethylsilyloxy)hex 2 yn 1 one, 144 
O
O
TBSO
O
 
 
Method A 
A mixture of alcohol 141 (60 mg, 0.15 mmol), 4 Å molecular sieves (150 mg) and 
NMO (30 mg, 0.22 mmol) in DCM (1 mL) was stirred at room temperature for 30 Murray N Robertson, 2009    113 
minutes.  TPAP (3 mg, 0.007 mmol) was added and the reaction mixture was 
stirred  for  14  hours  before  being  filtered  through  a  pad  of  silica  and 
concentrated.    Purification  by  flash  column  chromatography  (silica  gel  with 
EtOAc (10 %) in 40 60 petroleum ether as the eluant) afforded 101 as a yellow 
oil (36 mg, 0.098 mmol, 66 %).  
Method B 
A  78 ˚C solution of oxalyl chloride (0.03 mL, 0.34 mmol) in DCM (2 mL)  was 
treated with DMSO (0.05 mL, 0.67 mmol) dropwise and the reaction mixture was 
stirred for 30 minutes.  A solution of alcohol 141 (60 mg, 0.17 mmol) in DCM (1 
mL) was added dropwise via canula followed by a DCM (1 mL) rinse and the 
reaction mixture was stirred for 1 hour at  78 ˚C before triethylamine (0.19 mL, 
1.34 mmol) and DCM (2 mL) was added and the mixture allowed to warm up to 
room temperature over 45 minutes.  DCM (5 mL) was added and the solution was 
washed with HCl (1 M) (5 mL) and saturated aqueous sodium bicarbonate (5 mL).  
The organic fraction was dried over anhydrous MgSO4, filtered and concentrated 
at reduced pressure.  Purification by flash column chromatography (silica gel 
with EtOAc (20 %) in 40 60 petroleum ether as the eluant) afforded 144 as a 
yellow oil (58 mg, 0.16 mmol, 94 %). 
1H NMR (400 MHz, CDCl3) δ 0.05 (s, 3H), 0.06 (s, 3H), 0.87 (s, 9H), 1.25 (d, J = 
6.1 Hz, 3H), 1.37 (s, 3H), 1.62 (s, 3H), 2.21 2.30 (m, 1H), 2.36 2.42 (m, 1H), 
2.48 (dd, J = 17.0, 6.6 Hz, 1H), 2.56 (dd, J = 17.0, 5.5 Hz, 1H), 4.03 (sext, J = 
6.1 Hz, 1H), 4.41 (ddd, J = 9.5, 7.3, 3.9, Hz, 1H), 4.52 (d, J = 7.3 Hz, 1H), 5.08 
5.14 (m, 2H), 5.77 5.87 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ  4.7,  4.6, 18.1, 23.7, 25.4, 25.9, 27.2, 30.2, 34.8, 
66.9, 78.0, 81.7, 83.3, 96.5, 110.8, 117.8, 134.1, 186.5. 
HRMS (FAB
+) calcd for C20H35O4Si (M
++H): 367.2305.  Found 367.2307. 
[α]
26
D –20.4 (c=1.0, CHCl3) 
νmax (film)/cm
 1 3077, 2982, 2930, 2857, 2232, 1642, 1462, 1216. Murray N Robertson, 2009    114 
(S) 4 ((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 2,2,8,10,10,11,11 
heptamethyl 3,9 dioxa 2,10 disiladodec 5 yne, 146 
O
O
TBSO
TMSO
 
 
To a solution of alcohol 141 (120 mg, 0.32 mmol) in Et2O (1 mL) at 0 ˚C was 
added trimethylsilyl chloride (0.06 mL, 0.49 mmol) and pyridine (0.05 mL, 0.58 
mmol).  The resulting white slurry was stirred at room temperature for 20 hours, 
diluted  with  40 60  petroleum  ether  (2  mL),  filtered  through  alumina  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with Et2O (10 50 %) in 40 60 petroleum ether as the eluant) afforded 
146 as an inseparable mixture of diastereoisomers (55:45) (120 mg, 0.27 mmol, 
84 %) plus unreacted starting material (10 mg, 0.03 mmol, 9 %).  Yield based on 
starting material recovered, 93 %. 
1H NMR (400 MHz, CDCl3) δ 0.05 0.06 (m, 12H), 0.18 (s, 18H), 0.88,(s, 18H), 
1.20 1.26 (m, 6H), 1.34 (s, 6H), 1.47 (s, 3H), 1.48 (s, 3H), 2.25 2.33 (m, 4H), 
2.35 2.59  (m,  4H),  3.91 3.98  (m,  2H),  4.08 4.13  (m,  2H),  4.23 4.30  (m,  2H), 
4.30 4.42 (m, 2H), 5.08 5.18 (m, 4H), 5.82 5.92 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ  4.7,  4.6,  4.6, 0.5, 0.5, 18.2, 25.7, 26.0, 28.0, 
29.5, 29.9, 30.0, 32.0, 34.1, 34.4, 62.6, 62.6, 67.5, 67.7, 77.3, 77.3, 80.2, 80.7, 
81.1, 84.0, 108.4, 108.8, 116.8, 116.8, 135.5, 135.6. 
HRMS (CI
+) calcd for C23H45O4Si2 (M
++H): 441.2856.  Found 441.2853. 
νmax (film)/cm
 1 2965, 2921, 2856, 2222, 1250, 1083. Murray N Robertson, 2009    115 
(8S,Z) 4 ((4S,5S) 2,2 Dimethyl 5 propyl 1,3 dioxolan 4 yl) 
2,2,8,10,10,11,11 heptamethyl 3,9 dioxa 2,10 disiladodec 5 ene, 147 
O
O
TMSO
TBSO
 
 
To a stirred solution of alkyne 146 (110 mg, 0.26 mmol) in toluene (2 mL) was 
added palladium on barium sulphate (5 %) (90 mg) and quinoline (0.5 mL) at 
room temperature.  The flask was evacuated and purged with hydrogen 5 times 
and hydrogen was bubbled through the solution for 10 minutes.  After 5 hours 
under  hydrogen  the  reaction  mixture  was  filtered  through  celite  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with EtOAc (0 1 %) in 40 60 petroleum ether as the eluant) afforded 
147 as a colourless oil and only as one diastereomer (13 mg, 0.03 mmol, 12 %).  
1H NMR (400 MHz, CDCl3) δ 0.06 (s, 6H), 0.09 (s, 9H), 0.88 (s, 9H), 0.96 (t, J = 
7.1 Hz, 3H), 1.14 (d, J = 6.1 Hz, 3H), 1.30 (s, 3H), 1.37 (s, 3H), 1.50 1.66 (m, 
4H), 2.22 2.30 (m, 2H), 3.84 3.89 (m, 2H), 4.15 4.19 (m, 1H), 4.43 (dt, J = 8.9, 
0.8 Hz, 1H), 5.41 (ddt, J = 11.1, 9.2, 1.8 Hz, 1H), 5.61 (ddt, J = 11.1, 7.1, 0.8 
Hz, 1H). 
13C NMR (125MHz, CDCl3) δ  4.5,  4.3, 0.9, 14.3, 19.9, 24.0, 25.5, 26.0, 28.3,  
29.9, 32.1, 38.4, 67.4, 68.6, 77.8, 80.00, 107.5, 129.2, 132.1. 
HRMS (EI
+) calcd for C23H48O4Si2 (M
++H): 444.3091.  Found 444.3090. 
νmax (film)/cm
 1 2960, 2928, 2856, 1458, 1252, 1079. 
1 (((S) Pent 4 yn 2 yloxy)methyl) 4 methoxybenzene, 149
89 
OPMB
 
 
To a suspension of sodium hydride (60 % in mineral oil, 490 mg, 12.35 mmol) in 
DMF (50 mL) at 0 ˚C was added a solution of the freshly generated crude alcohol 
76 (0.81 g) in DMF (50 mL).  The mixture was stirred for 15 minutes and the Murray N Robertson, 2009    116 
para methoxybenzyl chloride (1.9 mL, 14.3 mmol) was added.  The reaction was 
allowed  to  reach  room  temperature  and  stirred  for  18  hours.  The  reaction 
mixture was then poured onto brine (250 mL) and extracted with Et2O (250 mL x 
3).  The organic fractions were concentrated at reduced pressure and washed 
with brine (200 mL), dried over anhydrous MgSO4, filtered and concentrated at 
reduced pressure.  Purification by flash column chromatography (silica gel with 
Et2O (30 %) in 40 60 petroleum ether as the eluant) afforded 149 as a cloudy 
white oil (1.61 g, 7.88 mmol, 83 % over 2 steps). 
1H NMR (400 MHz, CDCl3) δ 1.30 (d, J = 6.1 Hz, 3H), 2.01 (t, J = 2.7 Hz, 1H), 2.35 
(ddd, J = 16.6, 7.1, 2.7 Hz, 1H), 2.49 (ddd, J = 16.6, 4.9, 2.7 Hz, 1H), 3.65 3.70 
(m, 1H), 3.80 (s, 3H), 4.50 (s, 2H), 6.86 6.89 (m, 2H), 7.26 7.30 (m, 2H). 
13C  NMR  (100  MHz,  CDCl3)  δ  19.5,  26.0,  55.1,  70.0,  72.8,  73.0,  81.2,  113.7, 
129.1, 130.6, 159.1. 
HRMS (EI
+) calcd for C13H16O2 (M
+): 204.1150.  Found 204.1152. 
νmax (film)/cm
 1 2972, 2933, 2836, 2119, 1612, 1586, 1513, 1247, 1034. 
(S) 1 ((4R,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 5 (4 
methoxybenzyloxy)hex 2 yn 1 ol, 150 
O
O
PMBO
HO
 
 
A  78 ˚C solution of oxalyl chloride (0.25 mL, 2.90 mmol) in THF (10 mL), in a 
flask wrapped in tin foil to eliminate light was treated with DMSO (0.38 mL, 5.79 
mmol) dropwise and the reaction mixture was stirred for 30 minutes.  A solution 
of alcohol 125 (330 mg, 1.93 mmol) in THF (10 mL) was added dropwise and the 
reaction mixture was stirred for 1 hour at  78 ˚C before triethylamine (1.2 mL, 
8.61 mmol) and THF (5 mL) was added and the mixture allowed to warm up to 
room temperature over 30 minutes.  The reaction mixture was cooled to –78 ˚C 
and the solution of deprotonated alkyne was added the reaction mixture was Murray N Robertson, 2009    117 
allowed  to  warm  up  to  room  temperature  and  stirred  for  2.5  hours.    The 
reaction was quenched with saturated aqueous ammonium chloride (25 mL) and 
extracted with EtOAc (35 mL x 3).  The organic layers were combined, dried over 
anhydrous MgSO4, filtered and concentrated at reduced pressure.  Purification by 
flash column chromatography (silica gel with EtOAc (10 20 %) in 40 60 petroleum 
ether as the eluant) afforded 150 as a 55:45 mixture of diastereomers and as a 
yellow oil (128 mg, 0.35 mmol, 54 %). 
Deprotonation of alkyne 149 
To  a  solution  of  alkyne  149  (0.60  g,  2.92  mmol)  in  THF  (15  mL)  at  room 
temperature was added ethylmagnesium bromide solution (3.0 M, 0.77 mL, 2.31 
mmol) and stirring was continued for 2 hours. 
Major product 
1H NMR (400 MHz, CDCl3) δ 1.29 (d, J = 6.1 Hz, 3H), 1.36 (s, 3H), 1.51 (s, 3H), 
2.37 2.58 (m, 4H), 3.65 3.69 (m, 1H), 3.80 (s, 3H), 4.10 4.13 (m, 1H), 4.24 4.29 
(m, 1H), 4.41 4.44 (m, 1H), 4.48 (s, 2H), 5.08 5.17 (m, 2H), 5.82 5.92 (m, 1H), 
6.86 6.91 (m, 2H), 7.25 7.29 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 19.9, 25.5, 26.6, 27.6, 33.9, 55.4, 62.4, 70.5, 73.1, 
77.4, 79.8, 80.4, 84.5, 108.6, 113.9, 117.2, 129.4, 130.7, 135.1, 159.3. 
Minor product 
1H NMR (400 MHz, CDCl3) δ 1.27 (d, J = 4.9 Hz, 3H), 1.38 (s, 3H), 1.49 (s, 3H), 
2.37 2.58 (m, 4H), 3.65 3.69 (m, 1H), 3.81 (s, 3H), 4.10 4.13 (m, 1H), 4.24 4.29 
(m, 1H), 4.41 4.44 (m, 1H), 4.47 (s, 2H), 5.08 5.17 (m, 2H), 5.82 5.92 (m, 1H), 
6.86 6.91 (m, 2H), 7.25 7.29 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 19.9, 25.5, 26.5, 28.1, 34.2, 55.4, 61.4, 70.5, 73.1, 
77.4, 79.8, 80.4, 84.5, 108.6, 113.9, 117.2, 129.4, 130.7, 135.1, 159.3. 
HRMS (CI
+) calcd for C22H31O5 (M
++H): 375.2171.  Found 375.2173. 
νmax (film)/cm
 1 3447, 3074, 2983, 2868, 2835, 1612, 1586, 1513, 1248, 1172. Murray N Robertson, 2009    118 
((S) 1 ((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 5 (4 
methoxybenzyloxy)hex 2 ynyloxy)(tert butyl)dimethylsilane, 151 
O
O
PMBO
TBSO
 
 
To a solution of the alcohol 150 (370 mg, 1.0 mmol) in DCM (12 mL) at room 
temperature  was  added  imidazole  (200  mg,  3.0  mmol)  and  tert-
butyldimethylsilyl chloride (190 mg, 1.25 mmol) and stirred for 20 hours.  The 
reaction mixture was quenched with saturated aqueous sodium bicarbonate (10 
mL) and extracted with DCM (15 mL x 3).  The organic phase was washed with 
brine (50 mL), dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc (15 
%)  in  40 60  petroleum  ether  as  the  eluant)  afforded  151  as  an  inseparable 
mixture of diastereoisomers (55:45) yellow oil (420 mg, 0.09 mmol, 85 %). 
1H NMR (400 MHz, CDCl3) δ 0.10 0.18 (m, 16H), 0.89 (s, 9H), 0.91(s, 9H), 1.28 (d, 
J = 6.1 Hz, 3H), 1.29 (d, J = 6.1 Hz, 3H), 1.34 (s, 3H), 1.34 (s, 3H), 1.47 (s, 3H), 
1.29 (s, 3H), 2.31 2.61 (m, 8H), 3.60 3.70 (m, 2H), 3.80 (s, 3H), 3.80 (s, 3H), 
4.02 4.12 (m, 2H), 4.16 4.23 (m, 2H), 4.42 (dt, J = 6.8, 2.0 Hz, 1), 4.47 (s, 2H), 
4.49 (s, 2H), 5.00 5.10 (m, 3H), 5.11 5.14 (m, 1H), 5.83 5.94 (m, 2H), 6.85 6.88 
(m, 4H), 7.24 7.28 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ  4.8,  4.7,  4.4,  4.3, 18.2, 18.5, 19.8, 19.9, 25.7, 
25.8, 25.9, 26.0, 26.4, 26.6, 27.9, 28.1, 34.3, 34.5, 55.4, 62.6, 63.1, 70.5, 70.5, 
73.3,  73.4,  76.3,  76.4,  77.4,  80.3,  80.5,  108.5,  108.7,  113.9,  113.9,  118.2, 
118.4, 129.3, 129.3, 130.7, 130.8, 134.9, 134.9, 159.2, 159.3. 
νmax (film)/cm
 1 3074, 2983, 2930, 2857, 1613, 1513, 1378, 1249, 1076. 
HRMS (CI
+) calcd for C28H45O5Si (M
++H): 489.3036.  Found 489.3040. Murray N Robertson, 2009    119 
((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 6 (tert 
butyldimethylsilyloxy)hex 4 yn 2 ol, 152 
O
O
HO
TBSO
 
 
To a stirred solution of PMB ether 152 (230 mg, 0.47 mmol) in DCM (15 mL) at 0 
˚C was added pH 7 buffer (15 mL) and DDQ (140 mg, 0.61 mmol) and stirred for 
2 hours.  The reaction was quenched with saturated aqueous sodium bicarbonate 
(20 mL) and extracted with DCM (40 mL x 3).  The organic layers were combined, 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (0 10 %) in 
40 60 petroleum ether as the eluant) afforded 152 as an inseparable mixture of 
diastereoisomers (55:45) yellow oil (140 g, 0.38 mmol, 81 %). 
1H NMR (400 MHz, CDCl3) δ 0.10 (s, 3H), 0.13 (s, 3H), 0.18 (s, 3H), 0.89 (s, 9H), 
0.9, (s, 9H), 1.23 (d, J = 6.2 Hz, 3H), 1.25 (d, J = 6.2 Hz, 3H), 1.33 (s, 3H), 1.35 
(s, 3H), 1.47 (s, 3H), 1.52 (s, 3H), 2.22 2.77 (m, 8H), 3.89 4.01 (m, 2H), 4.01 
4.08 (m, 2H), 4.17 4.29 (m, 2H), 4.40 (dt, 5.4, J = 1.7 Hz, 1H), 4.46 (dt, J = 7.3, 
2.1, 1H), 5.06 5.17 (m, 4H), 5.82 5.97 (m, 2 H) 
13C NMR (100 MHz, CDCl3) δ  4.6,  4.5, 18.4, 23.8, 23.5, 25.3, 25.5, 25.9, 27.6, 
28.1, 30.4, 31.4, 33.9, 34.1, 61.7, 62.1, 67.7, 67.1, 76.8, 77.8, 79.7, 80.4, 85.6, 
85.7, 108.8, 109.0, 117.0, 117.2, 135.0, 135.4 
HRMS (FAB
+) calcd for C20H37O4Si (M
++H): 369.2461.  Found 369.2460.  
νmax (film)/cm
 1 3650, 2931, 2857, 2345, 1640, 1379, 1069. Murray N Robertson, 2009    120 
Methyl 4 methoxy 2 (methoxymethoxy) 6 vinylbenzoate, 153 
MeO
MOMO
OMe
O
 
 
A  0  ˚C  solution  of  phenol  108  (123  mg,  0.59  mmol)  in  acetone  (2  mL)  was 
treated with potassium carbonate (490 mg, 3.54 mmol), triethlyamine (0.45 mL, 
3.25  mmol)  and  chloromethyl  methyl  ether  (0.22  mL,  2.95  mmol)  and  was 
allowed to warm up to room temperature.  Additional acetone (2 mL) was added 
to  dilute  the  reaction  mixture  and  stirring  was  continued  for 17  hours.    The 
reaction mixture was diluted with EtOAc (5 mL), washed with saturated aqueous 
sodium hydroxide (5 mL) and HCl (1 M, 5 mL).  The organic fraction was dried 
over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (5 %) in 40 60 
petroleum ether as the eluant) to afford the desired product 153 as a colourless 
oil (81 mg, 0.32 mmol, 54 %) plus a unreacted starting material 108 (54 mg, 
0.259 mmol, 44 %).  Yield based on starting material recovered 97 %. 
1H NMR (400 MHz, CDCl3) δ 3.46 (s, 3H), 3.81 (s, 3H), 3.84 (s, 3H), 5.16 (s, 2H), 
5.32 (dd, J = 10.9, 0.7 Hz, 1H), 5.70 (dd, J = 17.3, 0.7 Hz, 1H), 6.65 (d, J = 2.2 
Hz, 1H), 6.70 (dd, J = 17.3, 10.9 Hz, 1H), 6.72 (d, J = 2.2 Hz, 1H). 
13C NMR (100MHz, CDCl3) δ 52.3, 55.4, 94.9, 101.0, 103.7, 109.5, 116.5, 130.9, 
137.4, 159.0, 161.1, 168.4. 
HRMS (EI
+) calcd for C13H16O5 (M
+): 252.0998.  Found 252.0997. 
νmax (film)/cm
 1 3092, 3001, 2952, 2836, 1729, 1655, 1599, 1434, 1321, 1152, 
1021. Murray N Robertson, 2009    121 
4 Methoxy 2 (methoxymethoxy) 6 vinylbenzoic acid, 154 
MeO
MOMO
OH
O
 
 
A solution of ester 153 (80 mg, 0.32 mmol) in dioxane (3 mL) was treated with 
aqueous sodium hydroxide (2 M, 2.4 mL, 4.76 mmol) and refluxed for 3 days.  
The reaction was allowed to cool down to room temperature, diluted with water 
(2 mL), acidified with HCl (1 M, 6 mL) and extracted with CHCl3 (10 mL x 3).  
The  organic  layers  were  combined,  dried over  anhydrous  MgSO4,  filtered  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with EtOAc as the eluant) afforded 154 as an off white solid (61 mg, 
0.26 mmol, 81 %). 
1H NMR (400 MHz, CDCl3) δ 3.51 (s, 3H), 3.84 (s, 3H), 5.24 (s, 2H), 5.36 (d, J = 
11.0 Hz, 1H), 5.70 (d, J = 17.3 Hz, 1H), 6.7 (d, J = 2.2 Hz, 1H), 6.8 (d, J = 2.2 
Hz, 1H), 7.10 (dd, J = 17.3, 11.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 52.5, 55.1, 56.6, 95.4, 100.8, 103.8, 114.1, 133.0, 
139.7, 165.4, 165.9, 171.2. 
HRMS (EI
+) calcd for C12H14O5 (M
+): 238.0841.  Found 238.0845. 
νmax (film)/cm
 1 2922, 1629, 1464, 1424, 1263. 
((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 6 (triisopropylsilyloxy)hex 4 
yn 2 yl 2,4,6 trichlorobenzoate, 164 
O
O
TIPSO
O
O
Cl
Cl Cl
 
 
1H NMR (400 MHz, CDCl3) δ 1.00 (s, 18H), 1.01 (s, 18H), 1.16 1.32 (m, 12H), 1.39 
1.44 (m, 6H), 1.89 2.69 (m, 8H), 3.99 4.19 (m, 6H), 4.48 (d, J = 6.4 Hz, 1H), Murray N Robertson, 2009    122 
4.55 (d, J = 6.3 Hz, 1H), 4.93 5.07 (m, 2H), 5.17 5.26 (m, 2H), 5.72 5.82 (m, 
2H), 7,28 (s, 2H), 7.30 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ 12.2, 12.4, 19.1, 19.2, 25.7, 25.9, 27.1, 28.0, 29.6, 
34.1,  34.3,  35.2,  62.6,  63.0,  69.7,  69.9,  70.5,  80.0,  80.7,  82.2,  82.5,  84.0, 
108.4,  108.7,  116.1,  117.0,  128.6,  132.6,  132.9,  135.1,  135.1,  138.8,  138.9, 
142.3, 142.6, 161.1, 165.2. 
HRMS (CI
+) calcd for C30H44Cl3O5Si (M
++H): 617.2024.  Found 617.2025 
νmax (film)/cm
 1 3079, 2941, 2864, 2347, 1743, 1579, 1548, 1460, 1271, 1118. 
2 Hydroxy 4 methoxy 6 vinylbenzoic acid, 175 
MeO
OH
OH
O
 
 
To a stirred solution of ester 108 (2.50g, 12.0 mmol) in dioxane (80 mL) was 
added aqueous NaOH (2.0 M, 90 mL, 180.2 mmol) and the resulting mixture was 
refluxed for 19 hours.  The reaction was allowed to cool to room temperature 
and acidified with HCl (1 M, 250 mL) and extracted with CHCl3 (350 mL x 3).  The 
organic  layers  were  combined,  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated  at  reduced  pressure  to  afford  the  crude  residue.    Washing  the 
crude with 40 60 petroleum ether allowed the isolation of acid 175 as off white 
crystals (2.22 g, 11.43 mmol, 95 %). 
1H NMR (400 MHz, CDCl3) δ 3.85 (s, 3H), 5.30 (dd, J = 10.8, 1.5 Hz, 1H), 5.51 (dd, 
J = 17.1, 1.5 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 6.55 (d, J = 2.6 Hz, 1H), 7.38 (dd, 
J = 17.1, 10.8 Hz, 1H), 11.38 (s, 1H). 
13C  NMR  (100  MHz,  CDCl3)  δ  55.7,  100.4,  102.4,  109.1,  116.7,  138.2,  145.0, 
165.3, 166.1, 175.4. 
HRMS (EI
+) calcd for C10H10O4 (M
+): 194.0579.  Found 194.0581. 
νmax (film)/cm
 1 2978, 1636, 1465, 1262, 1005. Murray N Robertson, 2009    123 
((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 6 (triisopropylsilyloxy)hex 4 
yn 2 yl 2 hydroxy 4 methoxy 6 vinylbenzoate, 176 
MeO
OH O
O
TIPSO
O
O  
 
To a stirred solution of alcohol 143 (90 mg, 0.22 mmol) in DCM (3 mL) at room 
temperature was added DMAP (30 mg, 0.26 mmol), DCC (0.10 g, 0.49 mmol) and 
acid 175 (4 mg, 0.21 mmol) and stirred for 24 hours before being diluted with 
water (2 mL) and extracted with EtOAc (5 mL x 3).  The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc (3 
%)  in  40 60  petroleum  ether  as  the  eluant)  afforded  176  as  an  inseparable 
mixture of diastereoisomers (55:45) (4 mg, 0.07 mmol, 32 %). 
1H NMR (400 MHz, CDCl3) δ 1.03 1.08 (m, 12H), 1.10 1.20 (m, 12H), 1.23 1.29 
(m, 12H), 1.31 (s, 6H), 1.33 (s, 6H), 1.45 (s, 6H), 2.49 2.71 (m, 8H), 3.82 (s, 6H), 
4.10 4.16  (m,  2H),  4.16 4.22  (m,  2H),  4.51 4.56  (m,  1H),  4.58 4.62  (m,  1H), 
5.05 5.07 (m, 2H), 5.16 5.27 (m, 4H), 5.41 (dd, J = 17.3, 1.1 Hz, 2H), 5.82 5.92 
(m, 2H), 6.41 (d, J = 2.4 Hz, 2H), 6.50 (d, J = 2.4 Hz, 2H), 7.29 7.41 (m, 2H), 
11.65 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ 12.3, 12.8, 18.1, 18.3, 19.6, 19.6, 26.1, 26.2, 27.8, 
28.0, 29.9, 34.3, 34.6, 55.6, 62.8, 63.2, 70.7, 70.9, 77.3, 77.4, 80.5, 80.5, 81.7, 
81.9, 82.0, 82.2, 100.3, 100.3, 103.8, 103.9, 108.5, 108.6, 108.6, 108.8, 115.6, 
115.7,  116.8,  116.9,  135.6,  135.6,  138.7,  138.8,  144.0,  144.1,  164.3,  165.2, 
165.2, 170.6. 
HRMS (FAB
+) calcd for C33H50O7SiNa (M
++Na): 609.3224.  Found 609.3220. 
νmax (film)/cm
 1 2935, 2865, 2345, 1653, 1608, 1255, 1063. Murray N Robertson, 2009    124 
((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 6 (tert 
butyldimethylsilyloxy)hex 4 yn 2 yl 2 hydroxy 4 methoxy 6 vinylbenzoate, 
177 
MeO
OH O
O
TBSO
O
O  
 
To a stirred solution of alcohol 152 (80 mg, 0.21 mmol) in DCM (3 mL) at room 
temperature was added DMAP (30 mg, 0.25 mmol), DCC (100 mg, 0.46 mmol) 
and acid 175 (40 mg, 0.21 mmol) and stirred for 40 hours before being diluted 
with water (2 mL) and extracted with DCM (5 mL x 3).  The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with DCM (75 
%)  in  40 60  petroleum  ether  as  the  eluant)  afforded  177  as  an  inseparable 
mixture of diastereoisomers (55:45) (80 mg, 0.14 mmol, 68 %). 
1H NMR (400 MHz, CDCl3) δ 0.05 0.09 (m, 12H), 0.86 0.87 (m, 18H), 1.28 1.32 
(m, 6H), 1.44 1.46 (m, 6H), 1.52 1.56 (m, 6H), 2.21 2.64 (m, 8H), 3.80 (s, 6H), 
3.99 4.18 (m, 6H), 4.40 (dt, J = 6.6, 1.9 Hz, 2H), 4.45 (dt, J = 7.0, 1.9 Hz, 2H), 
5.02 5.09 (m, 4H), 5.17 5.26 (m, 4H), 5.79 5.88 (m, 2H), 6.39 (d, J = 2.6 Hz, 
1H), 6.46 (d, J = 2.6 Hz, 1H), 7.24 7.36 (m, 2H), 11.60 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ  4.7,  4.6, 18.1, 18.3, 26.2, 26.1, 27.7, 28.5, 29.9, 
34.3, 34.6, 55.6, 62.8, 63.2, 70.7, 70.9, 77.3, 77.4, 80.4, 80.5, 81.9, 82.0, 82.3, 
82.2,  100.5,  100.6,  103.8,  104.0,  108.5,  108.6,  108.7,  108.8,  115.6,  115.8, 
116.8,  117.0,  135.6,  135.9,  138.7,  140.0,  144.1,  144.6,  165.0,  165.2,  165.3, 
170.6. 
HRMS (CI
+) calcd for C30H45O7Si (M
++H): 545.2935.  Found 545.2933. Murray N Robertson, 2009    125 
Methyl 4 methoxy 2 [(4 methoxybenzyl)oxy] 6 vinylbenzoate, 178 
MeO
PMBO
OMe
O
 
 
A stirred solution of alcohol 108 (1.50 g, 7.20 mmol) in DMF (75 mL), potassium 
carbonate  (1.49  g,  10.79  mmol),  tetrabutylammonium  iodide  (270  mg,  0.73 
mmol) and 4 methoxybenzyl chloride (1.46 mL, 10.79 mmol) was heated at 80 
˚C  for  15  hours.    The  reaction  was  then  allowed  to  cool  down  to  room 
temperature,  diluted  with  DCM  (75  mL),  washed  with  water  (100  mL)  and 
extracted with DCM (100 mL x 3).  The organic fractions were concentrated at 
reduced pressure to reduce the volume and were washed with brine (100 mL), 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (20 %) in 40 
60 petroleum ether as the eluant) afforded 178 as a colourless oil (2.25 g, 6.85 
mmol, 95 %). 
1H NMR (400 MHz, CDCl3) δ 3.81 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 5.01 (s, 2H), 
5.33 (dd, J = 10.9, 0.8 Hz, 1H), 5.71 (dd, J = 17.3, 0.8 Hz, 1H), 6.44 (d, J = 2.2 
Hz, 1H), 6.66 (d, J = 2.2 Hz,1H), 6.73 (dd, J = 17.3, 10.9 Hz, 1H), 6.85 6.91 (m, 
2H), 7.27 7.34 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 52.4, 55.4, 55.6, 70.5, 100.0, 102.0, 114.0, 117.2, 
128.7, 130.4, 133.9, 137.9, 157.4, 159.4, 161.5, 168.5. 
HRMS (EI
+) calcd for C19H20O5 (M
+): 328.1311.  Found 328.1309.  
νmax (film)/cm
 1 2950, 1726, 1514, 1247, 1159, 1031. Murray N Robertson, 2009    126 
((4S,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 6 (tert 
butyldimethylsilyloxy)hex 4 yn 2 yl 4 methoxy 2 (4 methoxybenzyloxy) 6 
vinylbenzoate, 180 
MeO
PMBO O
O
TBSO
O
O  
 
To a stirred solution of alcohol 152 (80 mg, 0.21 mmol) in DCM (3 mL) at room 
temperature was added DMAP (30 mg, 0.25 mmol), DCC (100 mg, 0.46 mmol) 
and crude acid 179 (89 mg) and stirred for 16 hours before being diluted with 
water  (2  mL)  and  extracted  with  DCM  (5  mL  x  3).    The  organic  layers  were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc (0 
20 %) in 40 60 petroleum ether as the eluant) afforded 180 as an inseparable 
mixture of diastereoisomers (55:45) (40 mg, 0.06 mmol, 31 %). 
1H NMR (400 MHz, CDCl3) 0.06 0.13 (m, 12H), 0.87 0.89 (m, 18H), 1.25 1.26 (m, 
6H),  1.32 1.35  (m,  6H),  1.45 1.47  (m,  6H),  2.35 2.69  (m,  8H),  3.78 3.80  (m, 
12H), 4.01 4.20 (m, 6H), 4.39 (dt, J = 6.8, 1.9 Hz, 1H), 4.46 (dt, J = 6.9, 1.8 Hz, 
1H), 4.97 (s, 4H), 5.04 5.12 (m, 4H), 5.13 5.30 (m, 2H), 5.31 5.36 (m, 2H), 5.68 
(d, J = 0.8 Hz, 1H), 5.73 (d, J = 0.8 Hz, 1H), 5.79 5.91 (m, 2H), 6.43 (d, J = 2.1 
Hz, 2H), 6.64 (d, J = 2.1 Hz, 2H), 6.87 6.89 (m, 2H), 7.27 7.31 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ  4.8,  4.7,  4.5,  3.8, 18.2, 18.4, 19.1, 19.2, 25.1, 
25.7, 25.9, 25.9, 27.9, 28.1, 29.8, 34.0, 34.3, 34.5, 49.4, 55.4, 55.6, 62.6, 63.0, 
69.7, 69.9, 70.5, 80.2, 80.5, 81.4, 81.9, 82.0, 82.2, 99.6, 101.8, 108.5, 108.7, 
114.0,  116.8,  117.2,  117.2,  129.1,  128.5,  133.9,  135.6,  135.6,  137.8,  157.3, 
159.6, 161.4, 167.2. 
HRMS (FAB
+) calcd for C38H52O8SiNa (M
++Na): 687.3329.  Found 687.3328. 
νmax (film)/cm
 1 3076, 2984, 2930, 2855, 1725, 1601, 1514, 1253, 1056. Murray N Robertson, 2009    127 
Methyl 2 ((E) 3 ((4S,5R) 5 ((tert butyldimethylsilyloxy)methyl) 2,2 dimethyl 
1,3 dioxolan 4 yl)prop 1 enyl) 6 hydroxy 4 methoxybenzoate, 182 
MeO
OH
OMe
O
O
O
OTBS
 
 
To a stirred solution of styrene 108 (0.05 g, 0.24 mmol) and alkene 192 (0.14 g, 
0.48  mmol)  in  DCM  (4  mL)  was  added  Hoveyda Grubbs  Catalyst  second 
Generation (0.05 g) and refluxed in the dark for 48 hours.  The reaction mixture 
was allowed to cool down to room temperature and was filtered through silica 
and  concentrated  at  reduced  pressure.    Purification  by  flash  column 
chromatography (silica gel Et2O (5 %) in 40 60 petroleum ether as the eluant) 
afforded 182 as a colourless oil (80 mg, 0.17 mmol, 73 %). 
1H NMR (400 MHz, CDCl3) δ 0.08 (s, 6H), 0.90 (s, 9H), 1.35 (s, 3H), 1.45 (s, 3H), 
2.44 2.60 (m, 2H), 3.64 3.75 (m, 2H), 3.81 (s, 3H), 3.90 (s, 3H), 4.19 4.07 (m, 
2H), 6.01 (dt, J = 15.6, 6.9 Hz, 1H), 6.38 (d, J = 2.6 Hz, 1H), 6.50 (d, J = 2.6 Hz, 
1H). 7.02 (d, J = 15.6 Hz, 1H), 11.65 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ  5.3,  5.2, 18.4, 25.7, 26.0, 28.4, 33.2, 52.1, 55.5, 
62.0, 77.3, 77.8, 99.9, 103.8, 108.1, 129.2, 133.0, 143.2, 164.1, 165.1, 171.9. 
HRMS (CI
+) calcd for C24H39O7Si (M
++H): 467.2465.  Found 467.2464 
Cobalt Complex, 186 
TBSO
O
O
O
Co
Co
(CO)3
(CO)3
 
 
To a solution of alkyne 144 (80 mg, 0.22 mmol) in toluene (15 mL) at room 
temperature was added dicobalt octacarbonyl (150 mg, 0.44 mmol) and stirred 
for  16  hours.    The  reaction  mixture  was  then  filtered  through  celite  and Murray N Robertson, 2009    128 
concentrated  at  reduced  pressure  to  give  the  crude  product.    No  further 
purification was carried out. 
1H NMR (400 MHz, CDCl3) δ 0.09 (s, 6H), 0.90 (s, 9H), 1.33 (d, J = 6.0 Hz, 3H), 
1.36 (s, 3H), 1.56 (s, 3H), 2.15 2.25 (m, 1H), 2.32 2.38 (m, 1H), 3.02 3.15 (m, 
2H), 3.99 4.08 (m, 1H), 4.48 4.54 (m, 1H), 4.89 (d, J = 6.8 Hz, 1H), 5.05 5.12 
(m, 2H), 5.76 5.89 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ  4.8,  4.7, 18.1, 24.7, 25.9, 27.7, 28.4, 33.7, 36.4, 
69.8, 71.3, 74.9, 80.5, 109.1, 116.2, 135.4, 206.7. 
νmax (film)/cm
 1 2919, 1649, 1359, 1065. 
Cobalt Complex, 188 
O
O
O
Co
Co HO
(CO)3
(CO)3
 
 
To a stirred solution of silyl ether 186 (140 mg, 0.22 mmol) in THF (4 mL) at 0 
˚C was added HF Pyr:Pyr:THF solution (1:4:10, 6 mL) and stirred for 18 hours 
before being slowly quenched with saturated aqueous sodium bicarbonate (30 
mL) and extracted with EtOAc (50 mL x 3).  The organic layers were combined 
and washed with citric acid (5 %, 100 mL), dried over anhydrous MgSO4, filtered 
and  concentrated  at  reduced  pressure.    Purification  by  flash  column 
chromatography (silica gel with EtOAc (10 %) in 40 60 petroleum ether as the 
eluant) afforded 188 as a dark red oil (50 mg, 0.09 mmol, 42 %). 
1H NMR (400 MHz, CDCl3) δ 1.36 (d, J = 6.9 Hz, 3H), 1.36 (s, 3H), 1.57 (s, 3H), 
2.17 2.29 (m, 1H), 2.64 2.39 (m, 1H), 2.64 (d, J = 4.4 Hz, 1H), 3.01 (dd, J = 
15.8, 9.2 Hz, 1H), 3.12 (dd, J = 15.8, 2.7 Hz, 1H), 3.94 4.02 (m, 1H), 4.46 4.57 
(m, 1H), 4.95 (d, J = 6.7 Hz, 1H), 5.06 5.14 (m, 2H), 5.78 5.89 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ 24.3, 25.3, 27.5, 35.7, 44.2, 68.5, 77.7, 82.3, 84.2, 
97.44, 110.1, 118.1, 134.0, 198.4, 198.5, 198.5, 198.6, 198.6, 198.6, 204.5. Murray N Robertson, 2009    129 
νmax (film)/cm
 1 3567, 2920, 1654, 1457, 1060. 
(((4R,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl)methoxy)(tert 
butyl)dimethylsilane, 192 
O
O
OTBS
 
 
To a stirred solution of alcohol 125 (1.87 g, 10.8 mmol) in DCM (50 mL) at room 
temperature  was  added  tert-butyldimethylsilyl  chloride  (2.17  g,  14.0  mmol), 
triethylamine  (2.71  mL,  19.44  mmol)  and  DMAP  (0.13  g,  1.1  mmol).    The 
reaction mixture was stirred for 14 hours before being quenched with saturated 
aqueous ammonium chloride (50 mL) and extracted with DCM (50 mL x 3).  The 
organic  layers  were  combined,  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated at reduced pressure.  Purification by flash column chromatography 
(silica gel with DCM (30 50 %) in 40 60 petroleum ether as the eluant) afforded 
192 as a colourless oil (2.94 g, 10.3 mmol, 95 %). 
1H NMR (400 MHz, CDCl3) δ 0.06 (s, 6H), 0.89 (s, 9H), 1.34 (s, 3H), 1.43 (s, 3H), 
2.29 2.45  (m,  2H),  3.61 3.71  (m,  2H),  4.09 4.13  (m,  1H),  4.19 4.23  (m,  1H), 
5.08 5.15 (m, 2H), 5.84 5.94 (m, 1H).   
13C NMR (100 MHz, CDCl3) δ  5.4,  5.4, 18.3, 25.2, 25.9, 28.2, 33.9, 61.9, 77.1, 
77.8, 107.9, 116.8, 135.3. 
HRMS (CI
+) calcd for C15H31O3Si (M
++H): 287.2042.  Found 287.2046. 
νmax (film)/cm
 1 2954, 2931, 1643, 1472, 1257, 1100. Murray N Robertson, 2009    130 
2 ((4S,5R) 5 ((tert Butyldimethylsilyloxy)methyl) 2,2 dimethyl 1,3 dioxolan 
4 yl)acetaldehyde, 193
90 
O
O
OTBS
O
H
 
 
A solution of alkene 192 (0.62 g, 2.2 mmol) in DCM (20 mL) was cooled to  78 ˚C.  
O3 was then bubbled through the solution for 1 hour before being purged with 
oxygen and allowed to warm up to room temperature.  The reaction mixture was 
treated  with  triphenylphosphine  (0.75  g,  2.86  mmol),  stirred  vigorously 
overnight and concentrated at reduced pressure.  The crude was dissolved in 
Et2O  (15  %)  in  40 60  petroleum  ether,  filtered  and  concentrated  at  reduced 
pressure.  Purification by flash column chromatography (silica gel with DCM (15 
100 %) in 40 60 petroleum ether as the eluant) afforded 193 as a colourless oil 
(210 mg, 0.73 mmol, 34 %) plus unreacted starting material 192 (430 mg, 1.43 
mmol, 66 %).  Yield based on starting material 100 %. 
1H NMR (400 MHz, CDCl3) δ 0.05 (s, 3H), 0.05 (s, 3H), 0.87 (s, 9H), 1.35 (s, 3H), 
1.41 (s, 3H), 2.76 (ddd, J = 17.1, 7.9, 1.8 Hz, 1H), 2.87 (ddd, J = 17.1, 5.9, 1.3 
Hz, 1H), 3.60 3.63 (m, 2H), 4.14 4.19 (m, 1H), 4.79 ((dd, J = 7.9, 5.9 Hz, 1H), 
9.79 (t, J = 1.5 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ  5.4,  5.3, 18.3, 25.1, 25.9, 27.5, 39.9, 61.8, 76.8, 
78.0, 108.7, 197.4. 
HRMS (CI
+) calcd for C14H29O4Si (M
++H): 289.1835.  Found 289.1839 
νmax (film)/cm
 1 2989, 2957, 2930, 2857, 1716, 1255, 1078. 
(Dibromomethyl)tributylstannane, 195
72 
SnBu3
Br Br  
 
A 0 ˚C stirred solution of diisopropylamine (0.58 mL, 4.2 mmol) in THF (4 mL) 
and Et2O (6 mL) was treated with n butyllithium (2.5 M in hexanes, 1.45 mL, 3.6 
mmol) and stirred for 15 minutes at 0 ˚C before being cooled to –95 ˚C.  A Murray N Robertson, 2009    131 
solution  of  dibromomethane  (0.27  mL,  3.9  mmol)  in  THF  (3  mL)  was  added 
slowly to the reaction mixture and stirring continued for 15 minutes at –90 ˚C.  A 
solution of tributyltin chloride 194 (1.17 mL, 3.0 mmol) in THF (3 mL) was added 
slowly and the reaction was allowed to warm to –63 ˚C for 1 hour.  The reaction 
was quenched with saturated aqueous ammonium chloride (5 mL) and allowed to 
rapidly warm to room temperature before removal of most of the solvents at 
reduced pressure.  The concentrated reaction mixture was diluted with water (9 
mL) and 40 60 petroleum ether (15 mL) and filtered through celite then finally 
extracted with 40 60 petroleum ether (15 mL x 3).   The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with in 40 60 
petroleum ether as the eluant) afforded 195 as a colourless oil (1.13 g, 2.44 
mmol, 81 %). 
1H NMR (400 MHz, CDCl3) δ 0.92 (t, J = 7.3 Hz, 9H), 1.11 1.16 (m, 6H), 1.30 1.39 
(m, 6H), 1.57 1.62 (m, 6H), 5.32 (t, J = 10.0 Hz, 1H).   
13C NMR (100 MHz, CDCl3) δ 11.8, 13.8, 27.4, 28.6, 28.7. 
tert Butyl(((4R,5S) 2,2 dimethyl 5 ((E) 3 (4,4,5,5 tetramethyl 1,3,2 
dioxaborolan 2 yl)allyl) 1,3 dioxolan 4 yl)methoxy)dimethylsilane, 204 
O
O
OTBS
B
O
O
 
 
To  a  solution  of  alkene  192  (200  mg,  0.69  mmol)  in  DCM  (2 mL)  was  added 
vinylboronic acid pinicol ester (0.08 mL, 0.48 mmol) and Grubbs first generation 
catalyst (2.5 %, 0.015 g) and refluxed in the dark for 13 hours.  The reaction 
mixture was allowed to cool down to room temperature, filtered through celite 
and  concentrated  at  reduced  pressure.    Purification  by  flash  column 
chromatography  (silica  gel  with  Et2O  (5  %)  in  40 60  petroleum  ether  as  the 
eluant) afforded 204 as a yellow oil as a 4:1 mixture of E:Z isomers (203 mg, 
0.49 mmol, 73 %). Murray N Robertson, 2009    132 
E product 
1H NMR (400 MHz, CDCl3) δ 0.05 (s, 6H), 0.88 (s, 9H), 1.26 (s, 12H), 1.37 (s, 3H), 
1.42 (s, 3H), 2.25 2.61 (m, 2H), 3.57 3.77 (m, 2H), 4.06 4.30 (m, 2H), 5.55 (dt, J 
= 18.0, 1.5 Hz, 1H), 6.68 (dt, J = 18.0, 6.4 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 5.3, 18.3, 24.9, 25.7, 26.0, 28.3, 35.9, 62.0, 76.5, 
77.8, 83.2, 108.1, 150.5. 
HRMS (CI
+) calcd for C21H42BO5Si (M
++H): 413.2895.  Found 413.2890. 
νmax (film)/cm
 1 2956, 2856, 1655, 1437, 1068. 
Z product 
1H NMR (400 MHz, CDCl3) δ 0.08 (s, 6H), 0.89 (s, 9H), 1.26 (s, 12H), 1.42 (s, 3H), 
1.44 (s, 3H), 2.25 2.61 (m, 2H), 3.57 3.77 (m, 2H), 4.06 4.30 (m, 2H), 5.48 (dt, J 
= 13.6, 1.5 Hz, 1H), 6.54 (dt, J = 13.6, 7.1 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 5.4, 18.4, 25.0, 25.7, 26.0, 27.8, 32.3, 62.0, 77.6, 
78.0, 83.0, 108.0, 151.6. 
HRMS (CI
+) calcd for C21H42BO5Si (M
++H): 413.2895.  Found 413.2890. 
νmax (film)/cm
 1 2929, 2856, 1631, 1424, 1259, 1076 Murray N Robertson, 2009    133 
(Z) 1 ((4R,5S) 5 ((tert Butyldimethylsilyloxy)methyl) 2,2 dimethyl 1,3 
dioxolan 4 yl) 4 ((4S,5R) 5 ((tert butyldimethylsilyloxy)methyl) 2,2 
dimethyl 1,3 dioxolan 4 yl)but 2 ene, 212 
OTBS
O
O
O
O
OTBS  
 
1H NMR (400 MHz, CDCl3) δ 0.06 (s, 12H), 0.88 (s, 18H), 1.33 (s, 3H), 1.42 (s, 3H), 
2.32 2.38 (m, 4H), 3.54 3.71 (m, 4H), 4.07 4.20 (m, 4H), 5.61 (d, J = 3.8 Hz, 
2H). 
13C NMR (100 MHz, CDCl3) δ  5.3,  5.2, 18.4, 25.7, 26.1, 28.3, 32.8, 62.1, 77.7, 
78.0, 108.0, 129.1. 
HRMS (CI
+) calcd for C28H57O6Si2 (M
++H): 545.3694.  Found 545.3689 
νmax (film)/cm
 1 2956, 2930, 2857, 1655, 1472, 1378, 1255, 1100. 
Methyl 2 ((E) 3 ((4S,5R) 5 ((tert butyldimethylsilyloxy)methyl) 2,2 dimethyl 
1,3 dioxolan 4 yl)prop 1 enyl) 4 methoxy 6 (methoxymethoxy)benzoate, 
213 
MeO
MOMO
OMe
O
O
O
OTBS
 
 
To a stirred solution of alcohol 210 (1.29 g, 2.77 mmol) in DCM (30 mL) at room 
temperature was added N,N diisopropylethylamine (1.45 mL, 8.32 mmol).  The 
reaction mixture was cooled down to 0 ˚C and bromomethyl methyl ether (0.45 
mL, 5.51 mmol) was added and the solution was allowed to warm up to room 
temperature  and  stirred  for  19  hours.    The  reaction  was  quenched  with 
saturated aqueous sodium bicarbonate (25 mL), extracted with Et2O (35 mL x 3), Murray N Robertson, 2009    134 
dried  over  anhydrous  MgSO4,  filtered  and  concentrated  at  reduced  pressure.  
Purification by flash column chromatography (silica gel with EtOAc (15 %) in 40 
60 petroleum ether as the eluant) afforded 213 as a colourless oil (1.27 g, 2.48 
mmol, 90 %). 
1H NMR (400 MHz, CDCl3) δ 0.07 (s, 6H), 0.89 (s, 9H), 1.34 (s, 3H), 1.43 (s, 3H), 
2.46 2.53 (m, 2H), 3.45 (s, 3H), 3.65 3.70 (m, 2H), 3.81 (s, 3H), 3.88 (s, 3H), 
4.11 4.15 (m, 1H), 4.20 4.25 (m, 1H), 5.15 (s, 2H), 6.23 6.31(m, 1H), 6.43 (d, J 
= 15.7 Hz, 1H), 6,59 (d, J = 2.2 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H).   
13C NMR (100 MHz, CDCl3) δ  5.3,  5.2, 18.4, 25.7, 26.0, 28.3, 33.4, 52.3, 55.6, 
56.3, 62.0, 77.2, 77.9, 95.0, 100.9, 103.7, 108.2, 116.6, 128.6, 130.6, 137.7, 
155.7, 161.4, 168.5. 
HRMS (CI
+) calcd for C26H43O8Si (M
++H): 511.2727.  Found 511.2721 
νmax (film)/cm
 1 2955, 2929, 2856, 1654, 1610, 1327, 1159, 1097. 
(S) 1 ((4R,5S) 5 Allyl 2,2 dimethyl 1,3 dioxolan 4 yl) 5 (4 Methyl 2 ((E) 3 
((4S,5R) 5 (hydroxymethyl) 2,2 dimethyl 1,3 dioxolan 4 yl)prop 1 enyl) 4 
methoxy 6 (methoxymethoxy)benzoate, 214 
MeO
MOMO
OMe
O
O
O
OH
 
 
A  solution  of  silyl  ether  213  (60  mg,  0.12  mmol)  in  THF  (2  mL)  at  room 
temperature was treated with TBAF (1 M, 0.23 mL, 0.23 mmol) and stirred for 30 
minutes.    The  reaction  was  quenched  with  saturated  aqueous  ammonium 
chloride (2 mL) and extracted with EtOAc (5 mL x 3).  The organic layers were 
combined, dried over anhydrous MgSO4, filtered and concentrated at reduced 
pressure.  Purification by flash column chromatography (silica gel with EtOAc 
(50 75 %) in 40 60 petroleum ether as the eluant) afforded 214 as an off white 
oil (50 mg, 0.12 mmol, 100 %). Murray N Robertson, 2009    135 
1H NMR (400 MHz, CDCl3) δ 1.38 (s, 3H), 1.50 (s, 3H), 1.86 (t, J = 6.1 Hz, 1H), 
2.39 2.48 (m, 1H), 2.50 2.59 (m, 1H), 3.46 (s, 3H), 3.68 (t, J = 5.8 Hz, 2H), 3.82 
(s, 3H), 3.90 (s, 3H), 4.21 (q, J = 5.8 Hz, 1H), 4.29 (dt, J = 8.0, 5.8 Hz, 1H), 5.16 
(s, 2H), 6.19 (ddd, J = 15.6, 7.8, 6.1 Hz, 1H), 6.47 (d, J = 15.6 Hz, 1H), 6.61 (d, 
J = 2.2 Hz, 1H), 6.67 (d, J = 2.2 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 25.4, 28.0, 33.2, 52.2, 55.4, 56.1, 61.3, 76.3, 77.8, 
94.7, 100.6, 103.6, 108.2, 116.2, 128.8, 129.6, 137.3, 155.5, 161.2, 168.4. 
HRMS (EI
+) calcd for C20H28O8 (M
+): 396.1784.  Found 396.1788 
νmax (film)/cm
 1 3503, 2988, 2937, 1727, 1601, 1576, 1433, 1267, 1154, 1047. 
[α]
25
D –5.6 (c=1.0, CH2Cl2) 
Methyl 2 ((3S,4S,6R,7S) 4 ((S) 4 (tert butyldimethylsilyloxy)pent 1 ynyl) 2,2 
dimethyltetrahydro 3αH [1,3]dioxolo[4,5 ]pyran 6 yl)acetate, 219 
O
O
O
O
MeO
OTBS
219  
 
A stirred solution of alcohol 100 (292 mg, 0.68 mmol) in diethyl ether (20 ml) at 
 78  °C  was  treated  with  potassium  tert  butoxide  (0.083  g  ,  0.68  mmol)  and 
stirred  for  3  hours  at   78  °C.    The  reaction  was  quenched  with  a  saturated 
ammonium chloride solution (15 ml) and extracted with EtOAc (30 ml).  The 
organic  layers  were  combined,  dried  over  NaSO4,  filtered  and  concentrated 
under vaccum.  Purification by flash column chromatography (silica gel, with 
EtOAc (2.5 %) in 40 60 petroleum ether as the eluant) generated the desired 
pyran rings 219 (32 mg, 0.08 mmol, 12 %) and 220 (145 mg, 0.34 mmol, 50 %).  
Unreacted  starting  alcohol  100  (46  mg,  0.11  mmol,  16  %)  was  also  cleanly 
recovered. 
1H NMR (500MHz, CDCl3) δ 0.07 (s, 3H), 0.07 (s, 3H), 0.88 (s, 9H), 1.23 (d, J = 6.1 
Hz, 3H), 1.23 1.26 (m, 1H), 1.34 (s, 3H), 1.52 (s, 3H), 2.30 (ddd, J = 16,5, 7.0, Murray N Robertson, 2009    136 
2.2 Hz, 1H), 2.36 2.42 (m, 2H), 2.43 2.51 (m, 2H), 2.67 (dd, J = 15.6, 7.2 Hz, 
1H), 3.97 (dd, J = 12.6, 5.9 Hz, 1H), 4.08 (dd, J = 5.2, 1.7 Hz, 1H), 4.27 4.33 (m, 
1H), 4.08 (dt, J = 4.1, 1.7 Hz, 1H), 4.87 4.89 (m, 1H) 
13C NMR (125MHz, CDCl3) δ 4.7,  4.5, 18.2, 23.5, 25.9, 26.5, 29.8, 31.1, 34.0, 
40.0, 51.9, 60.6, 65.9, 67.9, 70.6, 74.9, 77.7, 109.4, 171.3 
νmax(film)/cm
 1 2253 (m), 1726 (w), 1215 (s)1096 (m) 
HRMS calcd for C22H39O6Si1 (M
++H); 427.2510.  Found 427.2492 
[α]
20
D  4.3 (c=0.5, CHCl3) 
Methyl 2 ((3S,4R,6R,7S) 4 ((S) 4 (tert butyldimethylsilyloxy)pent 1 ynyl) 2,2 
dimethyltetrahydro 3αH [1,3]dioxolo[4,5 ]pyran 6 yl)acetate, 220 
O
O
O
O
MeO
OTBS
 
 
1H NMR (500MHz, CDCl3) δ 0.05 (s, 3H), 0.06 (s, 3H), 0.87 (s, 9H), 1.21 (d, J = 6.1 
Hz, 3H), 1.37 (s, 3H), 1.51 (s, 3H), 1.72 (ddd, J= 14.8, 11.8, 4.0 Hz, 1H), 2.14 
(dt, J = 14.9, 2.2 Hz, 1H), 2.27 (ddd, J = 16.5, 7.3, 2.0 Hz, 1H), 2.42 (m, 1H), 
2.40 (m, 1H), 2.64 (dd, J = 15.6, 7.4 Hz, 1H), 3.69 (s, 3H), 3.96 (m, 2H), 4.06 
(m, 2H), .4.37 (m, 1H) 
13C NMR (125MHz, CDCl3) δ  4.6,  4.6, 18.2, 23.6, 26.0, 26.2, 28.4, 30.0, 32.4, 
40.5, 51.9, 60.4, 67.8, 69.5, 72.0, 75.4, 84.1, 109.6, 171.1. 
νmax(film)/cm
 1 2251, 1745, 1351, 1050. 
HRMS calcd for C22H39O6Si1 (M
++H); 427.2510.  Found 427.2492 
[α]
20
D +32.9 (c=1.5, CHCl3)     137 
4  References 
1.  P. Delmotte and J. Delmotteplaquee, Nature, 1953, 171, 344 344. 
2.  N. Winssinger and S. Barluenga, Chemical Communications, 2007, 22 36. 
3.  H. J. Kwon, M. Yoshida, Y. Fukui, S. Horinouchi and T. Beppu, Cancer 
Research, 1992, 52, 6926 6930. 
4.  T. W. Schulte, S. Akinaga, S. Soga, W. Sullivan, B. Stensgard, D. Toft and 
L. M. Neckers, Cell Stress & Chaperones, 1998, 3, 100 108. 
5.  B. S. J. Blagg and T. A. Kerr, Medicinal Research Reviews, 2006, 26, 310 
338. 
6.  Y. Ikuina, N. Amishiro, M. Miyata, H. Narumi, H. Ogawa, T. Akiyama, Y. 
Shiotsu,  S.  Akinaga  and  C.  Murakata,  Journal  of  Medicinal  Chemistry, 
2003, 46, 2534 2541. 
7.  M. Lampilas and R. Lett, Tetrahedron Letters, 1992, 33, 773 776. 
8.  M. Lampilas and R. Lett, Tetrahedron Letters, 1992, 33, 777 780. 
9.  P.  Y.  Dakas,  S.  Barluenga,  F.  Totzke,  U.  Zirrgiebel  and  N.  Winssinger, 
Angewandte Chemie-International Edition, 2007, 46, 6899 6902. 
10.  B.  Atrash,  T.  S.  Cooper,  P.  Sheldrake,  P.  Workman  and  E.  McDonald, 
Tetrahedron Letters, 2006, 47, 2237 2240. 
11.  S.  Barluenga,  E.  Moulin,  P.  Lopez  and  N.  Winssinger,  Chemistry-a 
European Journal, 2005, 11, 4935 4952. 
12.  E. Moulin, V. Zoete, S. Barluenga, M. Karplus and N. Winssinger, Journal 
of the American Chemical Society, 2005, 127, 6999 7004. 
13.  R. C. Clevenger and B. S. J. Blagg, Organic Letters, 2004, 6, 4459 4462. 
14.  R. M. Garbaccio and S. J. Danishefsky, Organic Letters, 2000, 2, 3127 
3129. 
15.  G. A. Ellestad, F. M. Lovell, N. A. Perkinson, R. T. Hargreaves and W. J. 
McGahren, Journal of Organic Chemistry, 1978, 43, 2339 2343. 
16.  J.  Ninomiya Tsuji,  T.  Kajino,  K.  Ono,  T.  Ohtomo,  M.  Matsumoto,  M. 
Shiina, M. Mihara, M. Tsuchiya and K. Matsumoto, Journal of Biological 
Chemistry, 2003, 278, 18485 18490. 
17.  K.  Takehana,  S.  Sato,  T.  Kobayasi  and  T.  Maeda,  Biochemical  and 
Biophysical Research Communications, 1999, 257, 19 23. 
18.  Y. Cheng and W. H. Prusoff, Biochemical Pharmacology, 1973, 22, 3099 
3108. 
19.  P. Cohen, Nature Cell Biology, 2002, 4, E127 E130. Murray N Robertson, 2009    138 
20.  G.  Manning,  D.  B.  Whyte,  R.  Martinez,  T.  Hunter  and  S.  Sudarsanam, 
Science, 2002, 298, 1912. 
21.  P. Cohen, Nature Reviews Drug Discovery, 2002, 1, 309 315. 
22.  L. M. Coussens and Z. Werb, Nature, 2002, 420, 860 867. 
23.  V. Majithia and S. A. Geraci, American Journal of Medicine, 2007, 120, 
936 939. 
24.  T. K. Kvien, Pharmacoeconomics, 2004, 22, 1 12. 
25.  S. B. Hanauer, New England Journal of Medicine, 1996, 334, 841 848. 
26.  R. Corti, M. E. Farkouh and J. J. Badimon, American Journal of Medicine, 
2002, 113, 668 680. 
27.  R. Altman, Thrombosis Journal, 2003, 1, 2. 
28.  H. Kuper, H. O. Adami and D. Trichopoulos, Journal of Internal Medicine, 
2000, 248, 171 183. 
29.  H. Ohshima and H. Bartsch, Mutation Research, 1994, 305, 253 264. 
30.  S. M. Cohen, D. T. Purtilo and L. B. Ellwein, Modern Pathology, 1991, 4, 
371 382. 
31.  M.  G.  Wilkinson,  T.  S.  Pino,  S.  Tournier,  V.  Buck,  H.  Martin,  J. 
Christiansen, D. G. Wilkinson and J. B. A. Millar, Embo Journal, 1999, 18, 
4210 4221. 
32.  K.  Yamaguchi,  T.  Shirakabe,  H.  Shibuya,  K.  Irie,  I.  Oishi,  N.  Ueno,  T. 
Taniguchi, E. Nishida and K. Matsumoto, Science, 1995, 270, 2008 2011. 
33.  T. Moriguchi, N. Kuroyanagi, K. Yamaguchi, Y. Gotoh, K. Irie, T. Kano, K. 
Shirakabe,  Y.  Muro,  H.  Shibuya,  K.  Matsumoto,  E.  Nishida  and  M. 
Hagiwara, Journal of Biological Chemistry, 1996, 271, 13675 13679. 
34.  E. Moulin, S. Barluenga and N. Winssinger, Organic Letters, 2005, 7, 5637 
5639. 
35.  E. Nishida and Y. Gotoh, Trends in Biochemical Sciences, 1993, 18, 128 
131. 
36.  P.  C.  F.  Cheung,  D.  G.  Campbell,  A.  R.  Nebreda  and  P.  Cohen,  Embo 
Journal, 2003, 22, 5793 5805. 
37.  P. C. F. Cheung, A. R. Nebreda and P. Cohen, Biochemical Journal, 2004, 
378, 27 34. 
38.  C.  Dominguez,  D.  A.  Powers  and  N.  Tamayo,  Current  Opinion  in  Drug 
Discovery & Development, 2005, 8, 421 430. 
39.  D. M. Goldstein and T. Gabriel, Current Topics in Medicinal Chemistry, 
2005, 5, 1017 1029. Murray N Robertson, 2009    139 
40.  M.  R.  Lee  and  C.  Dominguez,  Current  Medicinal  Chemistry,  2005,  12, 
2979 2994. 
41.  J. Ninomiya Tsuji, K. Kishimoto, A. Hiyama, J. Inoue, Z. D. Cao and K. 
Matsumoto, Nature, 1999, 398, 252 256. 
42.  D. H. Williams, S. E. Wilkinson, T. Purton, A. Lamont, H. Flotow and E. J. 
Murray, Biochemistry, 1998, 37, 9579 9585. 
43.  A. Zhao, S. H. Lee, M. Mojena, R. G. Jenkins, D. R. Patrick, H. E. Huber, 
M. A. Goetz, O. D. Hensens, D. L. Zink, D. Vilella, A. W. Dombrowski, R. 
B. Lingham and L. Y. Huang, Journal of Antibiotics, 1999, 52, 1086 1094. 
44.  A. Schirmer, J. Kennedy, S. Murli, R. Reid and D. V. Santi, Proceedings of 
the National Academy of Sciences of the United States of America, 2006, 
103, 4234 4239. 
45.  J. G. Robertson, Biochemistry, 2005, 44, 5561 5571. 
46.  E. L. Kwak, R. Sordella, D. W. Bell, N. Godin Heymann, R. A. Okimoto, B. 
W. Brannigan, P. L. Harris, D. R. Driscoll, P. Fidias, T. J. Lynch, S. K. 
Rabindran, J. P. McGinnis, A. Wissner, S. V. Sharma, K. J. Isselbacher, J. 
Settleman  and  D.  A.  Haber,  Proceedings  of  the  National  Academy  of 
Sciences of the United States of America, 2005, 102, 7665 7670. 
47.  R. J. Gum, M. M. McLaughlin, S. Kumar, Z. L. Wang, M. J. Bower, J. C. 
Lee, J. L. Adams, G. P. Livi, E. J. Goldsmith and P. R. Young, Journal of 
Biological Chemistry, 1998, 273, 15605 15610. 
48.  Z. L. Wang, B. J. Canagarajah, J. C. Boehm, S. Kassisa, M. H. Cobb, P. R. 
Young, S. Abdel Meguid, J. L. Adams and E. J. Goldsmith, Structure with 
Folding & Design, 1998, 6, 1117 1128. 
49.  J. S. Sebolt Leopold and J. M. English, Nature, 2006, 441, 457 462. 
50.  K. Tatsuta, S. Takano, T. Sato and S. Nakano, Chemistry Letters, 2001, 
172 173. 
51.  J. Tsuji, I. Shimizu and I. Minami, Chemistry Letters, 1984, 1017 1020. 
52.  T. Mukaiyama, M. Usui and K. Saigo, Chemistry Letters, 1976, 49 50. 
53.  P. Selles and R. Lett, Tetrahedron Letters, 2002, 43, 4621 4625. 
54.  P. Selles and R. Lett, Tetrahedron Letters, 2002, 43, 4627 4631. 
55.  E. J. Corey, J. R. Cashman, T. M. Eckrich and D. R. Corey, Journal of the 
American Chemical Society, 1985, 107, 713 715. 
56.  K.  E.  Krakowiak,  P.  A.  Krakowiak  and  J.  S.  Bradshaw,  Tetrahedron 
Letters, 1993, 34, 777 778. Murray N Robertson, 2009    140 
57.  H.  C.  Brown,  C.  Subrahmanyam,  T.  Hamaoka,  N.  Ravindran,  D.  H. 
Bowman, S. Misumi, M. K. Unni, V. Somayaji and N. G. Bhat, Journal of 
Organic Chemistry, 1989, 54, 6068 6075. 
58.  R. M. Beesley, C. K. Ingold and J. F. Thorpe, Journal of the Chemical 
Society, 1915, 107, 1080 1106. 
59.  J. Barbat, J. Gelas and D. Horton,  Carbohydrate Research, 1983,  116, 
312 316. 
60.  D.  Boyall,  F.  Lopez,  H.  Sasaki,  D.  Frantz  and  E.  M.  Carreira,  Organic 
Letters, 2000, 2, 4233 4236. 
61.  P. G. McDougal, J. G. Rico, Y. I. Oh and B. D. Condon, Journal of Organic 
Chemistry, 1986, 51, 3388 3390. 
62.  D. Astruc, New Journal of Chemistry, 2005, 29, 42 56. 
63.  N.  Calderon,  H.  Y.  Chen  and  K.  W.  Scott,  Tetrahedron  Letters,  1967, 
3327 &. 
64.  A. K. Chatterjee, T. L. Choi, D. P. Sanders and R. H. Grubbs, Journal of 
the American Chemical Society, 2003, 125, 11360 11370. 
65.  J. L. Herisson and Y. Chauvin, Makromolekulare Chemie, 1971, 141, 161 
&. 
66.  X. D. Geng and S. J. Danishefsky, Organic Letters, 2004, 6, 413 416. 
67.  D. W. Cai and W. C. Still, Journal of Organic Chemistry, 1988, 53, 4641 
4643. 
68.  C. Mendes, S. Renard, M. Rofoo, M. C. Roux and G. Rousseau, European 
Journal of Organic Chemistry, 2003, 463 471. 
69.  N. Henry, M. N. Robertson and R. Marquez, Tetrahedron Letters, 2007, 
48, 6088 6091. 
70.  D.  G.  J.  Young,  J.  A.  Burlison  and  U.  Peters,  Journal  of  Organic 
Chemistry, 2003, 68, 3494 3497. 
71.  J. A. Burlison, J. M. Gray and D. G. J. Young, Tetrahedron Letters, 2001, 
42, 5363 5365. 
72.  D.  M.  Hodgson,  L.  T.  Boulton  and  G.  N.  Maw,  Tetrahedron,  1995,  51, 
3713 3724. 
73.  W.  Cabri,  I.  Candiani,  A.  Bedeschi  and  R.  Santi,  Journal  of  Organic 
Chemistry, 1992, 57, 3558 3563. 
74.  H. C. Brown, K. S. Bhat and R. S. Randad, Journal of Organic Chemistry, 
1989, 54, 1570 1576. Murray N Robertson, 2009    141 
75.  S. L. X. Martina and R. J. K. Taylor, Tetrahedron Letters, 2004, 45, 3279 
3282. 
76.  N. Morsy, T. Houdai, S. Matsuoka, N. Matsumori, S. Adachi, T. Oishi, M. 
Murata,  T.  Iwashita  and  T.  Fujita,  Bioorganic  &  Medicinal  Chemistry, 
2006, 14, 6548 6554. 
77.  J. de Vicente, B. Betzemeier and S. D. Rychnovsky, Organic Letters, 2005, 
7, 1853 1856. 
78.  E. M. Flamme and W. R. Roush, Organic Letters, 2005, 7, 1411 1414. 
79.  L. A. Paquette and S. K. Chang, Organic Letters, 2005, 7, 3111 3114. 
80.  S. BouzBouz and J. Cossy, Organic Letters, 2001, 3, 1451 1454. 
81.  A.  S.  Cotterill,  M.  Gill  and  N.  M.  Milanovic,  Journal  of  the  Chemical 
Society-Perkin Transactions 1, 1995, 1215 1223. 
82.  M.  T.  Diaz,  R.  L.  Perez,  E.  Rodriguez,  J.  L.  Ravelo  and  J.  D.  Martin, 
Synlett, 2001, 345 348. 
83.  R. S. Narayan and B. Borhan, Journal of Organic Chemistry, 2006,  71, 
1416 1429. 
84.  B. D. Schwartz, P. Y. Hayes, W. Kitching and J. J. De Voss, Journal of 
Organic Chemistry, 2005, 70, 3054 3065. 
85.  A. G. Schultz and N. J. Green, Journal of the American Chemical Society, 
1992, 114, 1824 1829. 
86.  K. J. Frankowski, J. E. Golden, Y. B. Zeng, Y. Lei and J. Aube, Journal of 
the American Chemical Society, 2008, 130, 6018 6024. 
87.  M.  Bieniek,  R.  Bujok,  M.  Cabaj,  N.  Lugan,  G.  Lavigne,  D.  Arlt  and  K. 
Grela,  Journal  of  the  American  Chemical  Society,  2006,  128,  13652 
13653. 
88.  T. Hjelmgaard, S. Faure, P. Lemoine, B. Viossat and D. J. Aitken, Organic 
Letters, 2008, 10, 841 844. 
89.  Y.  Kobayashi,  M.  Asano,  S.  Yoshida  and  A.  Takeuchi,  Organic  Letters, 
2005, 7, 1533 1536. 
90.  J. D. White, P. Kuntiyong and T. H. Lee, Organic Letters, 2006, 8, 6039 
6042.     142 
5  Appendix 
 
 
 Fast and eﬃcient synthesis of the complete LL-Z1640-2 framework
Neil Henry, Murray N. Robertson and Rodolfo Marquez*
WestCHEM, University of Glasgow, Joseph Black Building, University Avenue, Glasgow G12 8QQ, United Kingdom
Received 30 April 2007; revised 18 June 2007; accepted 27 June 2007
Available online 4 July 2007
Abstract—The convergent synthesis of the complete LL-Z1640-2 framework has been completed. This fast and eﬃcient approach
provides ﬂexible access into the resorcyclic lactones.
 2007 Elsevier Ltd. All rights reserved.
TAK1 is a member of the mitogen-activated protein ki-
nase kinase kinase (MAPKKK) family that phosphoryl-
ate and activate MKK3, MKK4, MKK6 and MKK7
MAPKKs, which in turn activate the c-Jun N-terminal
kinase (JNK) and p38 MAPKs.1 It has also been re-
cently demonstrated that TAK1 activates IkB kinases
(IKKs), ultimately leading to activation of the transcrip-
tion factor NF-jB.2
A signiﬁcant amount of work has been devoted in trying
to understand TAK1 and its role in the areas of cell
apoptosis, and tumour necrosis, as well as on proinﬂam-
matory diseases. Several lines of evidence tend to suggest
that TAK1 is a key participant in proinﬂammatory sig-
nalling pathways, i.e., by activating both JNK/p38
MAPKs and IKKs in the interleukin 1 (IL-1) signalling
pathway.3 The mechanism by which the IL-TAK1 sig-
nalling pathway is positively and negatively regulated
remains poorly understood, and their physiological
functions remain to be clariﬁed. However, it is believed
that selective inhibition of TAK1 might be eﬀective in
preventing inﬂammation and tissue destruction pro-
moted by proinﬂammatory cytokines.4
As a part of our biological chemistry programme in
understanding inﬂammatory responses, we were inter-
ested in the development of a potent and selective set
of chemical genetic probes that would allow us to under-
stand better the role of TAK1.
LL-Z1640-2 (also known as 5Z-7-oxo-zeaenol and
C292) (1) was isolated in 1978 from the culture broth
of fungal strain f6024.5 Although it was originally clas-
siﬁed as an anti-protozoan agent, it was not until 1999
that its cytokine release inhibiting activity was discov-
ered.6 LL-Z1640-2 (1) has been shown to be a selective
protein tyrosine kinase inhibitor, not inhibiting either
protein kinase A (PKA) or protein kinase C (PKC).7
Signiﬁcantly, preliminary data suggest that LL-Z1640-2
(1), can selectively and irreversibly inhibit the kinase
activity of puriﬁed TAK1 at very low concentrations
(IC50 8.1 nM). Furthermore, 1 had no eﬀect on the
kinase activity of other members of the MAPKKK fam-
ily (MEKK1 and ASK1).7 In addition LL-Z1640-2 (1)
has also been reported as having signiﬁcant activity ver-
sus tumour necrosis factor-alpha (TNF-a) production in
cells with an IC50 of 6 nM.6
LL-Z1640-2 (1) is structurally related to the 14-mem-
bered macrocyclic lactones hypothemycin (2), 87-
250904-F1 (3), zeaenol (4), 7-oxo-zeaenol (5), radicicol
(6), and various simpler zearalanone and zearalanols
(Fig. 1). However, 1 is unique amongst the resorcyclic
lactones in its potency in targeting TAK1, raising the
prospect of becoming a truly selective starting point in
chemical genetics research.8
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Tetrahedron Letters 48 (2007) 6088–6091Although there has been a signiﬁcant amount of work
dedicated to the synthesis of radicicol 6 by Danishefsky
and co-workers, eﬀorts towards LL-Z1640-2 (1), have
been rather limited. This lack of synthetic interest has
translated into a lack of chemical genetic probes
through which the active site of TAK1 could be
explored and understood.9,10
Herein, we report a ﬂexible and eﬃcient approach to the
synthesis of the complete LL-Z1640-2 (1) framework
and its C9 epimer, which molecular modelling should
be useful in helping elucidate the conformation of LL-
Z1640-2 (1) within the TAK1 active site. We believe that
our robust and cost eﬀective approach provides the
foundations which will allow these compounds to be
considered as realistic chemical biological leads for the
ﬁrst time.
Our convergent retrosynthetic analysis called for the
cleavage of the macrocyclic ring at the ester functional-
ity and the benzylic double bond, generating the vinyl
benzoic acid 8 and C1–C10 alcohol 9 (Scheme 1).
The synthesis of the vinyl benzoic acid unit 8 began with
commercially available methyl 2,4,6-trihydroxybenzoate
10 which was methylated selectively at the C4 position to
aﬀord the desired diol 12 in excellent yield.11 Mono-
silylation of diol 12 proceeded in good yield to produce
the TBS silyl ether 13, which was then converted to
the corresponding triﬂate 14 in quantitative yield
(Scheme 2).
A Stille coupling of the newly generated aryl triﬂate with
vinyltributyl tin proceeded in excellent yield to aﬀord the
desired vinyl benzene 15. Finally, saponiﬁcation of the
methyl ester proceeded with concomitant desilylation
to generate the free benzoic acid 16 in near quantitative
yield.
Our synthesis of the aliphatic C1–C10 unit began with
readily available (L L)-(+)-diethyl tartrate 11 which was
protected as the dimethyl ketal 17. Reduction of the
diester functionality generated the corresponding diol
unit, which upon selective hydroxyl group silylation pro-
vided TBS ether 18 in excellent yield.12 Swern oxidation
of alcohol 18 proceeded in quantitative yield to generate
the expected aldehyde 19, which upon treatment under
Corey–Fuchs oleﬁnation conditions gave the desired
alkyne 20 in high yield. The newly generated alkyne 20
was then alkylated with (S)-propylene oxide under
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alkynol 21 as a single diastereomer in good yield. Silyla-
tion proceeded eﬃciently to generate the bis-TBS silyl
ether 22 in very high yield (Scheme 3).
The last steps of the synthesis of the C1–C10 unit began
with selective deprotection of the primary TBS silyl
ether of alkyne 22 under carefully monitored conditions
to aﬀord the desired primary alcohol 23 in good yield.
Rewardingly, a one-pot oxidation–allylation sequence
proceeded to generate homoallylic alcohol 24 as a mix-
ture of diastereomers (1:1) in excellent yield over the
two steps (Scheme 4). No attempt was made to control
the stereochemistry of allylation as we wanted to access
both LL-Z1640-2 and its C9 anomer for biological
evaluation.
Having successfully completed the synthesis of the C1–
C10 unit, we focused our attention on the conversion
of the alkyne unit into the Z-alkene functionality pres-
ent in LL-Z1640-2 (1). Unfortunately, despite repeated
experimentation, all hydrogenation attempts failed to
provide us with the desired diene unit 26, aﬀording in-
stead the over-reduced alkane 25. We believe that this
over-reduction could be attributed to the presence of
the free homoallylic alcohol unit.
The loss of the key terminal alkene functionality during
the introduction of the internal alkene moiety prompted
us to re-evaluate the synthetic route. Our modiﬁed
approach to the synthesis of the C1–C10 unit of LL-
Z1640-2 began with the previously obtained bis-TBS
ether 22, which was selectively reduced to generate the
Z-oleﬁn 27 in quantitative yield and with complete ste-
reocontrol. Selective TBS group removal then provided
primary alcohol 28 in good yield. A similar one-pot
Swern oxidation–allylation procedure to that used
previously proceeded cleanly and in excellent yield to
complete the syntheses of the C1–C10 fragments of
LL-Z1640-2 and 9-epi-LL-Z1640-2, 29a and 29b, respec-
tively (Scheme 5).
Having successfully introduced both alkene units with
complete stereocontrol, we decided to introduce the
remaining units of the LL-Z1640-2 framework. Hence,
alkenes 29a/29b were protected to give the correspond-
ing PMB ethers 30a/b in quantitative yield. Careful
removal of the secondary TBS silyl ether aﬀorded sec-
ondary alcohols 31a/b required for the esteriﬁcation
(Scheme 6).
Gratifyingly, reaction of alcohols 31a/b with the previ-
ously described vinyl benzoic acid 16 proceeded cleanly
to generate esters 32a and 32b incorporating the entire
LL-Z1640-2 (1) and the 9-epi-LL-Z1640-2 frameworks
in good overall yields.
In conclusion, we have demonstrated a fast, high yield-
ing and ﬂexible approach to the synthesis of LL-Z1640-2
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6090 N. Henry et al. / Tetrahedron Letters 48 (2007) 6088–6091(1) and its C9-epimer taking advantage of two-direc-
tional chain functionalisation and of an eﬃcient syn-
thetic pathway. The completion of the synthesis as
well as the results of our biological assessment of all
the intermediates will be reported in due course.
Acknowledgements
We thank the Cunningham Trust, and the EPSRC for
supporting this work. M.N.R. thanks the BBSRC for
a postgraduate studentship. R.M. thanks Dr. Ian Sword
and the University of Glasgow, for ﬁnancial support.
References and notes
1. Moriguchi, T.; Kuroyagani, N.; Yamaguchi, K.; Gotoh,
Y.; Irie, K.; Kano, T.; Shirakabe, K.; Muro, Y.; Shibuya,
H.; Matsumoto, K.; Nishida, E.; Hagiwara, M. J. Biol.
Chem. 1996, 271, 13675.
2. (a) Shirakabe, K.; Yamaguchi, K.; Shibuya, H.; Irie, K.;
Matsuda, S.; Moriguchi, T.; Gotoh, Y.; Matsumoto, K.;
Nishida, E. J. Biol. Chem. 1997, 272, 8141; (b) Yamaguchi,
K.; Shirakabe, K.; Shibuya, H.; Irie, K.; Oishi, I.; Ueno,
N.; Taniguchi, T.; Nishida, E.; Matsumoto, K. Science
1995, 270, 2008.
3. (a) Ninomiya-Tsuji, J.; Kishimoto, K.; Hiyama, A.; Inoue,
J.; Cao, Z.; Matsumoto, K. Nature 1999, 398, 252; (b)
Shibuya, H.; Yamaguchi, K.; Shirakabe, K.; Tonegawa,
A.; Gotoh, Y.; Ueno, N.; Irie, K.; Nishida, E.; Matsu-
moto, K. Science 1996, 272, 1179.
4. Takaesu, G.; Kishida, S.; Hiyama, A.; Yamaguchi, K.;
Shibuya, H.; Irie, K.; Ninomiya-Tsuji, J.; Matsumoto, K.
Mol. Cell 2000, 5, 649.
5. Ellestad, G. A.; Lovell, F. M.; Perkinson, N. A.; Harg-
reaves, R. T.; McGahren, W. J. J. Org. Chem. 1978, 43,
2339.
6. Takehara, K.; Sato, S.; Kobayashi, T.; Maeda, T.
Biochem. Biophys. Res. Commun. 1999, 257, 19.
7. (a) Giese, N. A.; Lokker, N. Int Pat. WO9613259; Chem.
Abstr. 1996, 457801; (b) Nonomiya-Tsuji, J.; Kajino, T.;
Ono, K.; Ohtomo, T.; Matsumoto, M.; Shiina, M.;
Mihara, M.; Tsuchiya, M.; Matsumoto, K. J. Biol. Chem.
2003, 278, 18485.
8. (a) Kastelic, T.; Schnyder, J.; Leutwiler, A.; Traber, R.;
Streit, B.; Niggli, H.; MacKenzie, A.; Cheneval, D.
Cytokine 1996, 8, 751; (b) Elford, P. R.; Dixon, A. K.;
MacKenzie, A. R.; Leutwiler, A.; Schnyder, J. Pharmacol.
Commun. 1996, 7, 301; (c) Ohori, M.; Kinoshita, T.;
Yoshimura, S.; Warizaya, M.; Nakajima, H.; Miyake, H.
Biochem. Biophys. Res. Commun. 2007, 353, 633.
9. (a) Moulin, E.; Barluenga, S.; Winssinger, N. Org. Lett.
2005, 7, 5637; (b) Garbaccio, R. M.; Danishefsky, S. J.
Org. Lett. 2000, 2, 3127; (c) Garbaccio, R. M.; Stachel, S.
J.; Baeschlin, D. K.; Danishefsky, S. J. J. Am. Chem. Soc.
2001, 123, 10903; (d) Tichkowsky, I.; Lett, R. Tetrahedron
Lett. 2002, 43, 3997; (e) Tichkowsky, I.; Lett, R. Tetra-
hedron Lett. 2002, 43, 4003; (f) Lampilas, M.; Lett, R.
Tetrahedron Lett. 1992, 33, 773; (g) Winssinger, N.;
Barluenga, S. Chem. Commun. 2007, 22.
10. (a) Tatsuta, K.; Takano, S.; Sato, T.; Nakano, S. Chem.
Lett. 2001, 172; (b) Selles, P.; Lett, R. Tetrahedron Lett.
2002, 43, 5621; (c) Selles, P.; Lett, R. Tetrahedron Lett.
2002, 43, 4627.
11. Robertson, D. W.; Beedle, E. E.; Krushinski, J. H.;
Pollock, G. D.; Wilson, H.; Wyss, V. L.; Hayes, J. S. J.
Med. Chem. 1985, 28, 717.
12. White, J. D.; Kuntiyong, P.; Lee, T. H. Org. Lett. 2006, 8,
6039.
OO
TBSO
OTBS
TBSO
O
O
OH
MgBr
TBSO
O
O TBSO
TBSO
O
O HO
i) Swern
ii)
96% for 2 steps
H2, Pd/BaSO4
Quinoline
100%
HF.Pyr / Pyr
65% + SM
22 27
28 29a/29b
THF
Scheme 5.
TBSO
O
O
OH
TBSO
O
O
PMBO
HO
O
O
PMBO
OH
MeO
O
OH
DCC
OH
MeO
O
O
O
O
O
OMe
100%
HF.Pyr / Pyr
97%
67%
29a/b
NaH, PMBCl, 
TBAI, THF
30a/b
31a/b
16
32a
OH
MeO
O
O
O
O
O
OMe
32b
+
Scheme 6.
N. Henry et al. / Tetrahedron Letters 48 (2007) 6088–6091 6091